<?xml version="1.0" ?>
<document version="1.8" entity_encoding="single">
  <page number="1">
    <text>Musculoskeletal
Disorders and Dentistry

Dr Jee-Yun Leung
BDSc(Hons) MSc(SCD) DSCD(RCSEng) DClinDent(SND) MRACDS(SND) FANZASND
Specialist in Special Needs Dentistry
Senior Lecturer, The University of Western Australia
Consultant, Maxillofacial &amp; Dental Dept, Fiona Stanley Hospital

1

![](L8 Musculoskeletal Disorders_figures/img_ee125b4131ac17b8.webp)</text>
    <formatted_text>Dr Jee-Yun Leung
BDSc(Hons) MSc(SCD) DSCD(RCSEng) DClinDent(SND) MRACDS(SND) FANZASND

- Specialist in Special Needs Dentistry
- Senior Lecturer, The University of Western Australia
- Consultant, Maxillofacial &amp; Dental Dept, Fiona Stanley Hospital</formatted_text>
    <images>
      <img order="0" bbox="592,221,916,747" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="diagram" path="L8 Musculoskeletal Disorders_figures/img_ee125b4131ac17b8.webp">
        <description>A split-view anatomical diagram of the human body illustrating the musculoskeletal system, with the muscular system depicted on the left half and the skeletal system on the right. The figure includes labels for specific structures such as the sternocleidomastoid, biceps, and quadriceps muscles, alongside bones like the maxilla, mandible, humerus, and femur.</description>
      </img>
    </images>
  </page>
  <page number="2">
    <text>Lecture
Outcomes

Discuss the specific characteristics and dental needs of individuals with joint (e.g. osteoarthritis, rheumatoid arthritis) and bone (e.g. osteoporosis) disorders

Perform a risk assessment and make appropriate treatment adaptations to ensure safe and effective dental care

Work a patient up prior to commencement of bone-modifying drugs (e.g. bisphosphonates, denosumab, romosozumab)

Assess MRONJ risk prior to invasive dental procedures, and institute preventive measures

Appreciate management options of MRONJ

2025

![](L8 Musculoskeletal Disorders_figures/img_2e75a1f8a748d589.webp)
![](L8 Musculoskeletal Disorders_figures/img_05ff8f27da9d1978.webp)</text>
    <formatted_text>1. Discuss the specific characteristics and dental needs of individuals with joint (e.g. osteoarthritis, rheumatoid arthritis) and bone (e.g. osteoporosis) disorders

2. Perform a risk assessment and make appropriate treatment adaptations to ensure safe and effective dental care

3. Work a patient up prior to commencement of bone-modifying drugs (e.g. bisphosphonates, denosumab, romosozumab)

4. Assess MRONJ risk prior to invasive dental procedures, and institute preventive measures

5. Appreciate management options of MRONJ</formatted_text>
    <images>
      <img order="0" bbox="347,435,442,557" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="image" path="L8 Musculoskeletal Disorders_figures/img_2e75a1f8a748d589.webp"/>
      <img order="1" bbox="348,715,441,834" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="image" path="L8 Musculoskeletal Disorders_figures/img_05ff8f27da9d1978.webp"/>
    </images>
  </page>
  <page number="3">
    <text>**Chronic musculoskeletal disorders**

• muscles (eg sarcopenia)
• joints (eg osteoarthritis, rheumatoid arthritis)
• bones (eg osteoporosis, osteonecrosis, traumatic fractures)
• spine (eg back and neck pain)
• multiple body systems and locations (eg widespread and regional pain disorders, inflammatory or connective tissue diseases, systemic vasculitides, fibromyalgia).</text>
    <formatted_text>Chronic musculoskeletal disorders affect:

- **Muscles** (e.g. sarcopenia)
- **Joints** (e.g. osteoarthritis, rheumatoid arthritis)
- **Bones** (e.g. osteoporosis, osteonecrosis, traumatic fractures)
- **Spine** (e.g. back and neck pain)
- **Multiple body systems and locations** (e.g. widespread and regional pain disorders, inflammatory or connective tissue diseases, systemic vasculitides, fibromyalgia).</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="00:01:09" confidence="4" anchor="**Multiple body systems and locations** (e.g. widespread and regional pain disor">
- Muscles may also be affected by ==muscular dystrophy==.
- The most common symptom is ==pain==.
- Another common symptom is ==restricted mobility==.</insert>
    </audio_inserts>
  </page>
  <page number="4">
    <text>**Joint**
**disorders**

Osteoarthritis, Rheumatoid Arthritis

4

![](L8 Musculoskeletal Disorders_figures/img_c9b38b790ec3b76a.webp)</text>
    <formatted_text>- Osteoarthritis
- Rheumatoid Arthritis</formatted_text>
    <images>
      <img order="0" bbox="410,163,922,835" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="figure" path="L8 Musculoskeletal Disorders_figures/img_c9b38b790ec3b76a.webp">
        <description>A stylized medical illustration of a knee joint, depicted in translucent blue tones against a black background. The image highlights the articulation between the femur and tibia, with a glowing red area centered on the joint space to represent inflammation or pain.</description>
      </img>
    </images>
  </page>
  <page number="5">
    <text>Arthritis

• Osteoarthritis: Degenerative joint disease. Key feature is degeneration of articular cartilage (“wear and tear”).

• Rheumatoid arthritis: Systemic chronic immunologically mediated inflammatory disease affecting multiple tissues, but principally attacking the joints. Characterised by an autoantibody directed against IgG (rheumatoid factor, RF) $\rightarrow$ formation of immune complexes and activation of complement $\rightarrow$ synovial inflammation and destructive joint disease.

NORMAL JOINT
Muscle
Bursa
Bone
Cartilage
Synovial fluid
Synovial membrane
Joint capsule
Tendon

Eroded cartilage
Bone ends rub together

Bone erosion
Swollen inflamed synovial membrane

![OSTEOARTHRITIS](L8 Musculoskeletal Disorders_figures/img_c4eb5bd0d755a917.webp)
![RHEUMATOID ARTHRITIS](L8 Musculoskeletal Disorders_figures/img_7e9147bafeb530ae.webp)</text>
    <formatted_text>- **Osteoarthritis:** Degenerative joint disease. Key feature is degeneration of articular cartilage (&quot;wear and tear&quot;).
- **Rheumatoid arthritis:** Systemic chronic immunologically mediated inflammatory disease affecting multiple tissues, but principally attacking the joints. Characterised by an autoantibody directed against IgG (rheumatoid factor, RF) → formation of immune complexes and activation of complement → synovial inflammation and destructive joint disease.

#### Normal Joint

Muscle, bursa, bone, cartilage, synovial fluid, synovial membrane, joint capsule, tendon.

#### Inflamed Joint

Eroded cartilage; bone ends rub together. Bone erosion; swollen inflamed synovial membrane.</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="00:04:18" confidence="9" anchor="Eroded cartilage; bone ends rub together. Bone erosion; swollen inflamed synovia">

&gt; [!note] Lecturer — Joint Damage
&gt; Rheumatoid arthritis can affect the synovium, adjacent tissues and articular surfaces, with consequences beyond the joints. Osteoarthritis may also produce subchondral cysts and sclerosis in addition to deformed articular surfaces and bone spurs.
</insert>
    </audio_inserts>
    <images>
      <img order="0" bbox="232,605,395,816" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="diagram" path="L8 Musculoskeletal Disorders_figures/img_c4eb5bd0d755a917.webp" caption="OSTEOARTHRITIS">
        <description>Labelled diagram: A schematic cross-section of a normal synovial joint illustrating the arrangement of anatomical structures. The labels identify key components including Muscle, Bursa, Bone, Cartilage, Synovial fluid, Synovial membrane, Joint capsule, and Tendon.</description>
      </img>
      <img order="1" bbox="563,605,744,818" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="diagram" path="L8 Musculoskeletal Disorders_figures/img_7e9147bafeb530ae.webp" caption="RHEUMATOID ARTHRITIS">
        <description>A labelled anatomical diagram illustrating the pathology of rheumatoid arthritis in a joint. The image highlights two key features: 'Bone erosion' at the articular surface and a thickened, pink 'Swollen inflamed synovial membrane' surrounding the joint.</description>
      </img>
    </images>
  </page>
  <page number="6">
    <text>Arthritis

&lt;table&gt;
  &lt;tr&gt;
    &lt;th&gt;&lt;/th&gt;
    &lt;th&gt;Osteoarthritis&lt;/th&gt;
    &lt;th&gt;Rheumatoid Arthritis&lt;/th&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;Prevalence&lt;/td&gt;
    &lt;td&gt;Most common MSK disorder.&lt;br&gt;9% Australians&lt;/td&gt;
    &lt;td&gt;2&lt;sup&gt;nd&lt;/sup&gt; most common MSK disorder&lt;br&gt;(1/10 as common as OA).&lt;br&gt;1.8% Australians&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;Aetiology / Process&lt;/td&gt;
    &lt;td&gt;Degenerative&lt;br&gt;Multifactorial&lt;br&gt;Inflammatory result.&lt;/td&gt;
    &lt;td&gt;Autoimmune&lt;br&gt;Immunogenetically driven&lt;br&gt;Inflammatory cause.&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;Risk Groups&lt;/td&gt;
    &lt;td&gt;Age: &amp;gt;45yo M, &amp;gt;55yo F (onset late-middle or old age)&lt;br&gt;Sex: Female (2:1)&lt;br&gt;Genetic factors&lt;br&gt;Obesity&lt;br&gt;Joint malformation&lt;br&gt;Trauma&lt;br&gt;Occupation (labour, athletes)&lt;br&gt;Haemochromatosis&lt;br&gt;Paget disease&lt;br&gt;Gout&lt;/td&gt;
    &lt;td&gt;Genetic predisposition (HLA-DR3 genotype)&lt;br&gt;Sex: Female (3:1)&lt;br&gt;Age: 30-40yo (onset middle age)&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

![](L8 Musculoskeletal Disorders_figures/img_1210d5a90abc3c6f.webp)</text>
    <formatted_text>| | Osteoarthritis | Rheumatoid Arthritis |
| :--- | :--- | :--- |
| Prevalence | Most common MSK disorder. 9% Australians | 2nd most common MSK disorder (1/10 as common as OA). 1.8% Australians |
| Aetiology / Process | Degenerative. Multifactorial. Inflammatory result. | Autoimmune. Immunogenetically driven. Inflammatory cause. |
| Risk Groups | Age: &gt;45yo M, &gt;55yo F (onset late-middle or old age); Sex: Female (2:1); Genetic factors; Obesity; Joint malformation; Trauma; Occupation (labour, athletes); Haemochromatosis; Paget disease; Gout | Genetic predisposition (HLA-DR3 genotype); Sex: Female (3:1); Age: 30-40yo (onset middle age) |</formatted_text>
    <images>
      <img order="0" bbox="93,251,938,786" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="table" path="L8 Musculoskeletal Disorders_figures/img_1210d5a90abc3c6f.webp">
        <description>A comparison table distinguishing between Osteoarthritis and Rheumatoid Arthritis. The rows categorize the differences by Prevalence, Aetiology/Process, and Risk Groups, listing specific factors such as age of onset, gender ratios, and genetic predispositions for each condition.</description>
      </img>
    </images>
  </page>
  <page number="7">
    <text>Arthritis

&lt;table&gt;
  &lt;tr&gt;
    &lt;th&gt;&lt;/th&gt;
    &lt;th&gt;Osteoarthritis&lt;/th&gt;
    &lt;th&gt;Rheumatoid Arthritis&lt;/th&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;Synovial joint target&lt;/td&gt;
    &lt;td&gt;Large or weight-bearing joints (hips, knees, lower back, feet)&lt;br&gt;Frequently used (fingers)&lt;br&gt;Traumatised joints&lt;/td&gt;
    &lt;td&gt;Small joints (hand and feet)&lt;br&gt;Other joints with disease progression&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;Pathology&lt;/td&gt;
    &lt;td&gt;No pannus formation&lt;/td&gt;
    &lt;td&gt;Pannus formation&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;&lt;/td&gt;
    &lt;td&gt;No ankylosis&lt;/td&gt;
    &lt;td&gt;Bony and fibrous ankylosis&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;&lt;/td&gt;
    &lt;td&gt;Presenting symptoms - pain and stiffness of joints&lt;/td&gt;
    &lt;td&gt;Presenting symptoms – include malaise/fever in addition to pain and stiffness of joints&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;&lt;/td&gt;
    &lt;td&gt;Thinned and fibrillated cartilage&lt;/td&gt;
    &lt;td&gt;Eroded cartilage&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;&lt;/td&gt;
    &lt;td&gt;Bony spurs and osteophyte formation&lt;/td&gt;
    &lt;td&gt;-&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

![RHEUMATOID ARTHRITIS OSTE OA RTH RITIS](L8 Musculoskeletal Disorders_figures/img_59c5874a9ebe0cd0.webp)
![](L8 Musculoskeletal Disorders_figures/img_43a994a08d9d25ae.webp)</text>
    <formatted_text>| | Osteoarthritis | Rheumatoid Arthritis |
| :--- | :--- | :--- |
| Synovial joint target | Large or weight-bearing joints (hips, knees, lower back, feet); frequently used (fingers); traumatised joints | Small joints (hand and feet); other joints with disease progression |
| Pathology | No pannus formation | Pannus formation |
| | No ankylosis | Bony and fibrous ankylosis |
| | Presenting symptoms – pain and stiffness of joints | Presenting symptoms – include malaise/fever in addition to pain and stiffness of joints |
| | Thinned and fibrillated cartilage | Eroded cartilage |
| | Bony spurs and osteophyte formation | – |</formatted_text>
    <images>
      <img order="0" bbox="63,218,934,540" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="table" path="L8 Musculoskeletal Disorders_figures/img_59c5874a9ebe0cd0.webp" caption="RHEUMATOID ARTHRITIS OSTE OA RTH RITIS">
        <description>A comparative table distinguishing between Osteoarthritis and Rheumatoid Arthritis across various clinical features, including synovial joint targets, pathology, presenting symptoms, and cartilage changes.</description>
      </img>
      <img order="1" bbox="292,559,714,817" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="diagram" path="L8 Musculoskeletal Disorders_figures/img_43a994a08d9d25ae.webp">
        <description>A labelled medical illustration comparing the pathological changes in a knee joint affected by Rheumatoid Arthritis versus Osteoarthritis. The diagram highlights specific features such as pannus formation, inflammation, and eroding cartilage on the left (Rheumatoid), contrasting with osteophytes, bony spurs, subchondral sclerosis, and thinned/fibrillated cartilage on the right (Osteoarthritis).</description>
      </img>
    </images>
  </page>
  <page number="8">
    <text>&lt;h1&gt;Arthritis&lt;/h1&gt;

&lt;table&gt;
  &lt;tr&gt;
    &lt;th&gt;&lt;/th&gt;
    &lt;th&gt;Osteoarthritis&lt;/th&gt;
    &lt;th&gt;Rheumatoid Arthritis&lt;/th&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;Onset&lt;/td&gt;
    &lt;td&gt;Slow, over years&lt;/td&gt;
    &lt;td&gt;Rapid, over weeks to months&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;Symmetry&lt;/td&gt;
    &lt;td&gt;Asymmetric&lt;/td&gt;
    &lt;td&gt;Symmetric&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;Pain, disability&lt;/td&gt;
    &lt;td&gt;+&lt;/td&gt;
    &lt;td&gt;++&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;Joint deformities&lt;/td&gt;
    &lt;td&gt;Nodes (firm / bony hard)&lt;br/&gt;• Heberden – DIP&lt;br/&gt;• Bouchard – PIP&lt;br/&gt;• 1&lt;sup&gt;st&lt;/sup&gt; MCP joint at thumb base&lt;/td&gt;
    &lt;td&gt;Swellings (hot / tender) and deviations&lt;br/&gt;• Boutonniere deformity&lt;br/&gt;• Ulnar deviation MCP joints&lt;br/&gt;• Swan neck deformity fingers&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

![](L8 Musculoskeletal Disorders_figures/img_c8cc3ec8ff64085e.webp)
![Heberden's node Bouchard's node](L8 Musculoskeletal Disorders_figures/img_f1230d925d09eac5.webp)
![Rheumatoid arthritis (late stage) Boutonniere deformity of thumb Ulnar deviation of metacarpophalangeal joints Swan-neck deformity of fingers](L8 Musculoskeletal Disorders_figures/img_7de314af5ad9ec4e.webp)</text>
    <formatted_text>| | Osteoarthritis | Rheumatoid Arthritis |
| :--- | :--- | :--- |
| Onset | Slow, over years | Rapid, over weeks to months |
| Symmetry | Asymmetric | Symmetric |
| Pain, disability | + | ++ |
| Joint deformities | Nodes (firm / bony hard): Heberden – DIP; Bouchard – PIP; 1st MCP joint at thumb base | Swellings (hot / tender) and deviations: Boutonniere deformity; Ulnar deviation MCP joints; Swan neck deformity fingers |</formatted_text>
    <images>
      <img order="0" bbox="172,247,835,610" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="table" path="L8 Musculoskeletal Disorders_figures/img_c8cc3ec8ff64085e.webp">
        <description>A comparison table contrasting Osteoarthritis and Rheumatoid Arthritis across four clinical features: Onset, Symmetry, Pain/disability, and Joint deformities. The 'Joint deformities' row lists specific signs for each condition, including Heberden and Bouchard nodes for osteoarthritis, and Boutonniere, ulnar deviation, and Swan neck deformities for rheumatoid arthritis.</description>
      </img>
      <img order="1" bbox="392,643,610,806" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="figure" path="L8 Musculoskeletal Disorders_figures/img_f1230d925d09eac5.webp" caption="Heberden's node Bouchard's node">
        <description>A labelled anatomical illustration showing the dorsal view of a hand, comparing skeletal and soft tissue views. The diagram identifies specific joint locations for Heberden's node (distal interphalangeal joint) and Bouchard's node (proximal interphalangeal joint), highlighting them with reddish shading on the skeleton.</description>
      </img>
      <img order="2" bbox="642,623,812,818" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="figure" path="L8 Musculoskeletal Disorders_figures/img_7de314af5ad9ec4e.webp" caption="Rheumatoid arthritis (late stage) Boutonniere deformity of thumb Ulnar deviation of metacarpophalangeal joints Swan-neck deformity of fingers">
        <description>An anatomical illustration of a hand demonstrating late-stage rheumatoid arthritis deformities. The figure highlights specific pathological changes including Boutonniere deformity of the thumb, ulnar deviation of the metacarpophalangeal joints, and swan-neck deformity of the fingers.</description>
      </img>
    </images>
  </page>
  <page number="9">
    <text>&lt;h2&gt;Arthritis&lt;/h2&gt;

&lt;table&gt;
  &lt;tr&gt;
    &lt;th&gt;&lt;/th&gt;
    &lt;th&gt;Osteoarthritis&lt;/th&gt;
    &lt;th&gt;Rheumatoid Arthritis&lt;/th&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;Systemic signs and symptoms&lt;/td&gt;
    &lt;td&gt;None&lt;/td&gt;
    &lt;td&gt;Malaise, fever, cervical lymphadenopathy.&lt;br&gt;Obvious signs of inflammation.&lt;br&gt;May be assoc with other autoimmune conditions (e.g. SLE, Sjogren’s Dx).&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;Morning stiffness&lt;/td&gt;
    &lt;td&gt;Some&lt;/td&gt;
    &lt;td&gt;Pronounced (lasts &gt;1hr)&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;Other body systems affected&lt;/td&gt;
    &lt;td&gt;None&lt;/td&gt;
    &lt;td&gt;Cardiovascular (conduction defects, myocarditis, pericarditis, valvulitis, vasculitis)&lt;br&gt;Dermal/oral/para-oral (oral drug lesions, palmar erythema, Sjögren’s, subcutaneous rheumatoid nodules, TMJ arthritis, vasculitis, rashes)&lt;br&gt;Haematological (anaemia, leukopenia, thrombocytopenia); 1-2% have Felty’s syndrome (results in neutropenia)&lt;br&gt;Hepatic (abnormal liver function)&lt;br&gt;Muscular (wasting, weakness)&lt;br&gt;Neurological (benign trigeminal neuropathy, carpal tunnel, glove-and-stocking anaesthesia, various neuropathies)&lt;br&gt;Ocular&lt;br&gt;Osseous (osteoporosis)&lt;br&gt;Renal (amyloidosis, nephropathy)&lt;br&gt;Respiratory (bronchiolitis, fibrosis, lung nodules, pleurisy/pleural effusion)&lt;br&gt;Non-specific (fatigue, fever, malaise, weight loss)&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

![](L8 Musculoskeletal Disorders_figures/img_743b53bc8435ad2e.webp)</text>
    <formatted_text>| | Osteoarthritis | Rheumatoid Arthritis |
| :--- | :--- | :--- |
| Systemic signs and symptoms | None | Malaise, fever, cervical lymphadenopathy. Obvious signs of inflammation. May be assoc with other autoimmune conditions (e.g. SLE, Sjogren's Dx). |
| Morning stiffness | Some | Pronounced (lasts &gt;1hr) |
| Other body systems affected | None | Cardiovascular (conduction defects, myocarditis, pericarditis, valvulitis, vasculitis); Dermal/oral/para-oral (oral drug lesions, palmar erythema, Sjögren's, subcutaneous rheumatoid nodules, TMJ arthritis, vasculitis, rashes); Haematological (anaemia, leukopenia, thrombocytopenia); 1-2% have Felty's syndrome (results in neutropenia); Hepatic (abnormal liver function); Muscular (wasting, weakness); Neurological (benign trigeminal neuropathy, carpal tunnel, glove-and-stocking anaesthesia, various neuropathies); Ocular; Osseous (osteoporosis); Renal (amyloidosis, nephropathy); Respiratory (bronchiolitis, fibrosis, lung nodules, pleurisy/pleural effusion); Non-specific (fatigue, fever, malaise, weight loss) |</formatted_text>
    <images>
      <img order="0" bbox="62,242,939,812" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="table" path="L8 Musculoskeletal Disorders_figures/img_743b53bc8435ad2e.webp">
        <description>A comparative table contrasting Osteoarthritis and Rheumatoid Arthritis across three categories: systemic signs and symptoms, morning stiffness, and other body systems affected. The right column for Rheumatoid Arthritis lists extensive multi-system involvement including cardiovascular, dermal/oral, haematological, neurological, and respiratory manifestations.</description>
      </img>
    </images>
  </page>
  <page number="10">
    <text>Arthritis

| | Osteoarthritis | Rheumatoid Arthritis |
| :--- | :--- | :--- |
| **General treatment** | | |
| Lifestyle | Exercise&lt;br&gt;Weight control / diet | Exercise&lt;br&gt;Weight control / diet&lt;br&gt;Smoking cessation&lt;br&gt;Psychosocial interventions |
| Physical | Appropriate footwear&lt;br&gt;Walking aids&lt;br&gt;Heat/cold application&lt;br&gt;Topical analgesics&lt;br&gt;Physiotherapy | Rest (during acute phase), exercises (between flare-ups)&lt;br&gt;Splints&lt;br&gt;TENS machine&lt;br&gt;Thermotherapy&lt;br&gt;Topical analgesics&lt;br&gt;Physiotherapy |
| Medical | Anti-inflammatory medications (NSAIDs, COX-2 inhibitors)&lt;br&gt;Glucosamine / fish oil supplementation&lt;br&gt;Intra-articular corticosteroid injections | Anti-inflammatory medications (NSAIDs, COX-2 inhibitors)&lt;br&gt;Glucosamine / fish oil supplementation&lt;br&gt;Intra-articular corticosteroid injections&lt;br&gt;*Disease-modifying anti-rheumatic drugs (DMARDs) |
| Surgery | Osteotomy&lt;br&gt;Joint replacement (arthroplasty) | Arthrodesis&lt;br&gt;Resection&lt;br&gt;Synovectomy&lt;br&gt;Joint replacement (arthroplasty) |

![](L8 Musculoskeletal Disorders_figures/img_3dff8ca02b029ea4.webp)</text>
    <formatted_text>| | Osteoarthritis | Rheumatoid Arthritis |
| :--- | :--- | :--- |
| **General treatment – Lifestyle** | Exercise; weight control / diet | Exercise; weight control / diet; smoking cessation; psychosocial interventions |
| **Physical** | Appropriate footwear; walking aids; heat/cold application; topical analgesics; physiotherapy | Rest (during acute phase), exercises (between flare-ups); splints; TENS machine; thermotherapy; topical analgesics; physiotherapy |
| **Medical** | Anti-inflammatory medications (NSAIDs, COX-2 inhibitors); glucosamine / fish oil supplementation; intra-articular corticosteroid injections | Anti-inflammatory medications (NSAIDs, COX-2 inhibitors); glucosamine / fish oil supplementation; intra-articular corticosteroid injections; disease-modifying anti-rheumatic drugs (DMARDs) |
| **Surgery** | Osteotomy; joint replacement (arthroplasty) | Arthrodesis; resection; synovectomy; joint replacement (arthroplasty) |</formatted_text>
    <images>
      <img order="0" bbox="77,293,889,781" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="table" path="L8 Musculoskeletal Disorders_figures/img_3dff8ca02b029ea4.webp">
        <description>A comparison table contrasting the general treatment protocols for Osteoarthritis and Rheumatoid Arthritis. The rows categorize interventions into Lifestyle, Physical, Medical, and Surgery, listing specific management strategies such as exercise, physiotherapy, medications, and surgical options under each column.</description>
      </img>
    </images>
  </page>
  <page number="11">
    <text>Arthritis – Oral implications

Association with periodontitis: 2017 world workshop (AAP+ EFP)
• Albandar JM, Susin C, Hughes FJ. Manifestations of systemic diseases and conditions that affect the periodontal attachment apparatus: Case definitions and diagnostic considerations. J Periodontol. 2018 Jun;89 Suppl 1:S183-S203.

&lt;table&gt;
  &lt;tr&gt;
    &lt;th&gt;Disorder&lt;/th&gt;
    &lt;th&gt;Strength of association&lt;/th&gt;
    &lt;th&gt;Quality of evidence&lt;/th&gt;
    &lt;th&gt;Biologic mechanisms&lt;/th&gt;
    &lt;th&gt;Case definitions&lt;/th&gt;
    &lt;th&gt;Diagnostic considerations&lt;/th&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;Arthritis&lt;/td&gt;
    &lt;td&gt;Significant&lt;/td&gt;
    &lt;td&gt;Animal models, systematic review&lt;/td&gt;
    &lt;td&gt;Rheumatoid arthritis is an autoimmune disease; osteoarthritis is due to gradual deterioration of cartilage&lt;/td&gt;
    &lt;td&gt;• Joint pain, swelling, stiffness, redness, and limited motion&lt;br&gt;• Increased risk for loss of periodontal attachment and alveolar bone&lt;/td&gt;
    &lt;td&gt;• Clinical history and physical examination for arthritis&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

![](L8 Musculoskeletal Disorders_figures/img_b856b5182bb03581.webp)</text>
    <formatted_text>Association with periodontitis: 2017 world workshop (AAP + EFP)

*Albandar JM, Susin C, Hughes FJ. Manifestations of systemic diseases and conditions that affect the periodontal attachment apparatus: Case definitions and diagnostic considerations. J Periodontol. 2018 Jun;89 Suppl 1:S183-S203.*

| Disorder | Strength of association | Quality of evidence | Biologic mechanisms | Case definitions | Diagnostic considerations |
| :--- | :--- | :--- | :--- | :--- | :--- |
| Arthritis | Significant | Animal models, systematic review | Rheumatoid arthritis is an autoimmune disease; osteoarthritis is due to gradual deterioration of cartilage | Joint pain, swelling, stiffness, redness, and limited motion; increased risk for loss of periodontal attachment and alveolar bone | Clinical history and physical examination for arthritis |</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="00:09:34" confidence="6" anchor="Clinical history and physical examination for arthritis">

&gt; [!note] Lecturer — Shared Inflammation
&gt; The association between periodontitis and arthritis was related to inflammatory mechanisms shared by both conditions.
</insert>
    </audio_inserts>
    <images>
      <img order="0" bbox="31,526,959,662" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="table" path="L8 Musculoskeletal Disorders_figures/img_b856b5182bb03581.webp">
        <description>A table outlining the association between arthritis and periodontitis, with columns for Disorder, Strength of association, Quality of evidence, Biologic mechanisms, Case definitions, and Diagnostic considerations.</description>
      </img>
    </images>
  </page>
  <page number="12">
    <text>Rheumatoid
Arthritis –
Drugs and oral
side effects

&lt;table&gt;
  &lt;tr&gt;&lt;th colspan=&quot;2&quot;&gt;Oral adverse effects of drugs used in RA treatment&lt;sup&gt;2&lt;/sup&gt;&lt;/th&gt;&lt;/tr&gt;
  &lt;tr&gt;&lt;th&gt;Drug/Group&lt;/th&gt;&lt;th&gt;Adverse Effects&lt;/th&gt;&lt;/tr&gt;
  &lt;tr&gt;&lt;td&gt;Antimalarials, eg. hydroxychloroquine (Plaquenil)&lt;/td&gt;&lt;td&gt;Lichenoid reactions&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;Hyperpigmentation&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;&lt;td&gt;Anti-TNF agents (most of the biological DMARDs)&lt;/td&gt;&lt;td&gt;Candidosis; other infections&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;Erythema multiforme&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;Ulceration&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;&lt;td&gt;Corticosteroids&lt;/td&gt;&lt;td&gt;Candidosis&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;&lt;td&gt;Gold&lt;/td&gt;&lt;td&gt;Lichenoid reactions&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;Ulceration&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;&lt;td&gt;Leflunomide&lt;/td&gt;&lt;td&gt;Candidosis&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;Salivary swelling&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;Taste disturbance&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;&lt;td&gt;Methotrexate&lt;/td&gt;&lt;td&gt;Ulceration&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;&lt;td&gt;NSAIDs&lt;/td&gt;&lt;td&gt;Lichenoid reactions&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;Ulceration&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;&lt;td&gt;Penicillamine (old DMARD; rarely used)&lt;/td&gt;&lt;td&gt;Lichenoid reactions&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;Dysgeusia&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;Severe ulceration&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

![Oral adverse effects of drugs used in RA treatment²](L8 Musculoskeletal Disorders_figures/img_4d4d44b618b3c360.webp)</text>
    <formatted_text>Oral adverse effects of drugs used in RA treatment:

| Drug/Group | Adverse Effects |
| :--- | :--- |
| Antimalarials, e.g. hydroxychloroquine (Plaquenil) | Lichenoid reactions; hyperpigmentation |
| Anti-TNF agents (most of the biological DMARDs) | Candidosis; other infections; erythema multiforme; ulceration |
| Corticosteroids | Candidosis |
| Gold | Lichenoid reactions; ulceration |
| Leflunomide | Candidosis; salivary swelling; taste disturbance |
| Methotrexate | Ulceration |
| NSAIDs | Lichenoid reactions; ulceration |
| Penicillamine (old DMARD; rarely used) | Lichenoid reactions; dysgeusia; severe ulceration |</formatted_text>
    <images>
      <img order="0" bbox="358,188,972,803" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="table" path="L8 Musculoskeletal Disorders_figures/img_4d4d44b618b3c360.webp" caption="Oral adverse effects of drugs used in RA treatment²">
        <description>This table lists the oral adverse effects associated with various drugs used to treat Rheumatoid Arthritis. The columns categorize medications by drug or group (e.g., Antimalarials, Corticosteroids, NSAIDs) and detail their specific side effects, such as lichenoid reactions, candidosis, and ulceration.</description>
      </img>
    </images>
  </page>
  <page number="13">
    <text>Rheumatoid Arthritis –
Drugs and oral side effects

| | | |
| :--- | :--- | :--- |
| DMARDs | Conventional (1st line) | methotrexate*+; leflunomide* (Revlimid); sulfasalazine*; hydroxychloroquine (Plaquenil) |
| | Biological (2nd line) | abatacept* (Orencia); adalimumab*+ (Humira); certolizumab* (Cimzia); etanercept*+ (Enbrel); golimumab*+ (Simponi); infliximab*+ (Remicade); tocilizumab*+ (Actemra); |
| | Targeted (2nd line) | tofacitinib* (Xeljanz, Jakvinus) |
| Other agents | | azathioprine*, cyclosporine*, gold salts |

May combine with corticosteroids in induction phase

*agents causing *immunocompromise*
+Emerging case reports of *MRONJ* association
*Associated with DMARDs*

![](L8 Musculoskeletal Disorders_figures/img_d69032e85f7e3f6c.webp)</text>
    <formatted_text>| | | |
| :--- | :--- | :--- |
| DMARDs | Conventional (1st line) | methotrexate*+; leflunomide* (Revlimid); sulfasalazine*; hydroxychloroquine (Plaquenil) |
| | Biological (2nd line) | abatacept* (Orencia); adalimumab*+ (Humira); certolizumab* (Cimzia); etanercept*+ (Enbrel); golimumab*+ (Simponi); infliximab*+ (Remicade); tocilizumab*+ (Actemra) |
| | Targeted (2nd line) | tofacitinib* (Xeljanz, Jakvinus) |
| Other agents | | azathioprine*, cyclosporine*, gold salts |

May combine with corticosteroids in induction phase.

- \* agents causing *immunocompromise*
- \+ emerging case reports of *MRONJ* association
- *Associated with DMARDs*</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="00:10:32" confidence="4" anchor="Targeted (2nd line) | tofacitinib* (Xeljanz, Jakvinus)">

&gt; [!note] Lecturer — Targeted DMARDs
&gt; Targeted agents may produce fewer side effects than broadly immunosuppressive drugs because they act on more specific disease targets.
</insert>
    </audio_inserts>
    <images>
      <img order="0" bbox="92,318,930,603" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="table" path="L8 Musculoskeletal Disorders_figures/img_d69032e85f7e3f6c.webp">
        <description>A three-column table listing rheumatoid arthritis medications categorized by drug class (DMARDs, Other agents) and line of therapy (Conventional, Biological, Targeted), with specific generic and brand names provided for each category.</description>
      </img>
    </images>
  </page>
  <page number="14">
    <text>Arthritis – Dental Implications

| Dental implications (OA + RA) | Oral Manifestations: &lt;br&gt;• Possible TMJ involvement: stiffness, trismus, often asymptomatic &lt;br&gt;• Association with periodontal disease &lt;br&gt;&lt;br&gt;Access: &lt;br&gt;• Patient positioning: Consider neck/knee/back/leg supports; Semi-supine position (if supine uncomfortable) &lt;br&gt;• Timing of appointments: stiffness and pain greater in morning (book short appts in late morning or afternoon) &lt;br&gt;&lt;br&gt;Education: &lt;br&gt;• Reduced manual dexterity: impact on oral self-care; consider TB adaptations &lt;br&gt;&lt;br&gt;Surgical: &lt;br&gt;• Check medication list: &lt;br&gt; - Bleeding implications (e.g. NSAIDs, glucosamine) &lt;br&gt; - Long term corticosteroids (adrenal suppression $\rightarrow$ steroid supplementation) &lt;br&gt;• Patients with prosthetic joints (see next slides) |

![](L8 Musculoskeletal Disorders_figures/img_d8d29efaa69cf0da.webp)</text>
    <formatted_text>Dental implications (OA + RA):

- **Oral Manifestations:**
  - Possible TMJ involvement: stiffness, trismus, often asymptomatic
  - Association with periodontal disease
- **Access:**
  - Patient positioning: consider neck/knee/back/leg supports; semi-supine position (if supine uncomfortable)
  - Timing of appointments: stiffness and pain greater in morning (book short appts in late morning or afternoon)
- **Education:**
  - Reduced manual dexterity: impact on oral self-care; consider TB adaptations
- **Surgical:**
  - Check medication list:
    - Bleeding implications (e.g. NSAIDs, glucosamine)
    - Long term corticosteroids (adrenal suppression → steroid supplementation)
  - Patients with prosthetic joints (see next slides)</formatted_text>
    <audio_inserts count="2">
      <insert timestamp="00:11:45" confidence="3" anchor="Timing of appointments: stiffness and pain greater in morning (book short appts ">
    - ==Gradually recline the chair and check comfort at intervals; use towels, cushions or neck supports where appropriate.==</insert>
      <insert timestamp="00:12:40" confidence="5" anchor="Reduced manual dexterity: impact on oral self-care; consider TB adaptations">
    - ==Patients may need assistance with toothbrushing and interproximal cleaning.==</insert>
    </audio_inserts>
    <images>
      <img order="0" bbox="31,230,956,841" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="table" path="L8 Musculoskeletal Disorders_figures/img_d8d29efaa69cf0da.webp">
        <description>A two-column table titled 'Dental implications (OA + RA)' that lists clinical considerations under the headings Oral Manifestations, Access, Education, and Surgical. The content details management strategies such as patient positioning, appointment timing, medication checks for bleeding risks, and steroid supplementation.</description>
      </img>
    </images>
  </page>
  <page number="15">
    <text>Arthritis – Dental Implications

Additional for RA

Oral Manifestations:
• Increased predisposition for Sjögren syndrome → increased dental caries and oral candidiasis risk
• Severe cases: AOB, OSA
• Oral adverse effects of medications (see table): e.g. stomatitis, MRONJ associations

Surgery:
• GA: difficult intubation, dislocation atlanto-axial joint or dens # (avoid sudden jerking extension of the neck)

Spread:
• Immunosuppression: increased risk oral candidiasis, treat infections aggressively, ?surgical antibiotic prophylaxis

![](L8 Musculoskeletal Disorders_figures/img_da898bcb8e69eb11.webp)</text>
    <formatted_text>Additional for RA:

- **Oral Manifestations:**
  - Increased predisposition for Sjögren syndrome → increased dental caries and oral candidiasis risk
  - Severe cases: AOB, OSA
  - Oral adverse effects of medications (see table): e.g. stomatitis, MRONJ associations
- **Surgery:**
  - GA: difficult intubation, dislocation atlanto-axial joint or dens # (avoid sudden jerking extension of the neck)
- **Spread:**
  - Immunosuppression: increased risk oral candidiasis, treat infections aggressively, ?surgical antibiotic prophylaxis</formatted_text>
    <audio_inserts count="2">
      <insert timestamp="00:14:03" confidence="3" anchor="GA: difficult intubation, dislocation atlanto-axial joint or dens # (avoid sudde">

&gt; [!note] Lecturer — Anaesthetic Risk
&gt; Intubation and positioning may be hazardous when rheumatoid arthritis affects the atlantoaxial joint or dens. This is particularly important during general anaesthesia because the patient cannot provide feedback about discomfort.
</insert>
      <insert timestamp="00:17:36" confidence="5" anchor="- **Bone**  - **Primary osteoporosis:** androgen-oestrogen deficiency, lack of V">

&gt; [!note] Lecturer — RANK Pathway Dysregulation
&gt; Dysregulation of the RANK–RANK ligand pathway contributes to osteoporosis.
&gt;
&gt; - Possible influences include ageing, changes in the cytokine environment and oestrogen deficiency.
</insert>
    </audio_inserts>
    <images>
      <img order="0" bbox="66,238,954,798" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="table" path="L8 Musculoskeletal Disorders_figures/img_da898bcb8e69eb11.webp">
        <description>A two-column text table with a header cell labeled 'Additional for RA' and a body listing clinical considerations categorized under Oral Manifestations, Surgery, and Spread.</description>
      </img>
    </images>
  </page>
  <page number="16">
    <text>Prosthetic joints

• Is surgical antibiotic prophylaxis indicated for patient with a pre-existing joint prosthesis?

Guidelines / Antibiotic / Surgical prophylaxis / Principles of surgical antibiotic prophylaxis

**Principles of surgical antibiotic prophylaxis**

Is surgical antibiotic prophylaxis indicated for patients with a pre-existing joint prosthesis?

Although surgical procedures can result in incidental bacteraemia, there is a low risk of seeding of the joint prosthesis and subsequent infection. Accumulated evidence supports the same approach to surgical antibiotic prophylaxis for patients with and without a pre-existing joint prosthesis; neither the indication for prophylaxis nor the choice of antibiotic regimen is altered by the presence of a joint prosthesis. This is true even for procedures that commonly cause bacteraemia (eg tooth extractions, periodontal procedures, cystoscopy, insertion of an indwelling urinary catheter, perforating dermatological procedures). For patients with pre-existing joint prosthesis, the potential adverse effects of prophylaxis outweigh the potential benefits unless indicated [Note 4] [30].

Only give surgical antibiotic prophylaxis to patients with a pre-existing joint prosthesis if prophylaxis is indicated.

Note 4: For a detailed discussion of prevention of prosthetic joint infection in patients undergoing dental procedures, see the American Dental Association Council on Scientific Affairs evidence-based guideline on prevention of orthopaedic implant infection in patients undergoing dental procedures.

*Upcoming lecture:*
*Antibiotic Prophylaxis*</text>
    <formatted_text>Is surgical antibiotic prophylaxis indicated for patients with a pre-existing joint prosthesis?

#### Principles of Surgical Antibiotic Prophylaxis

Although surgical procedures can result in incidental bacteraemia, there is a low risk of seeding of the joint prosthesis and subsequent infection. Accumulated evidence supports the same approach to surgical antibiotic prophylaxis for patients with and without a pre-existing joint prosthesis; neither the indication for prophylaxis nor the choice of antibiotic regimen is altered by the presence of a joint prosthesis. This is true even for procedures that commonly cause bacteraemia (e.g. tooth extractions, periodontal procedures, cystoscopy, insertion of an indwelling urinary catheter, perforating dermatological procedures). For patients with pre-existing joint prosthesis, the potential adverse effects of prophylaxis outweigh the potential benefits unless indicated [Note 4] [30].

&gt; Only give surgical antibiotic prophylaxis to patients with a pre-existing joint prosthesis if prophylaxis is indicated.

Note 4: For a detailed discussion of prevention of prosthetic joint infection in patients undergoing dental procedures, see the American Dental Association Council on Scientific Affairs evidence-based guideline on prevention of orthopaedic implant infection in patients undergoing dental procedures.

*Upcoming lecture: Antibiotic Prophylaxis*</formatted_text>
  </page>
  <page number="17">
    <text>Prosthetic joints

Is surgical antibiotic prophylaxis indicated for patient with a pre-existing joint prosthesis?

American Dental Association Council on Scientific Affairs evidence-based guideline on prevention of orthopaedic implant infection in patients undergoing dental procedures.

https://www.ada.org/resources/research/science/evidence-based-dental-research/antibiotics-to-prevent-prosthetic-joint-infection/

17

SHARED DECISION-MAKING IS THE STANDARD

Patient’s overall health &amp; medical status
Recovery progress and healing
Risk factors for infection or complications
Urgency and nature of the dental condition
Patient values and preferences

Work with the patient and their orthopedic provider when needed to determine the best timing for care.

The ADA DOES NOT support any standard time frame for delaying dental care after joint replacement.

ROUTINE ANTIBIOTICS are usually NOT INDICATED for patients with prosthetic joints.

CLINICAL EVALUATION
For Patients with Prosthetic Joints undergoing Dental Procedure
INDIVIDUALIZE · COLLABORATE · DOCUMENT

Does the patient have a prosthetic joint?
Consult orthopedic provider if uncertain.

YES

MOVE AWAY FROM “AUTOMATIC PRESCRIBING OF ANTIBIOTICS”
Current evidence shows no proven benefit of routine antibiotic prophylaxis in preventing prosthetic joint infection for patients undergoing dental procedures. JADA, 2026.

Minimal evidence of benefit with chances of
Antibiotic resistance
Adverse drug reactions
C. difficile infection

Does the Patient have High-Risk Medical Factors?
• History of complications with joint replacement
• Immunocompromised status

NO
Most dental procedures are low risk for causing prosthetic joint infection. Focus On:
• Excellent Oral Hygiene
• Prevention and treatment of oral disease to reduce bacteremia

YES
Initiate SHARED DECISION-MAKING
Dentist + Patient + Orthopedic Provider collaborate
✔ Discuss patient values &amp; concerns
✔ Review medical history &amp; joint status
✔ Consider risks vs. benefits
✔ Make a joint decision on antibiotic prophylaxis

Chairside Script (Quick Use)
“Current evidence shows antibiotics aren’t routinely needed for joint replacements. Let’s review your health history and decide together what’s safest for you.”

Documentation Tip
Document the conversation, factors considered, who was involved in the decision, and the final plan.

Source: Shared decision making in oral health care for patients with prosthetic joint replacements. American Dental Association Council on Scientific Affairs position statement. Journal of the American Dental Association, 2026.

© 2026 American Dental Association. All Rights Reserved. Updated: 6/11/26
ADA American Dental Association®</text>
    <formatted_text>Is surgical antibiotic prophylaxis indicated for patients with a pre-existing joint prosthesis?

American Dental Association Council on Scientific Affairs evidence-based guideline on prevention of orthopaedic implant infection in patients undergoing dental procedures: https://www.ada.org/resources/research/science/evidence-based-dental-research/antibiotics-to-prevent-prosthetic-joint-infection/

#### Shared Decision-Making Is the Standard

Consider:
- Patient's overall health &amp; medical status
- Recovery progress and healing
- Risk factors for infection or complications
- Urgency and nature of the dental condition
- Patient values and preferences

Work with the patient and their orthopedic provider when needed to determine the best timing for care.

&gt; The ADA does not support any standard time frame for delaying dental care after joint replacement. Routine antibiotics are usually not indicated for patients with prosthetic joints.

#### Clinical Evaluation — For Patients with Prosthetic Joints Undergoing Dental Procedure (Individualize · Collaborate · Document)

Does the patient have a prosthetic joint? Consult orthopedic provider if uncertain.

- **Move away from &quot;automatic prescribing of antibiotics&quot;** — current evidence shows no proven benefit of routine antibiotic prophylaxis in preventing prosthetic joint infection for patients undergoing dental procedures (JADA, 2026). Minimal evidence of benefit with chances of:
  - Antibiotic resistance
  - Adverse drug reactions
  - C. difficile infection
- **Does the patient have high-risk medical factors?**
  - History of complications with joint replacement
  - Immunocompromised status
- **No:** Most dental procedures are low risk for causing prosthetic joint infection. Focus on excellent oral hygiene; prevention and treatment of oral disease to reduce bacteremia.
- **Yes:** Initiate shared decision-making — dentist + patient + orthopedic provider collaborate:
  - Discuss patient values &amp; concerns
  - Review medical history &amp; joint status
  - Consider risks vs. benefits
  - Make a joint decision on antibiotic prophylaxis

**Chairside script (quick use):** &quot;Current evidence shows antibiotics aren't routinely needed for joint replacements. Let's review your health history and decide together what's safest for you.&quot;

**Documentation tip:** Document the conversation, factors considered, who was involved in the decision, and the final plan.

*Source: Shared decision making in oral health care for patients with prosthetic joint replacements. American Dental Association Council on Scientific Affairs position statement. Journal of the American Dental Association, 2026.*

*© 2026 American Dental Association. All Rights Reserved. Updated: 6/11/26.*</formatted_text>
    <images>
      <img order="0" bbox="552,176,579,208" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="clipart">
        <description>A blue icon depicting a stylized person surrounded by two curved arrows forming a circle, symbolizing collaboration or a shared decision-making process.</description>
      </img>
      <img order="1" bbox="647,174,663,211" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="clipart">
        <description>A stylized blue line-art icon depicting a knee joint, used as a decorative symbol for prosthetic joints.</description>
      </img>
      <img order="2" bbox="737,177,765,208" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="clipart">
        <description>A blue triangular warning sign with an exclamation mark inside.</description>
      </img>
      <img order="3" bbox="841,176,862,208" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="clipart">
        <description>A simple blue line drawing of a molar tooth.</description>
      </img>
      <img order="4" bbox="921,176,958,208" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="clipart">
        <description>A simple blue line-art icon depicting two overlapping speech bubbles.</description>
      </img>
      <img order="5" bbox="531,289,563,330" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="clipart">
        <description>A white icon depicting a calendar with a clock overlay, set against a blue background.</description>
      </img>
      <img order="6" bbox="739,520,754,541" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="clipart">
        <description>A small, low-resolution blue icon depicting a stylized microorganism or bacterium with spiky edges and internal circular structures.</description>
      </img>
      <img order="7" bbox="737,544,754,563" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="clipart">
        <description>A blue, stylized icon resembling a chain link or an abstract looped shape.</description>
      </img>
      <img order="8" bbox="736,566,754,589" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="clipart">
        <description>A small, blue outline icon resembling a question mark or a stylized symbol.</description>
      </img>
      <img order="9" bbox="542,762,569,802" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="clipart">
        <description>A blue line-art icon depicting a tooth enclosed within a shield outline.</description>
      </img>
      <img order="10" bbox="937,291,964,328" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="clipart">
        <description>A white icon depicting a magnifying glass with a pill inside, set against a dark blue background.</description>
      </img>
      <img order="11" bbox="912,364,934,389" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="clipart">
        <description>A blue outline of a speech bubble containing three horizontal dots.</description>
      </img>
      <img order="12" bbox="914,557,935,583" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="clipart">
        <description>A blue icon depicting a pencil writing on or editing a document, commonly used to represent the concept of documentation.</description>
      </img>
    </images>
  </page>
  <page number="18">
    <text>**Bone**
**disorders**

Osteopenia, Osteoporosis

18

![](L8 Musculoskeletal Disorders_figures/img_3eb8d6bed071daea.webp)</text>
    <formatted_text>Osteopenia, Osteoporosis</formatted_text>
    <images>
      <img order="0" bbox="407,164,915,834" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="figure" path="L8 Musculoskeletal Disorders_figures/img_3eb8d6bed071daea.webp">
        <description>A 3D rendered illustration of trabecular bone structure, showing a porous network of thin bony struts and large voids. This visualizes the loss of bone density characteristic of osteoporosis.</description>
      </img>
    </images>
  </page>
  <page number="19">
    <text># Osteopenia and Osteoporosis

Definition: Loss of bone mineral density characterised by reduced mineralised bone mass, especially common in older women.

• Osteopenia: Bone densitometry: BMD 1 to 2.5 standard deviations (T score -1 to -2.5) below the peak bone mass of a 25yo individual.
   • precursor to osteoporosis

• Osteoporosis: Bone densitometry: BMD &gt;2.5 standard deviations (T score &lt; -2.5) below the peak bone mass of a 25yo individual.

![HEALTHY OSTEOPENIA OSTEOPOROSIS SEVERE OSTEOPOROSIS](L8 Musculoskeletal Disorders_figures/img_a33354ac9a86c385.webp)</text>
    <formatted_text>**Definition:** Loss of bone mineral density characterised by reduced mineralised bone mass, especially common in older women.

- **Osteopenia:** Bone densitometry: BMD 1 to 2.5 standard deviations (T score -1 to -2.5) below the peak bone mass of a 25yo individual.
  - Precursor to osteoporosis

- **Osteoporosis:** Bone densitometry: BMD &gt;2.5 standard deviations (T score &lt; -2.5) below the peak bone mass of a 25yo individual.</formatted_text>
    <images>
      <img order="0" bbox="491,616,846,848" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="figure" path="L8 Musculoskeletal Disorders_figures/img_a33354ac9a86c385.webp" caption="HEALTHY OSTEOPENIA OSTEOPOROSIS SEVERE OSTEOPOROSIS">
        <description>A comparative illustration showing four cross-sections of the proximal femur to demonstrate progressive bone loss. The specimens are labeled 'HEALTHY', 'OSTEOPENIA', 'OSTEOPOROSIS', and 'SEVERE OSTEOPOROSIS', visually depicting a transition from dense internal trabecular structure in the healthy bone to increasingly porous and sparse bone mass in the severe osteoporosis stage.</description>
      </img>
    </images>
  </page>
  <page number="20">
    <text>Osteoporosis - Aetiology

Metabolic bone disease that results
from an imbalance in osteoblastic
and osteoclastic activities.

STROMAL CELL / OSTEОBLAST
Osteoprotegerin (blocks RANK-RANK ligand interaction)
M-CSF
M-CSF receptor
RANK ligand
RANK (receptor)
OSTEOCLAST PRECURSOR
NFκB
Differentiation
OSTEOCLAST
RANK
BONE

![](L8 Musculoskeletal Disorders_figures/img_a7614f014b9ff4ab.webp)</text>
    <formatted_text>Metabolic bone disease that results from an imbalance in osteoblastic and osteoclastic activities.

#### RANK–RANK Ligand Pathway

- **Stromal cell / osteoblast**
  - Osteoprotegerin (blocks RANK–RANK ligand interaction)
  - M-CSF
  - M-CSF receptor
  - RANK ligand
- **Osteoclast precursor**
  - RANK (receptor)
  - NFκB
  - Differentiation
- **Osteoclast**
  - RANK
  - Bone</formatted_text>
    <images>
      <img order="0" bbox="563,256,909,828" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="diagram" path="L8 Musculoskeletal Disorders_figures/img_a7614f014b9ff4ab.webp">
        <description>A schematic diagram illustrating the cellular interactions involved in osteoclast differentiation and bone resorption. It depicts a stromal cell/osteoblast interacting with an osteoclast precursor via RANK ligand, M-CSF, and Osteoprotegerin, leading to NFκB activation and subsequent maturation into an osteoclast attached to bone.</description>
      </img>
    </images>
  </page>
  <page number="21">
    <text>Osteoporosis - Aetiology

• Primary osteoporosis: androgen-oestrogen deficiency, lack of Vit D, lack of exercise
• Secondary osteoporosis: corticosteroid use, hyperparathyroidism, diabetes, chronic liver disease, malabsorption or hyperthyroidism, excessive smoking/alcohol

![4 Osteoporosis.](L8 Musculoskeletal Disorders_figures/img_391dc697490b921f.webp)
![](L8 Musculoskeletal Disorders_figures/img_86818e0684ddf6f8.webp)</text>
    <formatted_text>- **Primary osteoporosis:** androgen-oestrogen deficiency, lack of Vit D, lack of exercise
- **Secondary osteoporosis:** corticosteroid use, hyperparathyroidism, diabetes, chronic liver disease, malabsorption or hyperthyroidism, excessive smoking/alcohol</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="00:18:18" confidence="7" anchor="Secondary osteoporosis: corticosteroid use, hyperparathyroidism, diabetes, chron">

&gt; [!note] Lecturer — Bone Loss Over Time
&gt; Bone formation during the first approximately 28 years of life and subsequent bone remodelling influence later osteopenia and osteoporosis.
&gt;
&gt; - From approximately 30 years of age, bone loss may occur at about 1% per year.
&gt; - Bone loss may increase to approximately 5% per year after menopause.
</insert>
    </audio_inserts>
    <images>
      <img order="0" bbox="652,306,948,745" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="diagram" path="L8 Musculoskeletal Disorders_figures/img_391dc697490b921f.webp" caption="4 Osteoporosis.">
        <description>A labelled schematic of a long bone (femur) flanked by two lists categorizing the causes of osteoporosis. The left column under 'Primary' lists Heredity, Gender, Race, and Age, while the right column under 'Secondary' lists factors such as Endocrine disease, Disuse, Smoking, Drugs, and Nutrition.</description>
      </img>
      <img order="1" bbox="746,301,832,732" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="figure" path="L8 Musculoskeletal Disorders_figures/img_86818e0684ddf6f8.webp">
        <description>Line drawing of a long bone, specifically the femur, illustrating its proximal head and neck and distal condyles. The visual serves as an anatomical reference for the skeletal system affected by osteoporosis.</description>
      </img>
    </images>
  </page>
  <page number="22">
    <text># Osteoporosis - Clinical Manifestations

• Usually asymptomatic.
• Increased bone fragility $\rightarrow$
  • vertebral crush fractures
  • femoral neck, distal radius, humerus fractures
  • Hip fractures: 20% one-year mortality risk in older adults
• Persistent lower back pain
• Kyphosis and loss of height

![Healthy spine](L8 Musculoskeletal Disorders_figures/img_09fe80745c25426b.webp)
![Weakened spine](L8 Musculoskeletal Disorders_figures/img_b130ebb79d550357.webp)</text>
    <formatted_text>- Usually asymptomatic.
- Increased bone fragility →
  - Vertebral crush fractures
  - Femoral neck, distal radius, humerus fractures
  - Hip fractures: 20% one-year mortality risk in older adults
- Persistent lower back pain
- Kyphosis and loss of height</formatted_text>
    <images>
      <img order="0" bbox="594,387,745,708" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="diagram" path="L8 Musculoskeletal Disorders_figures/img_09fe80745c25426b.webp" caption="Healthy spine">
        <description>An anatomical illustration of a healthy spine in lateral view, showing the natural curvature and intact vertebral bodies. A label identifies the 'Vertebra', pointing to one of the stacked bones separated by intervertebral discs.</description>
      </img>
      <img order="1" bbox="757,392,911,705" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="figure" path="L8 Musculoskeletal Disorders_figures/img_b130ebb79d550357.webp" caption="Weakened spine">
        <description>An anatomical illustration of a spinal segment showing a vertebral body with a wedge-shaped deformity and red fracture lines, labeled 'Wedge fracture'. This depicts the structural collapse associated with osteoporosis.</description>
      </img>
    </images>
  </page>
  <page number="23">
    <text>&lt;h2&gt;Osteoporosis – General Management&lt;/h2&gt;

&lt;table&gt;
  &lt;tr&gt;
    &lt;th style=&quot;background-color:#f0ad4e; color:white;&quot;&gt;Prevention&lt;/th&gt;
    &lt;th style=&quot;background-color:#5cb85c; color:white;&quot;&gt;Treatment&lt;/th&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style=&quot;padding: 10px;&quot;&gt;
      &lt;ul&gt;
        &lt;li&gt;Weight-bearing exercise&lt;/li&gt;
        &lt;li&gt;Calcium supplementation (dairy, green veg)&lt;/li&gt;
        &lt;li&gt;Hormone replacement therapy (HRT)&lt;/li&gt;
        &lt;li&gt;Avoiding risk factors&lt;/li&gt;
      &lt;/ul&gt;
    &lt;/td&gt;
    &lt;td style=&quot;padding: 10px;&quot;&gt;
      &lt;ul&gt;
        &lt;li&gt;Calcitonin&lt;/li&gt;
        &lt;li&gt;Vitamin D&lt;/li&gt;
        &lt;li&gt;Bisphosphonates&lt;/li&gt;
        &lt;li&gt;Denosumab&lt;/li&gt;
      &lt;/ul&gt;
    &lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;</text>
    <formatted_text>#### Prevention

- Weight-bearing exercise
- Calcium supplementation (dairy, green veg)
- Hormone replacement therapy (HRT)
- Avoiding risk factors

#### Treatment

- Calcitonin
- Vitamin D
- Bisphosphonates
- Denosumab</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="00:18:30" confidence="10" anchor="Hormone replacement therapy (HRT) - Avoiding risk factors">
    - ==During the first 20 years of life, bone formation is the major protective factor; later, prevention of bone loss becomes more important.==</insert>
    </audio_inserts>
  </page>
  <page number="24">
    <text>Osteoporosis – Dental Implications

Association with periodontitis: 2017 world workshop (AAP+ EFP)
• Albandar JM, Susin C, Hughes FJ. Manifestations of systemic diseases and conditions that affect the periodontal attachment apparatus: Case definitions and diagnostic considerations. J Periodontol. 2018 Jun;89 Suppl 1:S183-S203.

| Disorder | Strength of association | Quality of evidence | Biologic mechanisms | Case definitions | Diagnostic considerations |
| :--- | :--- | :--- | :--- | :--- | :--- |
| Osteoporosis | Significant | Animal models, surveys, longitudinal follow-up, case- control study, systematic reviews | Increased bone turnover leading to net bone loss, which can also be associated with other factors (such as estrogen level, vitamin D and calcium deficiency, lifestyle and behavioral factors) | • Decrease in bone mineral density and weakening of bone microarchitecture, leading to a high risk for bone fracture&lt;br&gt;• Higher prevalence and severity of radiographic alveolar bone loss&lt;br&gt;• No clear association with periodontitis (probing depth or clinical attachment loss) | • Clinical diagnosis |

• Imaging: Jaws are thinned and granular. Lamina dura appears thinned. Maxillary sinus may extend between roots of molars. OPG may display spinal osteoporosis.

![](L8 Musculoskeletal Disorders_figures/img_f4649a6c4fe1539a.webp)</text>
    <formatted_text>#### Association with Periodontitis: 2017 World Workshop (AAP + EFP)

*Albandar JM, Susin C, Hughes FJ. Manifestations of systemic diseases and conditions that affect the periodontal attachment apparatus: Case definitions and diagnostic considerations. J Periodontol. 2018 Jun;89 Suppl 1:S183-S203.*

| Disorder | Strength of association | Quality of evidence | Biologic mechanisms | Case definitions | Diagnostic considerations |
| :--- | :--- | :--- | :--- | :--- | :--- |
| Osteoporosis | Significant | Animal models, surveys, longitudinal follow-up, case-control study, systematic reviews | Increased bone turnover leading to net bone loss, which can also be associated with other factors (such as estrogen level, vitamin D and calcium deficiency, lifestyle and behavioral factors) | • Decrease in bone mineral density and weakening of bone microarchitecture, leading to a high risk for bone fracture&lt;br&gt;• Higher prevalence and severity of radiographic alveolar bone loss&lt;br&gt;• No clear association with periodontitis (probing depth or clinical attachment loss) | • Clinical diagnosis |

#### Imaging

Jaws are thinned and granular. Lamina dura appears thinned. Maxillary sinus may extend between roots of molars. OPG may display spinal osteoporosis.</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="00:19:36" confidence="7" anchor="Jaws are thinned and granular. Lamina dura appears thinned. Maxillary sinus may ">

&gt; [!note] Lecturer — Dental Associations
&gt; Osteoporosis has been associated with periodontitis in women, excessive alveolar bone loss, pathological fracture and possible effects involving the jaw bones.
&gt;
&gt; - Treatment of systemic osteoporosis might improve some aspects of jaw-bone osteoporosis in older adults.
&gt; - Dental implications include extractions, denture fit and implant placement.
</insert>
    </audio_inserts>
    <images>
      <img order="0" bbox="40,502,939,684" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="table" path="L8 Musculoskeletal Disorders_figures/img_f4649a6c4fe1539a.webp">
        <description>A table summarizing the association between osteoporosis and periodontitis, categorized by strength of association, quality of evidence, biologic mechanisms, case definitions, and diagnostic considerations.</description>
      </img>
    </images>
  </page>
  <page number="25">
    <text># Osteoporosis – Dental Implications

*   **Oral Manifestation:**
    *   Association with periodontitis
    *   Radiographic findings
*   **Access**
    *   Provide adequate mobility and positioning support (depending on severity of OP)
*   **Surgery**
    *   MRONJ risk (bone modifying drugs) – extractions, dentures, implants

25 Presentation title 20XX</text>
    <formatted_text>- **Oral manifestation:**
  - Association with periodontitis
  - Radiographic findings
- **Access:**
  - Provide adequate mobility and positioning support (depending on severity of OP)
- **Surgery:**
  - MRONJ risk (bone modifying drugs) – extractions, dentures, implants</formatted_text>
  </page>
  <page number="26">
    <text>**Bone Modifying Drugs**

26

![](L8 Musculoskeletal Disorders_figures/img_40b6e64abe40f6c6.webp)</text>
    <images>
      <img order="0" bbox="394,152,921,843" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="L8 Musculoskeletal Disorders_figures/img_40b6e64abe40f6c6.webp">
        <description>A product photograph showing a box of Prolia (denosumab) 60 mg/mL injection with a pre-filled syringe resting on top. The packaging identifies the drug as an Amgen product for subcutaneous use only, illustrating a specific bone-modifying agent.</description>
      </img>
    </images>
  </page>
  <page number="27">
    <text>A common referral to the dental clinic...

Consult - Dental - for Ongoing poor dental hygiene and care. Will need ongoing review and guidance with maintenance. Possibility of osteo medications that may require further follow up in the future. Thank you kindly
Consult Progress: Requested

Consult - Dental - for 89F from home w/ daughter, admitted for #NoF due to mechanical fall. Poor dentition. Ceased denosumab 1/52 ago. Seen by orthogeriatrics who would like to assess for suitability of resuming denosumab
Priority Level: Non-Urgent
Consult Progress: Requested</text>
    <formatted_text>A common referral to the dental clinic...

&gt; Consult - Dental - for ongoing poor dental hygiene and care. Will need ongoing review and guidance with maintenance. Possibility of osteo medications that may require further follow up in the future. Thank you kindly.
&gt;
&gt; Consult Progress: Requested

&gt; Consult - Dental - for 89F from home w/ daughter, admitted for #NoF due to mechanical fall. Poor dentition. Ceased denosumab 1/52 ago. Seen by orthogeriatrics who would like to assess for suitability of resuming denosumab.
&gt;
&gt; Priority Level: Non-Urgent
&gt;
&gt; Consult Progress: Requested</formatted_text>
  </page>
  <page number="28">
    <text>Example referrals to a SND clinic…

| | |
| :--- | :--- |
| Reason for referral | Broken lower right second incisor - below gum line |
| Full medical history and diagnoses | Advanced myeloma on bisphosphonates, |
| Medication list | Pomalidomide, Zometa, Dexamethasone, Targin, duloxetine |
| Dental history, including any dental treatment attempted | Dentist usually manages most care - OPG available on intelliviewre |

64 YO M Admitted under Haematology [ ] for CAR T Cell Monitoring CARTITUDE10 Trial

===PMHx===
1.Multiple myeloma diagnosed November 2025.
1.1Pancytopenia, leukoerythroblastic blood film, large IgA paraprotein.
1.2 Bonemarrow shows diffuse myeloma.
1.3Compression fractures in the spine.
1.4Commenced VRd therapy (Dr Hutchinson).
1.5Consented for CARTITUDE-10 clinical trial.
2.Osteoporosis.
3. Fatty liver disease.
4.Hyperlipidaemia.
5.Ischaemic heart disease, on aspirin therapy
6. Atraumatic compression fractures T5, T7, T12, L1, L5. (fromapproximately February 2025)
6.1 Multipleprevious vertebroplasties

On review today raised concern of loose tooth, right molar.

On examination:
Loose right upper molar
Nil petechiae
Nil jaw pain
Nil fevers
Isolated area of gum recession
Nil other loose teeth

We have requested a OPG prior to discharge and would appreciate a review from yourselves given the patients active immunotherapy and neutropaenia

Bloods
Neut 0.64
Hb 105
Lymp 0.16

![Reason for referral Broken lower right second incisor - below gum line Full medical history and diagnoses Advanced myeloma on bisphosphonates, Medication list Pomalidomide, Zometa, Dexamethasone, Targin, duloxetine Dental history, including any dental treatment attempted Dentist usually manages most care - OPG available on intelliviewre](L8 Musculoskeletal Disorders_figures/img_974a36d2369b9405.webp)</text>
    <formatted_text>Example referrals to a SND clinic…

- **Reason for referral:** Broken lower right second incisor - below gum line
- **Full medical history and diagnoses:** Advanced myeloma on bisphosphonates
- **Medication list:** Pomalidomide, Zometa, Dexamethasone, Targin, duloxetine
- **Dental history, including any dental treatment attempted:** Dentist usually manages most care - OPG available on intelliviewer

64 YO M admitted under Haematology for CAR T Cell Monitoring CARTITUDE10 Trial

**PMHx:**

1. Multiple myeloma diagnosed November 2025.
   - Pancytopenia, leukoerythroblastic blood film, large IgA paraprotein.
   - Bone marrow shows diffuse myeloma.
   - Compression fractures in the spine.
   - Commenced VRd therapy (Dr Hutchinson).
   - Consented for CARTITUDE-10 clinical trial.
2. Osteoporosis.
3. Fatty liver disease.
4. Hyperlipidaemia.
5. Ischaemic heart disease, on aspirin therapy.
6. Atraumatic compression fractures T5, T7, T12, L1, L5 (from approximately February 2025).
   - Multiple previous vertebroplasties.

On review today raised concern of loose tooth, right molar.

**On examination:**

- Loose right upper molar
- Nil petechiae
- Nil jaw pain
- Nil fevers
- Isolated area of gum recession
- Nil other loose teeth

We have requested an OPG prior to discharge and would appreciate a review from yourselves given the patient's active immunotherapy and neutropaenia.

**Bloods:**

- Neut 0.64
- Hb 105
- Lymp 0.16</formatted_text>
    <images>
      <img order="0" bbox="30,331,433,668" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="table" path="L8 Musculoskeletal Disorders_figures/img_974a36d2369b9405.webp" caption="Reason for referral Broken lower right second incisor - below gum line Full medical history and diagnoses Advanced myeloma on bisphosphonates, Medication list Pomalidomide, Zometa, Dexamethasone, Targin, duloxetine Dental history, including any dental treatment attempted Dentist usually manages most care - OPG available on intelliviewre">
        <description>A two-column table outlining a patient referral, listing categories such as reason for referral, medical history, medications, and dental history alongside their corresponding details.</description>
      </img>
    </images>
  </page>
  <page number="29">
    <text>MRONJ Definition

1. Current or previous treatment with antiresorptive therapy alone or in combination with immune modulators or anti-angiogenic medications
2. Exposed bone, or bone that can be probed through an intraoral or extraoral fistula in the maxillofacial region that has persisted for more than 8 weeks
3. No history of radiation therapy or no metastatic disease to the jaws.

(AAOMS 2022)

![](L8 Musculoskeletal Disorders_figures/img_ddce2e863d69bfc0.webp)</text>
    <formatted_text>1. Current or previous treatment with antiresorptive therapy alone or in combination with immune modulators or anti-angiogenic medications
2. Exposed bone, or bone that can be probed through an intraoral or extraoral fistula in the maxillofacial region that has persisted for more than 8 weeks
3. No history of radiation therapy or no metastatic disease to the jaws.

(AAOMS 2022)</formatted_text>
    <images>
      <img order="0" bbox="677,377,941,718" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="L8 Musculoskeletal Disorders_figures/img_ddce2e863d69bfc0.webp">
        <description>Clinical photo: An intraoral view showing exposed, necrotic bone in the posterior mandible adjacent to teeth. The yellowish-white sequestrum contrasts with the surrounding pink soft tissue and is consistent with the clinical presentation of osteonecrosis.</description>
      </img>
    </images>
  </page>
  <page number="30">
    <text>Clinical Presentation

Symptoms
• Jaw pain or toothache
• Halitosis
• Numbness or altered sensation (paraesthesia)

Signs
• Exposed bone in mandible or maxilla
• Localised swelling, tenderness of mucosa/gingiva
• Non healing extraction sockets
• Purulent discharge
• Pathological fracture
• Oro-cutaneous fistulae

![](L8 Musculoskeletal Disorders_figures/img_769f16293e984294.webp)
![](L8 Musculoskeletal Disorders_figures/img_9344f5e321a95a42.webp)</text>
    <formatted_text>#### Symptoms

- Jaw pain or toothache
- Halitosis
- Numbness or altered sensation (paraesthesia)

#### Signs

- Exposed bone in mandible or maxilla
- Localised swelling, tenderness of mucosa/gingiva
- Non-healing extraction sockets
- Purulent discharge
- Pathological fracture
- Oro-cutaneous fistulae</formatted_text>
    <images>
      <img order="0" bbox="109,596,252,745" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="L8 Musculoskeletal Disorders_figures/img_769f16293e984294.webp">
        <description>Clinical photo showing the lateral neck and jawline of a patient. A blue arrow points to a distinct linear scar or fistula tract located on the skin below the angle of the mandible.</description>
      </img>
      <img order="1" bbox="256,596,399,745" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="L8 Musculoskeletal Disorders_figures/img_9344f5e321a95a42.webp">
        <description>A cropped panoramic dental radiograph showing the mandible and maxilla. The image reveals multiple teeth with bright white restorations (fillings or crowns) and a distinct area of irregular, mottled bone density in the lower jaw, illustrating pathological changes.</description>
      </img>
    </images>
  </page>
  <page number="31">
    <text>American Association of Oral and Maxillofacial Surgeons’ Position Paper on Medication-Related Osteonecrosis of the Jaws—2022 Update
Salvatore L. Ruggiero, DMD, MD,* Thomas B. Dodson, DMD, MPH,† Tara Agbalao, DDS, MD, PhD,‡ Eric R. Carlson, DMD, MD, EdM,§ Brent B. Ward, DDS, MD,¶ and Deepak Kademani, DMD, MD†

AAOMS 2022 Guidelines

NHS Education for Scotland
Oral Health Management of Patients at Risk of Medication-related Osteonecrosis of the Jaw
Dental Clinical Guidance

SDCEP 2017 Guidelines – Updated 2022

RACGP
HEALTHYBONES AUSTRALIA
Osteoporosis management and fracture prevention in postmenopausal women and men over 50 years of age
March 2024

RACGP 2024 Guidelines

Medication-Related Osteonecrosis of the Jaw: MASCC/ISOO/ASCO Clinical Practice Guideline
Noam Yarom, DMD1,2; Charles L. Shapiro, MD1; Douglas E. Peterson, DMD, PhD3; Catherine H. Van Poznak, MD5; Kari Bohike, ScD6; Salvatore L. Ruggiero, DMD, MD7,8; Cesar A. Migliorati, DDS, MS, PhD9; Aliya Khan, MD10; Archie Morrison, DDS, MSc11,12; Holly Anderson13; Barbara A. Murphy, MD13; Deveria Alton-Johnson, MD, MMH14; Rui Amaral Mendes, DMD, PhD15; Beth Michelle Beadle, MD, PhD16; Sri Beier Jensen, DDS, PhD17; and Deborah P. Saunders, DMD18

Multinational Assoc of Supportive Care in Cancer, International Society of Oral Oncology, American Society of Clinical Oncology 2019

REVIEW
JBMR
Diagnosis and Management of Osteonecrosis of the Jaw: A Systematic Review and International Consensus
Aliya A Khan, Archie Morrison, David A Hanley, Dieter Felsenberg, Laurie K McCauley, Felice O’Ryan, Ian R Reid, Salvatore L Ruggiero, Akira Taguchi, Sotirios Tetrakis, Nelson B Watts, Maria Luisa Brandi, Edmund Peters, Teresa Guise, Richard Eastell, Angela M Cheung, Suzanne N Morin, Basel Masri, Cyrus Cooper, Sarah L Morgan, Barbara Obermayer-Pietsch, Bente L Langdahl, Rana Al Dabagh, K. Shawn Davison, David L Kendler, George K Sándor, Robert G Josse, Mohit Bhandari, Mohamed El Rabbany, Dominique D Pierroz, Riad Sulimani, Deborah P Saunders, Jacques P Brown, and Juliet Compston, on behalf of the International Task Force on Osteonecrosis of the Jaw

International Task Force on ONJ 2015 (ASBMR, AAOMS, CAOMS, CAOMP, ECTS, IBMS, IOF, ISCD, IAOMS, JSBMR, NOF, Osteoporosis Canada, PAOS, TES)

Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis
Executive summary of recommendations from the American Dental Association Council on Scientific Affairs
John W. Hellstein, DDS, MS; Robert A. Adler, MD; Beatrice Edwards, MD; Peter L. Jacobsen, PhD, DDS; John R. Kalmar, DMD, PhD; Sreenivas Koka, DDS, PhD; Cesar A. Migliorati, DDS, MS, PhD; Helen Ristic, PhD; for the American Dental Association Council on Scientific Affairs Expert Panel on Antiresorptive Agents

American Dental Association Council on Scientific Affairs 2011

Healthy Bones Australia
Healthy Bones Australia Consensus Statement: Medication-related Osteonecrosis of the Jaw (MRONJ) and Osteoporosis

Healthy Bones Australia 2026 ANZBMS, ADA, ESA, RHA

Dr Jee-Yun Leung</text>
    <formatted_text>#### AAOMS 2022 Guidelines

*Ruggiero SL, Dodson TB, Agbalao T, Carlson ER, Ward BB, Kademani D. American Association of Oral and Maxillofacial Surgeons' Position Paper on Medication-Related Osteonecrosis of the Jaws—2022 Update.*

#### SDCEP 2017 Guidelines – Updated 2022

*NHS Education for Scotland. Oral Health Management of Patients at Risk of Medication-related Osteonecrosis of the Jaw. Dental Clinical Guidance.*

#### RACGP 2024 Guidelines

*RACGP / Healthy Bones Australia. Osteoporosis management and fracture prevention in postmenopausal women and men over 50 years of age. March 2024.*

#### MASCC/ISOO/ASCO 2019

*Yarom N, Shapiro CL, Peterson DE, Van Poznak CH, Bohike K, Ruggiero SL, Migliorati CA, Khan A, Morrison A, Anderson H, Murphy BA, Alton-Johnson D, Amaral Mendes R, Beadle BM, Beier Jensen S, Saunders DP. Medication-Related Osteonecrosis of the Jaw: MASCC/ISOO/ASCO Clinical Practice Guideline.* Multinational Association of Supportive Care in Cancer, International Society of Oral Oncology, American Society of Clinical Oncology 2019.

#### International Task Force on ONJ 2015 (ASBMR, AAOMS, CAOMS, CAOMP, ECTS, IBMS, IOF, ISCD, IAOMS, JSBMR, NOF, Osteoporosis Canada, PAOS, TES)

*Khan AA, Morrison A, Hanley DA, Felsenberg D, McCauley LK, O'Ryan F, Reid IR, Ruggiero SL, Taguchi A, Tetrakis S, Watts NB, Brandi ML, Peters E, Guise T, Eastell R, Cheung AM, Morin SN, Masri B, Cooper C, Morgan SL, Obermayer-Pietsch B, Langdahl BL, Al Dabagh R, Davison KS, Kendler DL, Sándor GK, Josse RG, Bhandari M, El Rabbany M, Pierroz DD, Sulimani R, Saunders DP, Brown JP, Compston J. Diagnosis and Management of Osteonecrosis of the Jaw: A Systematic Review and International Consensus. JBMR (Review), on behalf of the International Task Force on Osteonecrosis of the Jaw.*

#### American Dental Association Council on Scientific Affairs 2011
*Hellstein JW, Adler RA, Edwards B, Jacobsen PL, Kalmar JR, Koka S, Migliorati CA, Ristic H. Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis. Executive summary of recommendations from the American Dental Association Council on Scientific Affairs.*

#### Healthy Bones Australia 2026 (ANZBMS, ADA, ESA, RHA)

*Healthy Bones Australia Consensus Statement: Medication-related Osteonecrosis of the Jaw (MRONJ) and Osteoporosis.*

Dr Jee-Yun Leung</formatted_text>
  </page>
  <page number="32">
    <text># Bone-Modifying Drugs
## (Anti-Resorptives – Mechanism of Action)

| **Bisphosphonates** | **Denosumab** | **Romosozumab** |
| :--- | :--- | :--- |
| • Inhibits enzymes essential to formation, recruitment and function of osteoclasts | • Fully human monoclonal antibody which inhibits osteoclast function | • Monoclonal antibody |
| • Binds to bone = High affinity for hydroxyapatite | • Binds to receptor activator nuclear κB factor ligand (RANKL) | • Wnt pathway = binds to and inhibits sclerostin (produced by osteocytes) |
| • Persists in skeletal tissue for significant periods (e.g. alendronate ½ life ~10 years) | • Does not bind to bone → effects on bone turnover diminish within 6 months | • Potent bone anabolic agent (builds bone) |
| | | • Very high risk men and post-menopausal women of osteoporotic minimal trauma fracture |

32 Dr Jee-Yun Leung 2025</text>
    <formatted_text>| Bisphosphonates | Denosumab | Romosozumab |
| :--- | :--- | :--- |
| Inhibits enzymes essential to formation, recruitment and function of osteoclasts | Fully human monoclonal antibody which inhibits osteoclast function | Monoclonal antibody |
| Binds to bone = high affinity for hydroxyapatite | Binds to receptor activator nuclear κB factor ligand (RANKL) | Wnt pathway = binds to and inhibits sclerostin (produced by osteocytes) |
| Persists in skeletal tissue for significant periods (e.g. alendronate ½ life ~10 years) | Does not bind to bone → effects on bone turnover diminish within 6 months | Potent bone anabolic agent (builds bone) |
| | | Very high risk men and post-menopausal women of osteoporotic minimal trauma fracture |</formatted_text>
  </page>
  <page number="33">
    <text># Bisphosphonates

**A** Inorganic pyrophosphate &amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; Bisphosphonate
*(Chemical structures shown)*

**B** Etidronate &amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; Clodronate &amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; Tiludronate
*(Chemical structures shown)*
Relative potency &amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 1 &amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 10 &amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 10

**C** Alendronate &amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; Risedronate &amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; Ibandronate &amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; Pamidronate &amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; Zoledronic acid
*(Chemical structures shown)*
Relative potency &amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 500 &amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 2000 &amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 1000 &amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 100 &amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 10,000

Bisphosphonate structures and approximate relative potencies$^6$ for osteoclast inhibition.

Non-nitrogenous (1$^{st}$ gen): Direct action on osteoblastic cells to $\uparrow$ bone formation without anti-angiogenic effects
$\rightarrow$ NOT assoc with MRONJ

Nitrogenous (2$^{nd}$ 3$^{rd}$ gen): $\downarrow$ osteoclastic bone resorption by entering osteoclast
$\rightarrow$ assoc with MRONJ</text>
    <formatted_text>#### Chemical Structures and Relative Potency

- **A:** Inorganic pyrophosphate vs Bisphosphonate *(chemical structures shown)*
- **B:** Etidronate, Clodronate, Tiludronate *(chemical structures shown)* — relative potency: 1, 10, 10
- **C:** Alendronate, Risedronate, Ibandronate, Pamidronate, Zoledronic acid *(chemical structures shown)* — relative potency: 500, 2000, 1000, 100, 10,000

Bisphosphonate structures and approximate relative potencies for osteoclast inhibition.

#### Generations and MRONJ Association

- **Non-nitrogenous (1st gen):** Direct action on osteoblastic cells to ↑ bone formation without anti-angiogenic effects → NOT associated with MRONJ
- **Nitrogenous (2nd, 3rd gen):** ↓ osteoclastic bone resorption by entering osteoclast → associated with MRONJ</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="00:51:04" confidence="4" anchor="Bisphosphonate structures and approximate relative potencies for osteoclast inhi">

&gt; [!note] Lecturer — Bisphosphonate Persistence
&gt; Bisphosphonates are commonly prescribed for approximately five to ten years for osteoporosis, but their long terminal persistence means they may remain relevant for approximately ten years afterward.
&gt;
</insert>
    </audio_inserts>
  </page>
  <page number="34">
    <text>Denosumab

Denosumab (Prolia®) – 6 monthly 60mg subcutaneous injection
• Osteoporosis

Denosumab (Xgeva®) – 4 weekly 120mg subcutaneous injection
• Solid cancer metastasis to bone
• Giant cell tumour of bone
• Hypercalcaemia of malignancy

![](L8 Musculoskeletal Disorders_figures/img_c4d71b609a7de06e.webp)
![](L8 Musculoskeletal Disorders_figures/img_32eb3c84c39f6780.webp)</text>
    <formatted_text>- **Denosumab (Prolia®)** – 6 monthly 60 mg subcutaneous injection
  - Osteoporosis
- **Denosumab (Xgeva®)** – 4 weekly 120 mg subcutaneous injection
  - Solid cancer metastasis to bone
  - Giant cell tumour of bone
  - Hypercalcaemia of malignancy</formatted_text>
    <images>
      <img order="0" bbox="494,360,775,522" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="L8 Musculoskeletal Disorders_figures/img_c4d71b609a7de06e.webp">
        <description>A photograph of the commercial packaging for Prolia (denosumab) 60 mg/mL, showing the product box and a pre-filled syringe.</description>
      </img>
      <img order="1" bbox="697,594,901,797" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="L8 Musculoskeletal Disorders_figures/img_32eb3c84c39f6780.webp">
        <description>A product photograph showing a box of Amgen's XGEVA (denosumab), accompanied by a single-use vial and a pre-filled syringe. The packaging prominently displays the brand name, generic drug name, dosage strength of 120 mg/1.7 mL, and 'Rx Only' designation.</description>
      </img>
    </images>
  </page>
  <page number="35">
    <text># Other drugs associated with MRONJ

| | |
| :--- | :--- |
| Well-documented | • Antiangiogenic drugs: bevacizumab, sunitinib, aflibercept |
| Possible association | • protein kinase inhibitors: axitinib, cabozantinib, dasatinib, everolimus, imatinib, osimertinib, pazopanib, regorafenib, sorafenib, temsirolimus&lt;br&gt;• monoclonal antibodies: adalimumab, infliximab, ipilimumab, nivolumab, ranibizumab, rituximab, romosozumab, tocilizumab&lt;br&gt;• antimetabolites: azacitidine, methotrexate&lt;br&gt;• tumour necrosis factor alpha inhibitor: etanercept. |

Scottish Dental Clinical Effectiveness Programme. Oral Health Management of Patients at Risk of Medication-related Osteonecrosis of the Jaw – Supplement March 2024 [Internet]. NHS Education for Scotland; 2024. Available from: https://www.sdcep.org.uk/media/d0sb4flf/sdcep-mronj-guidance-supplement_march-2024.pdf

35 Dr Jee-Yun Leung 2025</text>
    <formatted_text>- **Well-documented:**
  - Antiangiogenic drugs: bevacizumab, sunitinib, aflibercept
- **Possible association:**
  - Protein kinase inhibitors: axitinib, cabozantinib, dasatinib, everolimus, imatinib, osimertinib, pazopanib, regorafenib, sorafenib, temsirolimus
  - Monoclonal antibodies: adalimumab, infliximab, ipilimumab, nivolumab, ranibizumab, rituximab, romosozumab, tocilizumab
  - Antimetabolites: azacitidine, methotrexate
  - Tumour necrosis factor alpha inhibitor: etanercept

*Scottish Dental Clinical Effectiveness Programme. Oral Health Management of Patients at Risk of Medication-related Osteonecrosis of the Jaw – Supplement March 2024 [Internet]. NHS Education for Scotland; 2024. Available from: https://www.sdcep.org.uk/media/d0sb4flf/sdcep-mronj-guidance-supplement_march-2024.pdf*</formatted_text>
  </page>
  <page number="36">
    <text>Other drugs associated with MRONJ

36
2025

&lt;table&gt;
  &lt;tr&gt;
    &lt;th colspan=&quot;7&quot;&gt;Table 1. (A) Summary of the cases from the included case reports (n = 29). (B) Summary of the cases from the included cohort study (n = 3).&lt;/th&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;th&gt;&lt;/th&gt;
    &lt;th&gt;Sex, age&lt;/th&gt;
    &lt;th&gt;MAB&lt;/th&gt;
    &lt;th&gt;Indication&lt;/th&gt;
    &lt;th&gt;Jaw&lt;/th&gt;
    &lt;th&gt;MRONJ stage&lt;/th&gt;
    &lt;th&gt;Precipitating factor&lt;/th&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;1A.&lt;/td&gt;
    &lt;td&gt;&lt;/td&gt;
    &lt;td&gt;&lt;/td&gt;
    &lt;td&gt;&lt;/td&gt;
    &lt;td&gt;&lt;/td&gt;
    &lt;td&gt;&lt;/td&gt;
    &lt;td&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;First author (Country)&lt;/td&gt;
    &lt;td&gt;&lt;/td&gt;
    &lt;td&gt;&lt;/td&gt;
    &lt;td&gt;&lt;/td&gt;
    &lt;td&gt;&lt;/td&gt;
    &lt;td&gt;&lt;/td&gt;
    &lt;td&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;Allegra&lt;sup&gt;28&lt;/sup&gt; (Italy)&lt;/td&gt;
    &lt;td&gt;M, 56&lt;/td&gt;
    &lt;td&gt;Rituximab&lt;/td&gt;
    &lt;td&gt;Lymphoma&lt;/td&gt;
    &lt;td&gt;MD&lt;/td&gt;
    &lt;td&gt;2&lt;/td&gt;
    &lt;td&gt;Dental extraction&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;Bettini&lt;sup&gt;29&lt;/sup&gt; (Italy)&lt;/td&gt;
    &lt;td&gt;F, 57&lt;/td&gt;
    &lt;td&gt;Bevacizumab&lt;/td&gt;
    &lt;td&gt;Metastatic lung cancer&lt;/td&gt;
    &lt;td&gt;MD&lt;/td&gt;
    &lt;td&gt;2&lt;/td&gt;
    &lt;td&gt;Dental prosthesis use&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;Binello&lt;sup&gt;30&lt;/sup&gt; (Italy)&lt;/td&gt;
    &lt;td&gt;M, 47&lt;/td&gt;
    &lt;td&gt;Bevacizumab&lt;/td&gt;
    &lt;td&gt;Metastatic adenocarcinoma&lt;/td&gt;
    &lt;td&gt;MD&lt;/td&gt;
    &lt;td&gt;2&lt;/td&gt;
    &lt;td&gt;None identified&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;Decaux&lt;sup&gt;31&lt;/sup&gt; (Belgium)&lt;/td&gt;
    &lt;td&gt;F, 28&lt;/td&gt;
    &lt;td&gt;Pembrolizumab&lt;/td&gt;
    &lt;td&gt;Metastatic melanoma&lt;/td&gt;
    &lt;td&gt;MX&lt;/td&gt;
    &lt;td&gt;2&lt;/td&gt;
    &lt;td&gt;None identified&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;Disel&lt;sup&gt;32&lt;/sup&gt; (Turkey)&lt;/td&gt;
    &lt;td&gt;M, 51&lt;/td&gt;
    &lt;td&gt;Bevacizumab&lt;/td&gt;
    &lt;td&gt;Metastatic colon cancer&lt;/td&gt;
    &lt;td&gt;MD&lt;/td&gt;
    &lt;td&gt;1&lt;/td&gt;
    &lt;td&gt;None identified&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;Estio&lt;sup&gt;33&lt;/sup&gt; (USA)&lt;/td&gt;
    &lt;td&gt;F, 51&lt;/td&gt;
    &lt;td&gt;Bevacizumab&lt;/td&gt;
    &lt;td&gt;Metastatic breast cancer&lt;/td&gt;
    &lt;td&gt;MD&lt;/td&gt;
    &lt;td&gt;1&lt;/td&gt;
    &lt;td&gt;None identified&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;Favia&lt;sup&gt;34&lt;/sup&gt; (Italy)&lt;/td&gt;
    &lt;td&gt;F, 49&lt;/td&gt;
    &lt;td&gt;Infliximab&lt;/td&gt;
    &lt;td&gt;Crohn's disease&lt;/td&gt;
    &lt;td&gt;MD&lt;/td&gt;
    &lt;td&gt;3&lt;/td&gt;
    &lt;td&gt;Dental extraction&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;Ghosh&lt;sup&gt;35&lt;/sup&gt; (USA)&lt;/td&gt;
    &lt;td&gt;F, 86&lt;/td&gt;
    &lt;td&gt;Golimumab&lt;/td&gt;
    &lt;td&gt;Rheumatoid arthritis&lt;/td&gt;
    &lt;td&gt;MD&lt;/td&gt;
    &lt;td&gt;3&lt;/td&gt;
    &lt;td&gt;Dental extraction&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;Greuter&lt;sup&gt;36&lt;/sup&gt; (Switzerland)&lt;/td&gt;
    &lt;td&gt;F, 63&lt;/td&gt;
    &lt;td&gt;Bevacizumab&lt;/td&gt;
    &lt;td&gt;Metastatic breast cancer&lt;/td&gt;
    &lt;td&gt;MX&lt;/td&gt;
    &lt;td&gt;3&lt;/td&gt;
    &lt;td&gt;Dental extraction&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;Guida&lt;sup&gt;37&lt;/sup&gt; (Italy)&lt;/td&gt;
    &lt;td&gt;F, 58&lt;/td&gt;
    &lt;td&gt;Ipilimumab&lt;/td&gt;
    &lt;td&gt;Metastatic melanoma&lt;/td&gt;
    &lt;td&gt;MD&lt;/td&gt;
    &lt;td&gt;2&lt;/td&gt;
    &lt;td&gt;Dental extraction&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;Hopp&lt;sup&gt;38&lt;/sup&gt; (Brazil)&lt;/td&gt;
    &lt;td&gt;M, 58&lt;/td&gt;
    &lt;td&gt;Bevacizumab&lt;/td&gt;
    &lt;td&gt;Retinal vascular thrombosis&lt;/td&gt;
    &lt;td&gt;MD&lt;/td&gt;
    &lt;td&gt;1&lt;/td&gt;
    &lt;td&gt;None identified&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;Keribin&lt;sup&gt;39&lt;/sup&gt; (France)&lt;/td&gt;
    &lt;td&gt;M, 69&lt;/td&gt;
    &lt;td&gt;Rituximab&lt;/td&gt;
    &lt;td&gt;Lymphoma&lt;/td&gt;
    &lt;td&gt;Both&lt;/td&gt;
    &lt;td&gt;1&lt;/td&gt;
    &lt;td&gt;None identified&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;Kolodziejewski&lt;sup&gt;40&lt;/sup&gt; (Brazil)&lt;/td&gt;
    &lt;td&gt;M, 53&lt;/td&gt;
    &lt;td&gt;Infliximab&lt;/td&gt;
    &lt;td&gt;Crohn's disease&lt;/td&gt;
    &lt;td&gt;MD&lt;/td&gt;
    &lt;td&gt;3&lt;/td&gt;
    &lt;td&gt;None identified&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;Magrenanne&lt;sup&gt;41&lt;/sup&gt;&lt;br&gt;(Belgium)&lt;/td&gt;
    &lt;td&gt;M, 49&lt;/td&gt;
    &lt;td&gt;Bevacizumab&lt;/td&gt;
    &lt;td&gt;Glioblastoma multiforme&lt;/td&gt;
    &lt;td&gt;MD&lt;/td&gt;
    &lt;td&gt;3&lt;/td&gt;
    &lt;td&gt;Dental extraction&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;Manzie&lt;sup&gt;42&lt;/sup&gt; (Australia)&lt;/td&gt;
    &lt;td&gt;F, 76&lt;/td&gt;
    &lt;td&gt;Trastuzumab, pertuzumab&lt;/td&gt;
    &lt;td&gt;Metastatic breast cancer&lt;/td&gt;
    &lt;td&gt;MD&lt;/td&gt;
    &lt;td&gt;2&lt;/td&gt;
    &lt;td&gt;None identified&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;Marotta&lt;sup&gt;43&lt;/sup&gt; (Italy)&lt;/td&gt;
    &lt;td&gt;M, 67&lt;/td&gt;
    &lt;td&gt;Guselkumab&lt;/td&gt;
    &lt;td&gt;Psoriatic arthritis&lt;/td&gt;
    &lt;td&gt;MX&lt;/td&gt;
    &lt;td&gt;1&lt;/td&gt;
    &lt;td&gt;Dental extraction&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;Nisi&lt;sup&gt;44&lt;/sup&gt; (Italy)&lt;/td&gt;
    &lt;td&gt;M, 69&lt;/td&gt;
    &lt;td&gt;Pembrolizumab&lt;/td&gt;
    &lt;td&gt;Metastatic lung cancer&lt;/td&gt;
    &lt;td&gt;MX&lt;/td&gt;
    &lt;td&gt;2&lt;/td&gt;
    &lt;td&gt;None identified&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;Owoshi&lt;sup&gt;45&lt;/sup&gt; (USA)&lt;/td&gt;
    &lt;td&gt;M, 52&lt;/td&gt;
    &lt;td&gt;Ipilimumab&lt;/td&gt;
    &lt;td&gt;Metastatic pancreatic cancer&lt;/td&gt;
    &lt;td&gt;MD&lt;/td&gt;
    &lt;td&gt;2&lt;/td&gt;
    &lt;td&gt;None identified&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;Oz&lt;sup&gt;46&lt;/sup&gt; (Israel)&lt;/td&gt;
    &lt;td&gt;M, 79&lt;/td&gt;
    &lt;td&gt;Ranibizumab, bevacizumab&lt;/td&gt;
    &lt;td&gt;Macular degeneration&lt;/td&gt;
    &lt;td&gt;Both&lt;/td&gt;
    &lt;td&gt;2&lt;/td&gt;
    &lt;td&gt;Dental extraction&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;Pakosch&lt;sup&gt;47&lt;/sup&gt; (Germany)&lt;/td&gt;
    &lt;td&gt;F, 53&lt;/td&gt;
    &lt;td&gt;Bevacizumab&lt;/td&gt;
    &lt;td&gt;Metastatic pancreatic cancer&lt;/td&gt;
    &lt;td&gt;MD&lt;/td&gt;
    &lt;td&gt;2&lt;/td&gt;
    &lt;td&gt;Dental prosthesis use&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;Patel&lt;sup&gt;48&lt;/sup&gt; (UK)&lt;/td&gt;
    &lt;td&gt;M, 73&lt;/td&gt;
    &lt;td&gt;Pembrolizumab&lt;/td&gt;
    &lt;td&gt;Metastatic melanoma&lt;/td&gt;
    &lt;td&gt;MD&lt;/td&gt;
    &lt;td&gt;1&lt;/td&gt;
    &lt;td&gt;None identified&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;Penning&lt;sup&gt;49&lt;/sup&gt; (USA)&lt;/td&gt;
    &lt;td&gt;F, 44&lt;/td&gt;
    &lt;td&gt;Pembrolizumab&lt;/td&gt;
    &lt;td&gt;Lymphoma&lt;/td&gt;
    &lt;td&gt;Both&lt;/td&gt;
    &lt;td&gt;1&lt;/td&gt;
    &lt;td&gt;None identified&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;Pundole&lt;sup&gt;50&lt;/sup&gt; (USA)&lt;/td&gt;
    &lt;td&gt;M, 75&lt;/td&gt;
    &lt;td&gt;Nivolumab&lt;/td&gt;
    &lt;td&gt;Metastatic melanoma&lt;/td&gt;
    &lt;td&gt;MD&lt;/td&gt;
    &lt;td&gt;3&lt;/td&gt;
    &lt;td&gt;None identified&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;Roh&lt;sup&gt;51&lt;/sup&gt; (South Korea)&lt;/td&gt;
    &lt;td&gt;M, 36&lt;/td&gt;
    &lt;td&gt;Tocilizumab&lt;/td&gt;
    &lt;td&gt;COVID-19&lt;/td&gt;
    &lt;td&gt;MX&lt;/td&gt;
    &lt;td&gt;3&lt;/td&gt;
    &lt;td&gt;Odontogenic infection&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;Santos-Silva&lt;sup&gt;52&lt;/sup&gt; (Brazil)&lt;/td&gt;
    &lt;td&gt;M, 61&lt;/td&gt;
    &lt;td&gt;Bevacizumab&lt;/td&gt;
    &lt;td&gt;Metastatic renal cell carcinoma&lt;/td&gt;
    &lt;td&gt;MD&lt;/td&gt;
    &lt;td&gt;1&lt;/td&gt;
    &lt;td&gt;None identified&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;Serra&lt;sup&gt;53&lt;/sup&gt; (Italy)&lt;/td&gt;
    &lt;td&gt;M, 64&lt;/td&gt;
    &lt;td&gt;Bevacizumab&lt;/td&gt;
    &lt;td&gt;Metastatic lung cancer&lt;/td&gt;
    &lt;td&gt;MD&lt;/td&gt;
    &lt;td&gt;2&lt;/td&gt;
    &lt;td&gt;Dental extraction&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;Singh&lt;sup&gt;54&lt;/sup&gt; (USA)&lt;/td&gt;
    &lt;td&gt;M, 59&lt;/td&gt;
    &lt;td&gt;Ramucirumab&lt;/td&gt;
    &lt;td&gt;Metastatic lung cancer&lt;/td&gt;
    &lt;td&gt;MD&lt;/td&gt;
    &lt;td&gt;1&lt;/td&gt;
    &lt;td&gt;None identified&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;Sisalli&lt;sup&gt;55&lt;/sup&gt; (Italy)&lt;/td&gt;
    &lt;td&gt;F, 70&lt;/td&gt;
    &lt;td&gt;Adalimumab&lt;/td&gt;
    &lt;td&gt;Rheumatoid arthritis&lt;/td&gt;
    &lt;td&gt;MD&lt;/td&gt;
    &lt;td&gt;2&lt;/td&gt;
    &lt;td&gt;None identified&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;Ueda&lt;sup&gt;56&lt;/sup&gt; (Japan)&lt;/td&gt;
    &lt;td&gt;F, 66&lt;/td&gt;
    &lt;td&gt;Bevacizumab&lt;/td&gt;
    &lt;td&gt;Metastatic breast cancer&lt;/td&gt;
    &lt;td&gt;MD&lt;/td&gt;
    &lt;td&gt;3&lt;/td&gt;
    &lt;td&gt;Failed dental implant&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;1B.&lt;/td&gt;
    &lt;td&gt;&lt;/td&gt;
    &lt;td&gt;&lt;/td&gt;
    &lt;td&gt;&lt;/td&gt;
    &lt;td&gt;&lt;/td&gt;
    &lt;td&gt;&lt;/td&gt;
    &lt;td&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;Author (Country)&lt;/td&gt;
    &lt;td&gt;&lt;/td&gt;
    &lt;td&gt;&lt;/td&gt;
    &lt;td&gt;&lt;/td&gt;
    &lt;td&gt;&lt;/td&gt;
    &lt;td&gt;&lt;/td&gt;
    &lt;td&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;Brijs&lt;sup&gt;57&lt;/sup&gt; (Belgium)&lt;/td&gt;
    &lt;td&gt;F, 23&lt;/td&gt;
    &lt;td&gt;Infliximab, adalimumab&lt;/td&gt;
    &lt;td&gt;Crohn's disease&lt;/td&gt;
    &lt;td&gt;MX&lt;/td&gt;
    &lt;td&gt;3&lt;/td&gt;
    &lt;td&gt;Dental extraction&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;Brijs&lt;sup&gt;58&lt;/sup&gt; (Belgium)&lt;/td&gt;
    &lt;td&gt;F, 57&lt;/td&gt;
    &lt;td&gt;Infliximab&lt;/td&gt;
    &lt;td&gt;Ulcerative colitis&lt;/td&gt;
    &lt;td&gt;MD&lt;/td&gt;
    &lt;td&gt;1&lt;/td&gt;
    &lt;td&gt;Dental extraction&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;Brijs&lt;sup&gt;59&lt;/sup&gt; (Belgium)&lt;/td&gt;
    &lt;td&gt;M, 46&lt;/td&gt;
    &lt;td&gt;Infliximab, adalimumab&lt;/td&gt;
    &lt;td&gt;Crohn's disease&lt;/td&gt;
    &lt;td&gt;MD&lt;/td&gt;
    &lt;td&gt;2&lt;/td&gt;
    &lt;td&gt;Dental extraction&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td colspan=&quot;7&quot;&gt;F, female; M, male; MAB, monoclonal antibody; MD, mandible; MRONJ, medication-related osteonecrosis of the jaw; MX, maxilla.&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

*   Most common: Bevacizumab
*   Followed by: infliximab, pembrolizumab, adalimumab and rituximab

![Table 1. (A) Summary of the cases from the included case reports (n = 29). (B) Summary of the cases from the included cohort study (n = 3).](L8 Musculoskeletal Disorders_figures/img_0e330da8d71323fc.webp)</text>
    <formatted_text>**Table 1. (A) Summary of the cases from the included case reports (n = 29). (B) Summary of the cases from the included cohort study (n = 3).**

**(A) Case reports**

| First author (Country) | Sex, age | MAB | Indication | Jaw | MRONJ stage | Precipitating factor |
| :--- | :--- | :--- | :--- | :--- | :--- | :--- |
| Allegra (Italy) | M, 56 | Rituximab | Lymphoma | MD | 2 | Dental extraction |
| Bettini (Italy) | F, 57 | Bevacizumab | Metastatic lung cancer | MD | 2 | Dental prosthesis use |
| Binello (Italy) | M, 47 | Bevacizumab | Metastatic adenocarcinoma | MD | 2 | None identified |
| Decaux (Belgium) | F, 28 | Pembrolizumab | Metastatic melanoma | MX | 2 | None identified |
| Disel (Turkey) | M, 51 | Bevacizumab | Metastatic colon cancer | MD | 1 | None identified |
| Estio (USA) | F, 51 | Bevacizumab | Metastatic breast cancer | MD | 1 | None identified |
| Favia (Italy) | F, 49 | Infliximab | Crohn's disease | MD | 3 | Dental extraction |
| Ghosh (USA) | F, 86 | Golimumab | Rheumatoid arthritis | MD | 3 | Dental extraction |
| Greuter (Switzerland) | F, 63 | Bevacizumab | Metastatic breast cancer | MX | 3 | Dental extraction |
| Guida (Italy) | F, 58 | Ipilimumab | Metastatic melanoma | MD | 2 | Dental extraction |
| Hopp (Brazil) | M, 58 | Bevacizumab | Retinal vascular thrombosis | MD | 1 | None identified |
| Keribin (France) | M, 69 | Rituximab | Lymphoma | Both | 1 | None identified |
| Kolodziejewski (Brazil) | M, 53 | Infliximab | Crohn's disease | MD | 3 | None identified |
| Magrenanne (Belgium) | M, 49 | Bevacizumab | Glioblastoma multiforme | MD | 3 | Dental extraction |
| Manzie (Australia) | F, 76 | Trastuzumab, pertuzumab | Metastatic breast cancer | MD | 2 | None identified |
| Marotta (Italy) | M, 67 | Guselkumab | Psoriatic arthritis | MX | 1 | Dental extraction |
| Nisi (Italy) | M, 69 | Pembrolizumab | Metastatic lung cancer | MX | 2 | None identified |
| Owoshi (USA) | M, 52 | Ipilimumab | Metastatic pancreatic cancer | MD | 2 | None identified |
| Oz (Israel) | M, 79 | Ranibizumab, bevacizumab | Macular degeneration | Both | 2 | Dental extraction |
| Pakosch (Germany) | F, 53 | Bevacizumab | Metastatic pancreatic cancer | MD | 2 | Dental prosthesis use |
| Patel (UK) | M, 73 | Pembrolizumab | Metastatic melanoma | MD | 1 | None identified |
| Penning (USA) | F, 44 | Pembrolizumab | Lymphoma | Both | 1 | None identified |
| Pundole (USA) | M, 75 | Nivolumab | Metastatic melanoma | MD | 3 | None identified |
| Roh (South Korea) | M, 36 | Tocilizumab | COVID-19 | MX | 3 | Odontogenic infection |
| Santos-Silva (Brazil) | M, 61 | Bevacizumab | Metastatic renal cell carcinoma | MD | 1 | None identified |
| Serra (Italy) | M, 64 | Bevacizumab | Metastatic lung cancer | MD | 2 | Dental extraction |
| Singh (USA) | M, 59 | Ramucirumab | Metastatic lung cancer | MD | 1 | None identified |
| Sisalli (Italy) | F, 70 | Adalimumab | Rheumatoid arthritis | MD | 2 | None identified |
| Ueda (Japan) | F, 66 | Bevacizumab | Metastatic breast cancer | MD | 3 | Failed dental implant |

**(B) Cohort study**

| Author (Country) | Sex, age | MAB | Indication | Jaw | MRONJ stage | Precipitating factor |
| :--- | :--- | :--- | :--- | :--- | :--- | :--- |
| Brijs (Belgium) | F, 23 | Infliximab, adalimumab | Crohn's disease | MX | 3 | Dental extraction |
| Brijs (Belgium) | F, 57 | Infliximab | Ulcerative colitis | MD | 1 | Dental extraction |
| Brijs (Belgium) | M, 46 | Infliximab, adalimumab | Crohn's disease | MD | 2 | Dental extraction |

F, female; M, male; MAB, monoclonal antibody; MD, mandible; MRONJ, medication-related osteonecrosis of the jaw; MX, maxilla.

- Most common: bevacizumab
- Followed by: infliximab, pembrolizumab, adalimumab and rituximab</formatted_text>
    <images>
      <img order="0" bbox="475,240,889,699" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="table" path="L8 Musculoskeletal Disorders_figures/img_0e330da8d71323fc.webp" caption="Table 1. (A) Summary of the cases from the included case reports (n = 29). (B) Summary of the cases from the included cohort study (n = 3).">
        <description>This table lists individual cases of medication-related osteonecrosis of the jaw (MRONJ) associated with monoclonal antibodies, categorized into case reports (1A) and a cohort study (1B). It details patient demographics (sex, age), the specific drug used (MAB), the medical indication for treatment, the affected jaw location (mandible or maxilla), the MRONJ stage, and any precipitating factors like dental extraction.</description>
      </img>
    </images>
  </page>
  <page number="37">
    <text># Pathogenesis

• Majority: dental intervention impacting bone
  • e.g. extractions, ill-fitting dentures, sharp teeth

• May occur spontaneously

• Likely multi-factorial - current hypotheses:
  • Suppression of bone turnover
  • Inhibition of angiogenesis
  • Toxic effect on soft tissues
  • Inflammation or infection

![](L8 Musculoskeletal Disorders_figures/img_3abea347b0cc224c.webp)
![](L8 Musculoskeletal Disorders_figures/img_bdf199c2c221fdb9.webp)
![BAD FIT](L8 Musculoskeletal Disorders_figures/img_5f7db384c3723592.webp)</text>
    <formatted_text>- Majority: dental intervention impacting bone
  - e.g. extractions, ill-fitting dentures, sharp teeth
- May occur spontaneously
- Likely multi-factorial - current hypotheses:
  - Suppression of bone turnover
  - Inhibition of angiogenesis
  - Toxic effect on soft tissues
  - Inflammation or infection</formatted_text>
    <images>
      <img order="0" bbox="600,276,830,440" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="L8 Musculoskeletal Disorders_figures/img_3abea347b0cc224c.webp">
        <description>Clinical photograph showing a dental extraction site with forceps holding the removed tooth root.</description>
      </img>
      <img order="1" bbox="542,603,736,815" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="L8 Musculoskeletal Disorders_figures/img_bdf199c2c221fdb9.webp">
        <description>Clinical photograph showing a close-up view of teeth in the mouth, specifically highlighting a fractured or broken tooth structure adjacent to gum tissue.</description>
      </img>
      <img order="2" bbox="755,469,951,653" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="L8 Musculoskeletal Disorders_figures/img_5f7db384c3723592.webp" caption="BAD FIT">
        <description>Clinical photo: A man holds up a maxillary denture with yellowed teeth, demonstrating its poor fit relative to his mouth. An arrow points from the text 'BAD FIT' to the prosthetic device.</description>
      </img>
    </images>
  </page>
  <page number="38">
    <text>&lt;div style=&quot;color: red; font-family: cursive;&quot;&gt;DW ab number)&lt;/div&gt;

&lt;h1&gt;Incidence of MRONJ&lt;/h1&gt;

&lt;table&gt;
  &lt;thead&gt;
    &lt;tr&gt;
      &lt;th&gt;Drug&lt;/th&gt;
      &lt;th&gt;Background MRONJ Incidence&lt;/th&gt;
      &lt;th&gt;Post-extraction MRONJ Incidence&lt;/th&gt;
    &lt;/tr&gt;
  &lt;/thead&gt;
  &lt;tbody&gt;
    &lt;tr&gt;
      &lt;td colspan=&quot;3&quot;&gt;Therapy of osteoporosis&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;Bisphosphonates (oral)&lt;br&gt;e.g. alendronate, risedronate&lt;/td&gt;
      &lt;td&gt;0.02 – 0.05% (BP class)&lt;/td&gt;
      &lt;td&gt;0 – 0.15% (BP class)&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;Bisphosphonates (IV)&lt;br&gt;e.g. ibandronate, pamidronate, zolendronate&lt;/td&gt;
      &lt;td&gt;&amp;lt;0.02% (zolendronate)&lt;/td&gt;
      &lt;td&gt;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;Denosumab&lt;/td&gt;
      &lt;td&gt;0.04 – 0.3%&lt;/td&gt;
      &lt;td&gt;1%&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;Romosozumab&lt;/td&gt;
      &lt;td&gt;0.03 – 0.05%&lt;/td&gt;
      &lt;td&gt;Insufficient data&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td colspan=&quot;3&quot;&gt;Therapy for multiple myeloma or metastatic bone cancer&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;Bisphosphonates (IV)&lt;br&gt;e.g. ibandronate, pamidronate, zolendronate&lt;/td&gt;
      &lt;td&gt;&amp;lt;5% (zolendronate)&lt;br&gt;Range: 0 – 18%&lt;/td&gt;
      &lt;td&gt;1 – 5% (BP class)&lt;br&gt;Range: 1.6 – 14.8%&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;Denosumab&lt;/td&gt;
      &lt;td&gt;&amp;lt;5%&lt;br&gt;Range: 0 – 6.9%&lt;/td&gt;
      &lt;td&gt;Insufficient data&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;Antiangiogenic drugs&lt;br&gt;e.g. TKIs (cabozantinib, lenvatinib, sunitinib), anti-VEGF monoclonal antibodies (e.g. bevacizumab)&lt;/td&gt;
      &lt;td&gt;Insufficient data to quantify. Estimated lower than BP/DMB&lt;/td&gt;
      &lt;td&gt;Insufficient data&lt;/td&gt;
    &lt;/tr&gt;
  &lt;/tbody&gt;
&lt;/table&gt;

Ruggiero SL, Dodson TB, Aghaloo T, et al. American Association of Oral and Maxillofacial Surgeons’ Positon Paper on Medication-Related Osteonecrosis of the Jaws – 2022 Updates. J Oral Maxillofac Surg. 2022; 80(5): 920-943.

![](L8 Musculoskeletal Disorders_figures/img_e4a00b466448e6e5.webp)</text>
    <formatted_text>| Drug | Background MRONJ Incidence | Post-extraction MRONJ Incidence |
| :--- | :--- | :--- |
| **Therapy of osteoporosis** | | |
| Bisphosphonates (oral), e.g. alendronate, risedronate | 0.02 – 0.05% (BP class) | 0 – 0.15% (BP class) |
| Bisphosphonates (IV), e.g. ibandronate, pamidronate, zolendronate | &lt;0.02% (zolendronate) | |
| Denosumab | 0.04 – 0.3% | 1% |
| Romosozumab | 0.03 – 0.05% | Insufficient data |
| **Therapy for multiple myeloma or metastatic bone cancer** | | |
| Bisphosphonates (IV), e.g. ibandronate, pamidronate, zolendronate | &lt;5% (zolendronate); range: 0 – 18% | 1 – 5% (BP class); range: 1.6 – 14.8% |
| Denosumab | &lt;5%; range: 0 – 6.9% | Insufficient data |
| Antiangiogenic drugs, e.g. TKIs (cabozantinib, lenvatinib, sunitinib), anti-VEGF monoclonal antibodies (e.g. bevacizumab) | Insufficient data to quantify. Estimated lower than BP/DMB | Insufficient data |

*Ruggiero SL, Dodson TB, Aghaloo T, et al. American Association of Oral and Maxillofacial Surgeons' Position Paper on Medication-Related Osteonecrosis of the Jaws – 2022 Updates. J Oral Maxillofac Surg. 2022; 80(5): 920-943.*</formatted_text>
    <images>
      <img order="0" bbox="84,241,954,767" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="table" path="L8 Musculoskeletal Disorders_figures/img_e4a00b466448e6e5.webp">
        <description>A table titled &quot;Incidence of MRONJ&quot; displaying background and post-extraction rates for various drugs used in osteoporosis therapy (oral/IV bisphosphonates, denosumab, romosozumab) and cancer therapy (IV bisphosphonates, denosumab, antiangiogenic drugs).</description>
      </img>
    </images>
  </page>
  <page number="39">
    <text>&lt;span style=&quot;color:red;&quot;&gt;* Know these numbers&lt;/span&gt;

&lt;h2&gt;Incidence of MRONJ&lt;/h2&gt;

**Osteoporosis &lt; Cancer = 0.05-1% vs &lt;5%**

**Osteoporosis: bisphosphonates &lt; denosumab (1 order higher)**
*   Background: &lt;0.05% vs &lt;0.3%
*   Extractions: &lt;0.15% vs 1%

**Cancer: bisphosphonates ≈ denosumab (5%)**
*   Ranges up to 18% BP and 7% DMB

**Risk/consequence of skeletal events &gt; MRONJ risk**

Ruggiero SL, Dodson TB, Aghaloo T, et al. American Association of Oral and Maxillofacial Surgeons’ Positon Paper on Medication-Related Osteonecrosis of the Jaws – 2022 Updates. J Oral Maxillofac Surg. 2022; 80(5): 920-943.</text>
    <formatted_text>*Know these numbers*

- Osteoporosis &lt; Cancer = 0.05–1% vs &lt;5%
- **Osteoporosis: bisphosphonates &lt; denosumab (1 order higher)**
  - Background: &lt;0.05% vs &lt;0.3%
  - Extractions: &lt;0.15% vs 1%
- **Cancer: bisphosphonates ≈ denosumab (5%)**
  - Ranges up to 18% BP and 7% DMB
- Risk/consequence of skeletal events &gt; MRONJ risk

*Ruggiero SL, Dodson TB, Aghaloo T, et al. American Association of Oral and Maxillofacial Surgeons' Position Paper on Medication-Related Osteonecrosis of the Jaws – 2022 Updates. J Oral Maxillofac Surg. 2022; 80(5): 920-943.*</formatted_text>
    <audio_inserts count="2">
      <insert timestamp="00:32:05" confidence="3" anchor="- Risk/consequence of skeletal events &gt; MRONJ risk">
- ==Dental alveolar operations were identified as a predisposing event in approximately 62–82% of MRONJ cases.==</insert>
      <insert timestamp="00:14:33" confidence="4" anchor="Oral infections should be treated promptly because of concern that infection may">

&gt; [!note] Lecturer — Infection Management
&gt; Immunosuppressed patients may have an increased risk of oral candidiasis. Oral infections should be treated promptly because infection may progress to bacteraemia.
</insert>
    </audio_inserts>
  </page>
  <page number="40">
    <text>Risk Factors

**Key risk factors:**
* History of MRONJ
* Cancer regimens drugs that increase MRONJ risk
* &gt;4 years bisphosphonate therapy

**Significant risk factors:**
* Poor oral health / periodontal disease
* Invasive dental procedures
* Ill-fitting dentures
* Uncontrolled diabetes mellitus
* Tobacco use

**Other possible risk factors:**
* Chemotherapy
* Profound immunocompromise
* Corticosteroids
* Cancer site
* Renal disease / dialysis
* Erythropoietin therapy / anaemia
* Hyperthyroidism
* Gender, ethnicity, increasing age</text>
    <formatted_text>#### Key Risk Factors

- History of MRONJ
- Cancer regimen drugs that increase MRONJ risk
- &gt;4 years bisphosphonate therapy

#### Significant Risk Factors

- Poor oral health / periodontal disease
- Invasive dental procedures
- Ill-fitting dentures
- Uncontrolled diabetes mellitus
- Tobacco use

#### Other Possible Risk Factors

- Chemotherapy
- Profound immunocompromise
- Corticosteroids
- Cancer site
- Renal disease / dialysis
- Erythropoietin therapy / anaemia
- Hyperthyroidism
- Gender, ethnicity, increasing age</formatted_text>
  </page>
  <page number="41">
    <text># Prevention of MRONJ

*   Medical practitioner to refer for dental assessment prior to commencing drug

*   Dentist should:
    *   Undertake a comprehensive oral examination (including pulp tests and radiographs)
    *   Eliminate dental caries (e.g. restorations, extractions)
    *   Establish periodontal health (e.g. debridement, extractions)
    *   Encourage good oral hygiene

*   Invasive dental procedures should be completed prior to commencing drug
    *   Osteoporosis: less ideally, complete invasive dental procedures within 6 months of the first dose

*   Regular dental review is essential to monitor oral health

41 Presentation title 20XX</text>
    <formatted_text>- Medical practitioner to refer for dental assessment prior to commencing drug
- Dentist should:
  - Undertake a comprehensive oral examination (including pulp tests and radiographs)
  - Eliminate dental caries (e.g. restorations, extractions)
  - Establish periodontal health (e.g. debridement, extractions)
  - Encourage good oral hygiene
- Invasive dental procedures should be completed prior to commencing drug
  - Osteoporosis: less ideally, complete invasive dental procedures within 6 months of the first dose
- Regular dental review is essential to monitor oral health</formatted_text>
  </page>
  <page number="42">
    <text># “Dentally Fit?”

“Dental Clearance”

42

![](L8 Musculoskeletal Disorders_figures/img_09dbd7b77d4d268a.webp)</text>
    <formatted_text>&quot;Dentally Fit?&quot; — &quot;Dental Clearance&quot;</formatted_text>
    <images>
      <img order="0" bbox="404,167,921,836" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="L8 Musculoskeletal Disorders_figures/img_09dbd7b77d4d268a.webp">
        <description>A close-up photograph of a smiling person's mouth, showing white teeth and pink lips. The image is cropped into a circle with a gold border.</description>
      </img>
    </images>
  </page>
  <page number="43">
    <text>**Patients at Risk of MRONJ:**
**Prior to Drug Therapy**

Prioritise care that will reduce **mucosal trauma**, and/or may help avoid foreseeable oral surgery that may **impact bone**, and/or may risk **infection/bacteraemia**:

*   Radiographs to identify possible areas of infection/pathology
*   Undertake remedial dental work
*   Extract any teeth of poor prognosis without delay
*   Minimise periodontal / dental infection or disease
*   Adjust/replace poorly fitting dentures

Dr Jee-Yun Leung</text>
    <formatted_text>**Patients at Risk of MRONJ: Prior to Drug Therapy**

Prioritise care that will reduce **mucosal trauma**, and/or may help avoid foreseeable oral surgery that may **impact bone**, and/or may risk **infection/bacteraemia**:

- Radiographs to identify possible areas of infection/pathology
- Undertake remedial dental work
- Extract any teeth of poor prognosis without delay
- Minimise periodontal / dental infection or disease
- Adjust/replace poorly fitting dentures

Dr Jee-Yun Leung</formatted_text>
  </page>
  <page number="44">
    <text>Potential sources of
oral infection prior to
urgent medical
treatment

Boguslawska-Kapala et al. Oral health of adult patients undergoing
hematopoietic cell transplantation. Pre-transplant assessment and
care. 2017:96;1135-1145.

&lt;!--TABLE_START--&gt;&lt;table&gt; &lt;tbody&gt; &lt;tr&gt; &lt;td colspan=&quot;3&quot;&gt; Table I Potential foci of infection and local trauma/bleeding factors within the stomatognathic system in patients undergoing HCT [12, 15–23] &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td&gt; Focus of infection &lt;/td&gt; &lt;td&gt; Advanced caries &lt;/td&gt; &lt;td&gt; -Cavities in which excavation may lead to pulpal exposure, &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td&gt; &lt;/td&gt; &lt;td&gt; &lt;/td&gt; &lt;td&gt; -Cavities that can harbor fungal organisms, &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td&gt; &lt;/td&gt; &lt;td&gt; &lt;/td&gt; &lt;td&gt; -Unrestorable carious teeth, &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td&gt; &lt;/td&gt; &lt;td&gt; &lt;/td&gt; &lt;td&gt; -Compromised, large restorations &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td&gt; &lt;/td&gt; &lt;td&gt; Moderate/advanced gingivitis and periodontitis &lt;/td&gt; &lt;td&gt; - Furcation involvement greater than II grade, &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td&gt; &lt;/td&gt; &lt;td&gt; &lt;/td&gt; &lt;td&gt; -Advanced tooth mobility, &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td&gt; &lt;/td&gt; &lt;td&gt; &lt;/td&gt; &lt;td&gt; -Periodontal pockets ≥6 mm, &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td&gt; &lt;/td&gt; &lt;td&gt; &lt;/td&gt; &lt;td&gt; -Advanced recession (loss of two-third bone support) &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td&gt; &lt;/td&gt; &lt;td&gt; Dental-pulp/periapical pathology &lt;/td&gt; &lt;td&gt; -Nonvital/inflamed dental pulp, &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td&gt; &lt;/td&gt; &lt;td&gt; &lt;/td&gt; &lt;td&gt; -Chronic/acute periapical pathology &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td&gt; &lt;/td&gt; &lt;td&gt; Others &lt;/td&gt; &lt;td&gt; -Pericoronitis, &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td&gt; &lt;/td&gt; &lt;td&gt; &lt;/td&gt; &lt;td&gt; -Sub, supra-gingival calculus, &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td&gt; &lt;/td&gt; &lt;td&gt; &lt;/td&gt; &lt;td&gt; -Partially erupted teeth, &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td&gt; &lt;/td&gt; &lt;td&gt; &lt;/td&gt; &lt;td&gt; -Root tips (not fully covered by bone or showing radiolucency), &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td&gt; &lt;/td&gt; &lt;td&gt; &lt;/td&gt; &lt;td&gt; -Cysts, &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td&gt; &lt;/td&gt; &lt;td&gt; &lt;/td&gt; &lt;td&gt; -Mucosal lesions, &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td&gt; &lt;/td&gt; &lt;td&gt; &lt;/td&gt; &lt;td&gt; -Leaking crowns and fillings &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td&gt; Local bleeding factors &lt;/td&gt; &lt;td&gt; &lt;/td&gt; &lt;td&gt; -Fractured teeth and/or restorations, &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td&gt; &lt;/td&gt; &lt;td&gt; &lt;/td&gt; &lt;td&gt; -Sharp edges of teeth and/or restorations, &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td&gt; &lt;/td&gt; &lt;td&gt; &lt;/td&gt; &lt;td&gt; -Ill-fitting dentures, &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td&gt; &lt;/td&gt; &lt;td&gt; &lt;/td&gt; &lt;td&gt; -Orthodontic appliances, &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td&gt; &lt;/td&gt; &lt;td&gt; &lt;/td&gt; &lt;td&gt; -Teeth contacting directly to the opposing mucosa &lt;/td&gt; &lt;/tr&gt; &lt;/tbody&gt; &lt;/tbody&gt; &lt;/table&gt;
&lt;!--TABLE_END--&gt;

![Table I Potential foci of infection and local trauma/bleeding factors within the stomatognathic system in patients undergoing HCT 12, 15–23](L8 Musculoskeletal Disorders_figures/img_f8773c1175defb6e.webp)</text>
    <formatted_text>Potential sources of oral infection prior to urgent medical treatment

**Table I. Potential foci of infection and local trauma/bleeding factors within the stomatognathic system in patients undergoing HCT**

- **Focus of infection — Advanced caries:**
  - Cavities in which excavation may lead to pulpal exposure
  - Cavities that can harbor fungal organisms
  - Unrestorable carious teeth
  - Compromised, large restorations
- **Moderate/advanced gingivitis and periodontitis:**
  - Furcation involvement greater than II grade
  - Advanced tooth mobility
  - Periodontal pockets ≥6 mm
  - Advanced recession (loss of two-third bone support)
- **Dental-pulp/periapical pathology:**
  - Nonvital/inflamed dental pulp
  - Chronic/acute periapical pathology
- **Others:**
  - Pericoronitis
  - Sub-, supra-gingival calculus
  - Partially erupted teeth
  - Root tips (not fully covered by bone or showing radiolucency)
  - Cysts
  - Mucosal lesions
  - Leaking crowns and fillings
- **Local bleeding factors:**
  - Fractured teeth and/or restorations
  - Sharp edges of teeth and/or restorations
  - Ill-fitting dentures
  - Orthodontic appliances
  - Teeth contacting directly to the opposing mucosa

*Boguslawska-Kapala et al. Oral health of adult patients undergoing hematopoietic cell transplantation. Pre-transplant assessment and care. 2017:96;1135-1145.*</formatted_text>
    <images>
      <img order="0" bbox="428,331,926,650" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="table" path="L8 Musculoskeletal Disorders_figures/img_f8773c1175defb6e.webp" caption="Table I Potential foci of infection and local trauma/bleeding factors within the stomatognathic system in patients undergoing HCT [12, 15–23]">
        <description>A table titled 'Table I Potential foci of infection and local trauma/bleeding factors within the stomatognathic system in patients undergoing HCT'. The table categorizes risks into 'Focus of infection' (listing advanced caries, gingivitis/periodontitis, dental-pulp pathology, and others) and 'Local bleeding factors', with corresponding bulleted lists detailing specific conditions like cavities, furcation involvement, and fractured teeth.</description>
      </img>
    </images>
  </page>
  <page number="45">
    <text>Therefore, **if systemic conditions permit**, initiation of antiresorptive therapy should be delayed until dental health is optimized. $^{173,208}$ This decision must be made in conjunction with the treating physician and dentist and other specialists involved in the care of the patient. There is widespread consensus that optimizing dental health prior to initiating therapy is efficacious and of paramount importance.$^{38,185,186,209}$

AAOMS 2022 MRONJ Guidelines

Ruggiero SL, Dodson TB, Aghaloo T, Carlson ER, Ward BB, Kademani D. American Association of Oral and Maxillofacial Surgeons’ Position Paper on Medication-Related Osteonecrosis of the Jaws—2022 Update. *J Oral Maxillofac Surg*. 2022;80(5):920–43.

45
20XX</text>
    <formatted_text>Therefore, **if systemic conditions permit**, initiation of antiresorptive therapy should be delayed until dental health is optimized. This decision must be made in conjunction with the treating physician and dentist and other specialists involved in the care of the patient. There is widespread consensus that optimizing dental health prior to initiating therapy is efficacious and of paramount importance.

#### AAOMS 2022 MRONJ Guidelines

*Ruggiero SL, Dodson TB, Aghaloo T, Carlson ER, Ward BB, Kademani D. American Association of Oral and Maxillofacial Surgeons' Position Paper on Medication-Related Osteonecrosis of the Jaws—2022 Update. J Oral Maxillofac Surg. 2022;80(5):920–43.*</formatted_text>
  </page>
  <page number="46">
    <text>When medical condition requires prompt initiation of treatment...

&lt;table&gt;
  &lt;tr&gt;
    &lt;th colspan=&quot;4&quot;&gt;TABLE 3. Descriptions of Complete, Partial, and Minimal Dental Evaluation Protocols Based on the Type of Dental and/or Periodontal Pathology&lt;sup&gt;153&lt;/sup&gt;&lt;/th&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;th&gt;Dental Pathology&lt;/th&gt;
    &lt;th&gt;Complete&lt;sup&gt;154,155&lt;/sup&gt;&lt;/th&gt;
    &lt;th&gt;Partial&lt;sup&gt;156,157&lt;/sup&gt;&lt;/th&gt;
    &lt;th&gt;Minimal, Incomplete, or No Clearance&lt;sup&gt;154-158&lt;/sup&gt;&lt;/th&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;Caries&lt;/td&gt;
    &lt;td&gt;Restore all teeth&lt;/td&gt;
    &lt;td&gt;Mild/moderate caries were restored if time permitted&lt;/td&gt;
    &lt;td&gt;Intervention only if symptomatic&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;Severe caries/pulp involvement/ dental abscess&lt;/td&gt;
    &lt;td&gt;Root canal treatment or extract&lt;/td&gt;
    &lt;td&gt;&lt;/td&gt;
    &lt;td&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td rowspan=&quot;3&quot;&gt;Apical periodontitis&lt;/td&gt;
    &lt;td&gt;Retreat&lt;/td&gt;
    &lt;td&gt;Symptomatic lesions and lesions ≥ 5 mm were treated&lt;/td&gt;
    &lt;td&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;Apicoectomy&lt;/td&gt;
    &lt;td&gt;Asymptomatic lesions and lesions &amp;lt; 5 mm were observed&lt;/td&gt;
    &lt;td&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;Extract&lt;/td&gt;
    &lt;td&gt;&lt;/td&gt;
    &lt;td&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td rowspan=&quot;4&quot;&gt;Advanced periodontal disease&lt;/td&gt;
    &lt;td&gt;Extract teeth with:&lt;/td&gt;
    &lt;td&gt;Extract teeth with:&lt;/td&gt;
    &lt;td&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;Probing depth ≥ 6 mm&lt;/td&gt;
    &lt;td&gt;Probing depth ≥ 8 mm&lt;/td&gt;
    &lt;td&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;Furcation I, II, III; Mobility III&lt;/td&gt;
    &lt;td&gt;Mobility III&lt;/td&gt;
    &lt;td&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;Severe inflammation&lt;/td&gt;
    &lt;td&gt;Severe inflammation&lt;/td&gt;
    &lt;td&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td rowspan=&quot;2&quot;&gt;Partially erupted third molars&lt;/td&gt;
    &lt;td&gt;Extract&lt;/td&gt;
    &lt;td&gt;Asymptomatic teeth were observed&lt;/td&gt;
    &lt;td&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;&lt;/td&gt;
    &lt;td&gt;Partially erupted third molars with purulence of pericoronitis were extracted&lt;/td&gt;
    &lt;td&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td colspan=&quot;4&quot;&gt;NOTE. The proper protocol should be selected by the oncologist and dentist according to the patient's medical status.&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

• Yarom et al. Medication-Related Osteonecrosis of the Jaw: MASCC/ISOO/ASCO Clinical Practice Guideline. J Clin Oncol. 2019;37(25):2270-2290.
• Hong et al. A systematic review of dental disease management in cancer patients. Support Care Cancer. 2018;26:155-174.

Dr Jee-Yun Leung 2025

![TABLE 3. Descriptions of Complete, Partial, and Minimal Dental Evaluation Protocols Based on the Type of Dental and/or Periodontal Pathology](L8 Musculoskeletal Disorders_figures/img_50ae1a8d5c30c5db.webp)</text>
    <formatted_text>When medical condition requires prompt initiation of treatment…

**Table 3. Descriptions of Complete, Partial, and Minimal Dental Evaluation Protocols Based on the Type of Dental and/or Periodontal Pathology**

| Dental Pathology | Complete | Partial | Minimal, Incomplete, or No Clearance |
| :--- | :--- | :--- | :--- |
| Caries | Restore all teeth | Mild/moderate caries were restored if time permitted | Intervention only if symptomatic |
| Severe caries/pulp involvement/dental abscess | Root canal treatment or extract | | |
| Apical periodontitis | Retreat; apicoectomy; extract | Symptomatic lesions and lesions ≥5 mm were treated; asymptomatic lesions and lesions &lt;5 mm were observed | |
| Advanced periodontal disease | Extract teeth with: probing depth ≥6 mm; furcation I, II, III; mobility III; severe inflammation | Extract teeth with: probing depth ≥8 mm; mobility III; severe inflammation | |
| Partially erupted third molars | Extract | Asymptomatic teeth were observed; partially erupted third molars with purulence or pericoronitis were extracted | |

NOTE. The proper protocol should be selected by the oncologist and dentist according to the patient's medical status.

- *Yarom et al. Medication-Related Osteonecrosis of the Jaw: MASCC/ISOO/ASCO Clinical Practice Guideline. J Clin Oncol. 2019;37(25):2270-2290.*
- *Hong et al. A systematic review of dental disease management in cancer patients. Support Care Cancer. 2018;26:155-174.*

Dr Jee-Yun Leung 2025</formatted_text>
    <images>
      <img order="0" bbox="231,330,794,712" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="table" path="L8 Musculoskeletal Disorders_figures/img_50ae1a8d5c30c5db.webp" caption="TABLE 3. Descriptions of Complete, Partial, and Minimal Dental Evaluation Protocols Based on the Type of Dental and/or Periodontal Pathology">
        <description>This table outlines dental evaluation protocols categorized by pathology type (Caries, Apical periodontitis, Advanced periodontal disease, Partially erupted third molars) and treatment intensity. The columns define the specific interventions for 'Complete', 'Partial', and 'Minimal' clearance levels, such as restoring all teeth versus intervention only if symptomatic.</description>
      </img>
    </images>
  </page>
  <page number="47">
    <text>*   Advise patient of MRONJ with medication they are taking, but ensure they understand the &lt;span style=&quot;color: red;&quot;&gt;risk is small&lt;/span&gt;, so that they are not discouraged from taking their BMD or from undergoing dental treatment.
*   &lt;span style=&quot;color: red;&quot;&gt;Personalised preventive advice&lt;/span&gt; to optimise oral health (healthy diet, reduce sugar, maintain oral hygiene, fluoride, cease smoking, limit alcohol, regular dental checks)
*   Ensure &lt;span style=&quot;color: red;&quot;&gt;dentures&lt;/span&gt; are well-fitting

**Bone-Modifying Drugs: Work-Up**

Dr Jee-Yun Leung</text>
    <formatted_text>**Bone-Modifying Drugs: Work-Up**

- Advise patient of MRONJ with medication they are taking, but ensure they understand the **risk is small**, so that they are not discouraged from taking their BMD or from undergoing dental treatment.
- **Personalised preventive advice** to optimise oral health (healthy diet, reduce sugar, maintain oral hygiene, fluoride, cease smoking, limit alcohol, regular dental checks)
- Ensure **dentures** are well-fitting

Dr Jee-Yun Leung</formatted_text>
  </page>
  <page number="48">
    <text>**Current BMDs - Assessing MRONJ Risk prior to Invasive Dental Procedures**

*   **Assess if patient is at low or higher risk** of developing MRONJ based on their medical condition, type and duration of therapy, and any other complicating factors (eg. glucocorticoid medication and length of exposure to drugs).

**Table 3.1 Patient Risk Categories**

| Low Risk | Higher Risk |
| :--- | :--- |
| **If any of the following is present:**&lt;br&gt;• Patients being treated for osteoporosis or other non-malignant diseases of bone (e.g. Paget’s disease) with oral bisphosphonates for **less than 5 years** who are **not** concurrently being treated with systemic glucocorticoids.&lt;br&gt;• Patients being treated for osteoporosis or other non-malignant diseases of bone with quarterly or yearly infusions of intravenous bisphosphonates for **less than 5 years** who are **not** concurrently being treated with systemic glucocorticoids.&lt;br&gt;• Patients being treated for osteoporosis or other non-malignant diseases of bone with denosumab who are **not** being treated with systemic glucocorticoids. | **If any of the following is present:**&lt;br&gt;• Patients being treated for osteoporosis or other non-malignant diseases of bone (e.g. Paget’s disease) with oral bisphosphonates or quarterly or yearly infusions of intravenous bisphosphonates for **more than 5 years**.&lt;br&gt;• Patients being treated for osteoporosis or other non-malignant diseases of bone with bisphosphonates or denosumab **for any length of time** who are being concurrently treated with systemic glucocorticoids.&lt;br&gt;• Patients being treated with anti-resorptive or anti-angiogenic drugs (or both) as part of the management of cancer.&lt;br&gt;• Patients with a previous diagnosis of MRONJ. |

N.B. Patients who have taken bisphosphonate drugs at any time in the past and those who have taken denosumab in the last nine months are allocated to a risk group as if they are still taking the drug.

SDCEP 2017 Guidelines – Updated 2022

Therapeutic Guidelines – Oral &amp; Dental v4 2026

48 — Dr Jee-Yun Leung — 2025

![Table 3.1 Patient Risk Categories](L8 Musculoskeletal Disorders_figures/img_17e7d1e26489ce0f.webp)
![Figure 3.1. Assessment of Patient Risk](L8 Musculoskeletal Disorders_figures/img_d4fdeb39aba932a7.webp)
![](L8 Musculoskeletal Disorders_figures/img_8e3cfc047b5aa26e.webp)</text>
    <formatted_text>**Current BMDs - Assessing MRONJ Risk prior to Invasive Dental Procedures**

- **Assess if patient is at low or higher risk** of developing MRONJ based on their medical condition, type and duration of therapy, and any other complicating factors (e.g. glucocorticoid medication and length of exposure to drugs).

**Table 3.1 Patient Risk Categories**

| Low Risk | Higher Risk |
| :--- | :--- |
| If any of the following is present: • Patients being treated for osteoporosis or other non-malignant diseases of bone (e.g. Paget's disease) with oral bisphosphonates for **less than 5 years** who are **not** concurrently being treated with systemic glucocorticoids. • Patients being treated for osteoporosis or other non-malignant diseases of bone with quarterly or yearly infusions of intravenous bisphosphonates for **less than 5 years** who are **not** concurrently being treated with systemic glucocorticoids. • Patients being treated for osteoporosis or other non-malignant diseases of bone with denosumab who are **not** being treated with systemic glucocorticoids. | If any of the following is present: • Patients being treated for osteoporosis or other non-malignant diseases of bone (e.g. Paget's disease) with oral bisphosphonates or quarterly or yearly infusions of intravenous bisphosphonates for **more than 5 years**. • Patients being treated for osteoporosis or other non-malignant diseases of bone with bisphosphonates or denosumab **for any length of time** who are being concurrently treated with systemic glucocorticoids. • Patients being treated with anti-resorptive or anti-angiogenic drugs (or both) as part of the management of cancer. • Patients with a previous diagnosis of MRONJ. |

N.B. Patients who have taken bisphosphonate drugs at any time in the past and those who have taken denosumab in the last nine months are allocated to a risk group as if they are still taking the drug.

*SDCEP 2017 Guidelines – Updated 2022*

*Therapeutic Guidelines – Oral &amp; Dental v4 2026*

Dr Jee-Yun Leung 2025</formatted_text>
    <images>
      <img order="0" bbox="25,445,312,705" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="table" path="L8 Musculoskeletal Disorders_figures/img_17e7d1e26489ce0f.webp" caption="Table 3.1 Patient Risk Categories">
        <description>Table: This figure displays a two-column table categorizing patients into 'Low Risk' and 'Higher Risk' groups for developing MRONJ based on their medical history and drug therapy duration.</description>
      </img>
      <img order="1" bbox="338,313,614,762" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="diagram" path="L8 Musculoskeletal Disorders_figures/img_d4fdeb39aba932a7.webp" caption="Figure 3.1. Assessment of Patient Risk">
        <description>A flowchart titled 'Figure 3.1. Assessment of Patient Risk' that guides the user through a series of yes/no questions regarding MRONJ diagnosis, cancer management drugs, and bisphosphonate or denosumab usage to categorize patients into 'NO RISK', 'LOW RISK', or 'HIGHER RISK'. The decision path includes specific criteria such as duration of drug therapy (less than or greater than 5 years) and concurrent treatment with systemic glucocorticoids.</description>
      </img>
      <img order="2" bbox="663,311,947,778" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="diagram" path="L8 Musculoskeletal Disorders_figures/img_8e3cfc047b5aa26e.webp">
        <description>A clinical decision flowchart illustrating the assessment process for determining a patient's risk of developing MRONJ prior to invasive dental procedures. The diagram guides users through sequential questions regarding previous diagnoses, cancer management drugs, and duration of antiresorptive therapy (bisphosphonates or denosumab) to categorize patients as either low or high risk.</description>
      </img>
    </images>
  </page>
  <page number="49">
    <text>**Current BMDs – Assessing MRONJ Risk prior to Invasive Dental Procedures**

Patients can undergo invasive dental procedures in general dental practice, after a discussion of the risk assessment and precautions

**Figure 13.75 Precautions for managing patients at increased risk of MRONJ undergoing an invasive dental procedure**

Inform the patient of the risk of medication-related osteonecrosis of the jaw and obtain informed consent for the procedure.

See advice on Drug holidays and scheduling of procedures in patients at risk of MRONJ.

Do not use antibiotic prophylaxis to reduce the risk of medication-related osteonecrosis of the jaw – there is insufficient evidence to support this practice [2]. However, an active infection should be treated.

Ensure optimal oral hygiene before and after the procedure [8].

Reduce the plaque load with mechanical debridement and pre- and postprocedural chlorhexidine mouthwash [8].

Consider root retention techniques to avoid extractions.

Minimise trauma and periosteum stripping, and use sutures to close any mucosal flaps that are raised.

Monitor the oral wound until it heals – healing may be slow.

Do not debride nonhealing wounds.

Refer to an oral and maxillofacial surgeon if bone is still visible 8 weeks after the invasive dental procedure.

49 Dr Jee-Yun Leung 2025</text>
    <formatted_text>**Current BMDs – Assessing MRONJ Risk prior to Invasive Dental Procedures**

Patients can undergo invasive dental procedures in general dental practice, after a discussion of the risk assessment and precautions.

**Figure 13.75 Precautions for managing patients at increased risk of MRONJ undergoing an invasive dental procedure**

- Inform the patient of the risk of medication-related osteonecrosis of the jaw and obtain informed consent for the procedure.
- See advice on drug holidays and scheduling of procedures in patients at risk of MRONJ.
- Do not use antibiotic prophylaxis to reduce the risk of medication-related osteonecrosis of the jaw – there is insufficient evidence to support this practice. However, an active infection should be treated.
- Ensure optimal oral hygiene before and after the procedure.
- Reduce the plaque load with mechanical debridement and pre- and post-procedural chlorhexidine mouthwash.
- Consider root retention techniques to avoid extractions.
- Minimise trauma and periosteum stripping, and use sutures to close any mucosal flaps that are raised.
- Monitor the oral wound until it heals – healing may be slow.
- Do not debride non-healing wounds.
- Refer to an oral and maxillofacial surgeon if bone is still visible 8 weeks after the invasive dental procedure.

Dr Jee-Yun Leung 2025</formatted_text>
    <images>
      <img order="0" bbox="158,357,846,758" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="procedure" caption="Figure 13.75 Precautions for managing patients at increased risk of MRONJ undergoing an invasive dental procedure">
        <description>The image displays a text-based list of clinical precautions for managing patients at increased risk of medication-related osteonecrosis of the jaw (MRONJ) undergoing invasive dental procedures. The guidelines cover informed consent, drug holiday scheduling, antibiotic prophylaxis advice, oral hygiene measures like chlorhexidine mouthwash, and specific surgical techniques such as root retention and minimising trauma.</description>
      </img>
    </images>
  </page>
  <page number="50">
    <text>Current BMDs – Assessing MRONJ Risk prior to Invasive Dental Procedures

Healthy Bones Australia Consensus Statement:
Medication-Related Osteonecrosis Of The Jaw (MRONJ) and Osteoporosis
HEALTHYBONES AUSTRALIA

Patient Factors
Low Risk
• Anti-resorptive therapy for osteoporosis
• Duration of BP and/or Dmba for &lt;4 years
• No adverse systemic conditions
• No other adverse drugs
• Good baseline dentition

High Risk
• Duration of BP and/or Dmba ≥4 years
• Systemic conditions:
  • Diabetes with poor control
  • Anaemia, poor nutrition
  • Inflammatory rheumatic disorders
  • Smoking
• Adverse Drugs:
  • Anti-angiogenic or tyrosine kinase inhibitor (TKI) for cancer
  • Glucocorticoids
• Active dental infection, poor oral health, periodontal disease, protracted dental infection

Procedural Factors
Low Risk
• Simple extraction and/or minor, non-invasive procedure
• Uncomplicated implant placement
• Not involving posterior mandible

High Risk
• Extensive surgical site (e.g. ≥3 contiguous teeth)
• Presence of mandibular tori
• Implants or extractions in posterior mandible (molar/premolar)

Patient Risk | Procedural Risk | MRONJ Risk
[Warning Icon] Antiresorptive Therapy for Cancer -&gt; Very High [Red Light]
High + High -&gt; High [Red Light]
Low + High -&gt; Intermediate [Orange Light]
High + Low -&gt; Intermediate [Orange Light]
Low + Low -&gt; Low [Green Light]

MRONJ Risk | Management Precautions
[Red Traffic Light]
• Refer to Specialist Centre or practitioner with MRONJ expertise
• Discussion with osteoporosis specialist regarding ongoing use of antiresorptives and treatment goals

[Orange Traffic Light]
• Minimise active dental infection
• Antibacterial mouthwash ≥ 1 week prior and following extraction
• Consider periprocedural antibiotics*
• Atraumatic surgical approach
• Consider primary closure with tension-free sutures (if appropriate)**
• Close wound safely, monitor oral hygiene, frequent follow-up
• Consider referral to Specialist Centre or practitioner with MRONJ experience

[Green Traffic Light]
• General precautions
• Advise low MRONJ risk
• Proceed with routine extractions and implants
• Consider primary closure (if appropriate)**
• Close wound safely, monitor oral hygiene, frequent follow-up

*The benefit of postoperative antibiotic use to prevent MRONJ is unclear. Individual patient risk assessment is warranted.
**Primary closure is not routinely recommended. This is appropriate in select cases.

50 Dr Jee-Yun Leung 2025

![MRONJ Risk Stratification in Patients with Osteoporosis](L8 Musculoskeletal Disorders_figures/img_4a4980d05e752139.webp)</text>
    <formatted_text>**Healthy Bones Australia Consensus Statement: Medication-Related Osteonecrosis Of The Jaw (MRONJ) and Osteoporosis**

#### Patient Factors

- **Low Risk:**
  - Anti-resorptive therapy for osteoporosis
  - Duration of BP and/or Dmba for &lt;4 years
  - No adverse systemic conditions
  - No other adverse drugs
  - Good baseline dentition
- **High Risk:**
  - Duration of BP and/or Dmba ≥4 years
  - Systemic conditions: diabetes with poor control; anaemia, poor nutrition; inflammatory rheumatic disorders; smoking
  - Adverse drugs: anti-angiogenic or tyrosine kinase inhibitor (TKI) for cancer; glucocorticoids
  - Active dental infection, poor oral health, periodontal disease, protracted dental infection

#### Procedural Factors

- **Low Risk:**
  - Simple extraction and/or minor, non-invasive procedure
  - Uncomplicated implant placement
  - Not involving posterior mandible
- **High Risk:**
  - Extensive surgical site (e.g. ≥3 contiguous teeth)
  - Presence of mandibular tori
  - Implants or extractions in posterior mandible (molar/premolar)

#### MRONJ Risk Stratification

| Patient Risk | Procedural Risk | MRONJ Risk |
| :--- | :--- | :--- |
| Antiresorptive therapy for cancer | — | Very High (red) |
| High | High | High (red) |
| Low | High | Intermediate (orange) |
| High | Low | Intermediate (orange) |
| Low | Low | Low (green) |

#### Management Precautions by MRONJ Risk

- **Red traffic light:**
  - Refer to specialist centre or practitioner with MRONJ expertise
  - Discussion with osteoporosis specialist regarding ongoing use of antiresorptives and treatment goals
- **Orange traffic light:**
  - Minimise active dental infection
  - Antibacterial mouthwash ≥1 week prior and following extraction
  - Consider periprocedural antibiotics*
  - Atraumatic surgical approach
  - Consider primary closure with tension-free sutures (if appropriate)**
  - Close wound safely, monitor oral hygiene, frequent follow-up
  - Consider referral to specialist centre or practitioner with MRONJ experience
- **Green traffic light:**
  - General precautions
  - Advise low MRONJ risk
  - Proceed with routine extractions and implants
  - Consider primary closure (if appropriate)**
  - Close wound safely, monitor oral hygiene, frequent follow-up

\* The benefit of postoperative antibiotic use to prevent MRONJ is unclear. Individual patient risk assessment is warranted.

\*\* Primary closure is not routinely recommended. This is appropriate in select cases.

Dr Jee-Yun Leung 2025</formatted_text>
    <images>
      <img order="0" bbox="189,269,450,795" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="diagram" path="L8 Musculoskeletal Disorders_figures/img_4a4980d05e752139.webp" caption="MRONJ Risk Stratification in Patients with Osteoporosis">
        <description>A risk stratification diagram for MRONJ in patients with osteoporosis, divided into 'Patient Factors' and 'Procedural Factors' lists categorized by Low Risk (green) and High Risk (red). The lower section illustrates a decision matrix combining patient and procedural risks to determine the final MRONJ risk level, indicated by red, orange, or green traffic light icons.</description>
      </img>
    </images>
  </page>
  <page number="51">
    <text>&lt;h2&gt;Current BMDs: Drug Holidays - Bisphosphonates&lt;/h2&gt;

&lt;div style=&quot;display: flex; gap: 20px;&quot;&gt;
  &lt;div style=&quot;flex: 1; border: 2px solid black; padding: 15px; background-color: #f0f0f0; box-shadow: 5px 5px 0px #d4a017;&quot;&gt;
    &lt;h3&gt;AAOMS 2014&lt;/h3&gt;
    &lt;p&gt;Asymptomatic patients – Oral BP for osteoporosis&lt;/p&gt;
    &lt;ul&gt;
      &lt;li&gt;Oral BP &amp;lt;4 years + no risk factors = no delays/allegation.&lt;/li&gt;
      &lt;li&gt;Oral BP &amp;lt;4 years + concomitant corticosteroids or anti-angiogenics = consider discontinuation at least 2 months pre-op, if systemic conditions permit. Restart when osseous healing (3 months).&lt;/li&gt;
      &lt;li&gt;Oral BP &amp;gt;4 years ± concomitant medical therapy = consider discontinuation for 2 months pre-op, if systemic conditions permit. Restart when osseous healing (3 months).&lt;/li&gt;
    &lt;/ul&gt;
  &lt;/div&gt;

  &lt;div style=&quot;flex: 1; border: 2px solid black; padding: 15px; background-color: #f0f0f0; box-shadow: 5px 5px 0px #d4a017;&quot;&gt;
    &lt;h3&gt;AAOMS 2022&lt;/h3&gt;
    &lt;ul&gt;
      &lt;li&gt;Difficult to establish or refute efficacy of drug holidays $\rightarrow$ working group evenly split&lt;/li&gt;
      &lt;li&gt;Rarity of MRONJ in these patient populations $\rightarrow$ insufficient data for RCTs&lt;/li&gt;
      &lt;li&gt;2020 systematic review: variety of papers had differing conclusions&lt;/li&gt;
      &lt;li&gt;Factors for consideration: disease-related risk (cancer vs OP), drug-dosing frequency, therapy duration, comorbidities, other medications (chemo, steroids, antiangiogenics), degree of infection/inflammation, extent of surgery&lt;/li&gt;
    &lt;/ul&gt;
  &lt;/div&gt;
&lt;/div&gt;

Ruggiero SL, Dodson TB, Aghaloo T, Carlson ER, Ward BB, Kademani D. American Association of Oral and Maxillofacial Surgeons’ Position Paper on Medication-Related Osteonecrosis of the Jaws—2022 Update. J Oral Maxillofac Surg. 2022;80(5):920–43.
Ottesen C, Schiodt M, Gotfredsen K. Efficacy of a high-dose antiresorptive drug holiday to reduce the risk of medication-related osteonecrosis of the jaw (MRONJ): A systematic review. Heliyon. 2020;6(4):e03795–e03795.

**Dr Jee-Yun Leung**</text>
    <formatted_text>#### AAOMS 2014

Asymptomatic patients – oral BP for osteoporosis

- Oral BP &lt;4 years + no risk factors = no delays/alteration.
- Oral BP &lt;4 years + concomitant corticosteroids or anti-angiogenics = consider discontinuation at least 2 months pre-op, if systemic conditions permit. Restart when osseous healing (3 months).
- Oral BP &gt;4 years ± concomitant medical therapy = consider discontinuation for 2 months pre-op, if systemic conditions permit. Restart when osseous healing (3 months).

#### AAOMS 2022

- Difficult to establish or refute efficacy of drug holidays → working group evenly split
- Rarity of MRONJ in these patient populations → insufficient data for RCTs
- 2020 systematic review: variety of papers had differing conclusions
- Factors for consideration: disease-related risk (cancer vs OP), drug-dosing frequency, therapy duration, comorbidities, other medications (chemo, steroids, antiangiogenics), degree of infection/inflammation, extent of surgery

*Ruggiero SL, Dodson TB, Aghaloo T, Carlson ER, Ward BB, Kademani D. American Association of Oral and Maxillofacial Surgeons' Position Paper on Medication-Related Osteonecrosis of the Jaws—2022 Update. J Oral Maxillofac Surg. 2022;80(5):920–43.*

*Ottesen C, Schiodt M, Gotfredsen K. Efficacy of a high-dose antiresorptive drug holiday to reduce the risk of medication-related osteonecrosis of the jaw (MRONJ): A systematic review. Heliyon. 2020;6(4):e03795–e03795.*

Dr Jee-Yun Leung</formatted_text>
  </page>
  <page number="52">
    <text>**Current BMDs: Drug Holidays prior to Invasive Dental Procedures**

*   **Controversial** – evidence to support or refute inconclusive
*   Responsibility for drug holiday is prescribing practitioner, together with clinical judgement of the dentist, and in discussion with the patient

Ruggiero SL, Dodson TB, Aghaloo T, Carlson ER, Ward BB, Kademani D. American Association of Oral and Maxillofacial Surgeons’ Position Paper on Medication-Related Osteonecrosis of the Jaws—2022 Update. J Oral Maxillofac Surg. 2022;80(5):920–43.
Ottesen C, Schiodt M, Gotfredsen K. Efficacy of a high-dose antiresorptive drug holiday to reduce the risk of medication-related osteonecrosis of the jaw (MRONJ): A systematic review. Heliyon. 2020;6(4):e03795–e03795.
Yarom N, et al. Medication-Related Osteonecrosis of the Jaw: MASCC/ISOO/ASCO Clinical Practice Guideline. 2019;37(25):2270-2290
Therapeutic Guidelines: Oral &amp; Dental version 4 2026

Dr Jee-Yun Leung</text>
    <formatted_text>**Current BMDs: Drug Holidays prior to Invasive Dental Procedures**

- **Controversial** – evidence to support or refute inconclusive
- Responsibility for drug holiday is prescribing practitioner, together with clinical judgement of the dentist, and in discussion with the patient

*Ruggiero SL, Dodson TB, Aghaloo T, Carlson ER, Ward BB, Kademani D. American Association of Oral and Maxillofacial Surgeons' Position Paper on Medication-Related Osteonecrosis of the Jaws—2022 Update. J Oral Maxillofac Surg. 2022;80(5):920–43.*

*Ottesen C, Schiodt M, Gotfredsen K. Efficacy of a high-dose antiresorptive drug holiday to reduce the risk of medication-related osteonecrosis of the jaw (MRONJ): A systematic review. Heliyon. 2020;6(4):e03795–e03795.*

*Yarom N, et al. Medication-Related Osteonecrosis of the Jaw: MASCC/ISOO/ASCO Clinical Practice Guideline. 2019;37(25):2270-2290*

*Therapeutic Guidelines: Oral &amp; Dental version 4 2026*

Dr Jee-Yun Leung</formatted_text>
  </page>
  <page number="53">
    <text>Current BMDs - Denosumab

53
Presentation title
20XX

![](L8 Musculoskeletal Disorders_figures/img_afbcb9155fe6773e.webp)</text>
    <formatted_text>Current BMDs - Denosumab</formatted_text>
    <images>
      <img order="0" bbox="423,291,464,358" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="figure" path="L8 Musculoskeletal Disorders_figures/img_afbcb9155fe6773e.webp">
        <description>A graphic image featuring the word &quot;Bone&quot; in white text against a dark, abstract background with green and blue cellular-like structures.</description>
      </img>
    </images>
  </page>
  <page number="54">
    <text>**Current BMDs - Denosumab**

Osteoporotic patients with 6-monthly S.C. denosumab can delay any non-urgent invasive dental Tx in an asymptomatic tooth until **3-4 months after the last dose**

This allows **6-8 weeks for healing** prior to resumption of denosumab

Denosumab discontinuation $\rightarrow$ rebound risk of **spontaneous vertebral fractures**
*   Onset of bone loss and # risk starts **within 4 weeks of the missed dose**
*   $\uparrow$risk occurred mostly within the **first 2-6 months of discontinuation**
*   **#s mostly occur within 6-20 months** of denosumab discontinuation

Ruggiero SL, Dodson TB, Aghaloo T, Carlson ER, Ward BB, Kademani D. American Association of Oral and Maxillofacial Surgeons’ Position Paper on Medication-Related Osteonecrosis of the Jaws—2022 Update. *J Oral Maxillofac Surg*. 2022;80(5):920–43.
Cummings SR, Ferrari S, Eastell R, et al. Vertebral fractures after discontinuation of denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension. *J Bone Miner Res*. 2018;33(2):190-198
Lamy O, Stoll D, Aubrey-Rozir et al. Stopping denosumab. *Curr Osteoporos Rep*. 2019;17:8-15

Dr Jee-Yun Leung

![Prolia® Effects on Serum CTx Levels Over the 6-month Dosing Interval.](L8 Musculoskeletal Disorders_figures/img_5a0d002eb9c4340b.webp)</text>
    <formatted_text>**Current BMDs - Denosumab**

Osteoporotic patients with 6-monthly S.C. denosumab can delay any non-urgent invasive dental Tx in an asymptomatic tooth until **3–4 months after the last dose**.

This allows **6–8 weeks for healing** prior to resumption of denosumab.

Denosumab discontinuation → rebound risk of **spontaneous vertebral fractures**

- Onset of bone loss and fracture risk starts **within 4 weeks of the missed dose**
- ↑ risk occurred mostly within the **first 2–6 months of discontinuation**
- **Fractures mostly occur within 6–20 months** of denosumab discontinuation

*Ruggiero SL, Dodson TB, Aghaloo T, Carlson ER, Ward BB, Kademani D. American Association of Oral and Maxillofacial Surgeons' Position Paper on Medication-Related Osteonecrosis of the Jaws—2022 Update. J Oral Maxillofac Surg. 2022;80(5):920–43.*

*Cummings SR, Ferrari S, Eastell R, et al. Vertebral fractures after discontinuation of denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension. J Bone Miner Res. 2018;33(2):190-198*

*Lamy O, Stoll D, Aubrey-Rozir et al. Stopping denosumab. Curr Osteoporos Rep. 2019;17:8-15*

Dr Jee-Yun Leung</formatted_text>
    <images>
      <img order="0" bbox="2,225,352,449" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="chart" path="L8 Musculoskeletal Disorders_figures/img_5a0d002eb9c4340b.webp" caption="Prolia® Effects on Serum CTx Levels Over the 6-month Dosing Interval.">
        <description>This dual-axis line graph illustrates the pharmacokinetic relationship between denosumab concentration and bone turnover over a 12-month period. The green line represents Serum Denosumab Concentration (ng/ml), showing peaks following dosing at months 0 and 6, while the grey triangle-marked line depicts the Mean Change in Serum CTx from Baseline (%), which drops significantly when drug levels are high and rebounds as they decline.</description>
      </img>
    </images>
  </page>
  <page number="55">
    <text>**Current BMDs: Drug Holidays - Denosumab**

*   Denosumab discontinuation $\rightarrow$ rebound risk of multiple **spontaneous vertebral fractures**
*   FREEDOM study and its extension (2018): risk of rebound vertebral fractures $\uparrow$ from 1.2 (on-treatment period) to 7.1 (denosumab cessation) per 100 participant-years of discontinuation.
    *   $\uparrow$ occurred mostly within the first 2-6 months of discontinuation
*   Lamy et al (2019):
    *   Onset of bone loss and # risk starts within 4 weeks of the missed dose
    *   Significant # risk occurs after 2${}^{\text{nd}}$ dose of denosumab
    *   #s mostly occur within 6-20 months of denosumab discontinuation
    *   If denosumab is discontinued, bone density declines to pre-treatment levels within 12 months

Ruggiero SL, Dodson TB, Aghaloo T, Carlson ER, Ward BB, Kademani D. American Association of Oral and Maxillofacial Surgeons’ Position Paper on Medication-Related Osteonecrosis of the Jaws—2022 Update. J Oral Maxillofac Surg. 2022;80(5):920–43.
Cummings SR, Ferrari S, Eastell R, et al. Vertebral fractures after discontinuation of denosumab: A post hoc analysis of the randomized placebo controlled FREEDOM trial and its extension. J Bone Miner Res 2018;33(2):190–98.
Lamy O, Stoll D, Aubrey-Rozir et al. Stopping denosumab. Curr Osteoporos Rep. 2019;17:8-15

Dr Jee-Yun Leung</text>
    <formatted_text>**Current BMDs: Drug Holidays - Denosumab**

- Denosumab discontinuation → rebound risk of multiple **spontaneous vertebral fractures**
- FREEDOM study and its extension (2018): risk of rebound vertebral fractures ↑ from 1.2 (on-treatment period) to 7.1 (denosumab cessation) per 100 participant-years of discontinuation.
  - ↑ occurred mostly within the first 2–6 months of discontinuation
- Lamy et al (2019):
  - Onset of bone loss and fracture risk starts within 4 weeks of the missed dose
  - Significant fracture risk occurs after 2nd dose of denosumab
  - Fractures mostly occur within 6–20 months of denosumab discontinuation
  - If denosumab is discontinued, bone density declines to pre-treatment levels within 12 months

*Ruggiero SL, Dodson TB, Aghaloo T, Carlson ER, Ward BB, Kademani D. American Association of Oral and Maxillofacial Surgeons' Position Paper on Medication-Related Osteonecrosis of the Jaws—2022 Update. J Oral Maxillofac Surg. 2022;80(5):920–43.*

*Cummings SR, Ferrari S, Eastell R, et al. Vertebral fractures after discontinuation of denosumab: A post hoc analysis of the randomized placebo controlled FREEDOM trial and its extension. J Bone Miner Res 2018;33(2):190–98.*

*Lamy O, Stoll D, Aubrey-Rozir et al. Stopping denosumab. Curr Osteoporos Rep. 2019;17:8-15*

Dr Jee-Yun Leung</formatted_text>
  </page>
  <page number="56">
    <text>&lt;h2&gt;Current BMD: Drug Holidays –&lt;br&gt;Therapeutic Guidelines Oral &amp; Dental v4 2026&lt;/h2&gt;

&lt;ul&gt;
  &lt;li&gt;*There is &lt;span style=&quot;color:red&quot;&gt;no evidence that drug holidays reduce risk&lt;/span&gt; of MRONJ.
    &lt;ul&gt;
      &lt;li&gt;If bone-invasive dental procedure cannot be avoided but is not urgent, temporary discontinuation of AR therapy, or timing procedure to coincide with a low serum drug concentration, have been suggested.&lt;/li&gt;
      &lt;li&gt;These practices are based on extrapolation of the drug pharmacokinetics in the serum and on bone physiology; however &lt;u&gt;no available outcome evidence to support&lt;/u&gt;.&lt;/li&gt;
    &lt;/ul&gt;
  &lt;/li&gt;
  &lt;li&gt;*&lt;span style=&quot;color:red&quot;&gt;Clinical judgement of treating doctors/dentists&lt;/span&gt; is required to determine appropriate management of each patient.
    &lt;ul&gt;
      &lt;li&gt;Recommendations in international guidelines are inconsistent. Vary depending on indication for AR drugs, duration of therapy, and presence of additional risk factors.&lt;/li&gt;
      &lt;li&gt;Decision to alter AR therapy lies with practitioner responsible for managing the AR drug.&lt;/li&gt;
    &lt;/ul&gt;
  &lt;/li&gt;
  &lt;li&gt;AR drugs for osteoporosis:
    &lt;ul&gt;
      &lt;li&gt;&lt;span style=&quot;color:red&quot;&gt;Benefits of continued therapy&lt;/span&gt; outweigh low risk of MRONJ.&lt;/li&gt;
      &lt;li&gt;Bisphosphonates = Although stopping for short period unlikely to cause harm in a patient at low risk of fracture, no evidence that this reduces MRONJ risk.&lt;/li&gt;
    &lt;/ul&gt;
  &lt;/li&gt;
  &lt;li&gt;AR drugs for cancer:
    &lt;ul&gt;
      &lt;li&gt;Decision to alter AR therapy lies with &lt;span style=&quot;color:red&quot;&gt;specialist managing the cancer&lt;/span&gt;.&lt;/li&gt;
    &lt;/ul&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;hr/&gt;
56 &amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;...... Dr Jee-Yun Leung ...... &amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp...... 2025</text>
    <formatted_text>- There is **no evidence that drug holidays reduce risk** of MRONJ.
  - If bone-invasive dental procedure cannot be avoided but is not urgent, temporary discontinuation of AR therapy, or timing procedure to coincide with a low serum drug concentration, have been suggested.
  - These practices are based on extrapolation of the drug pharmacokinetics in the serum and on bone physiology; however **no available outcome evidence to support**.
- **Clinical judgement of treating doctors/dentists** is required to determine appropriate management of each patient.
  - Recommendations in international guidelines are inconsistent. Vary depending on indication for AR drugs, duration of therapy, and presence of additional risk factors.
  - Decision to alter AR therapy lies with practitioner responsible for managing the AR drug.
- AR drugs for osteoporosis:
  - **Benefits of continued therapy** outweigh low risk of MRONJ.
  - Bisphosphonates = although stopping for short period unlikely to cause harm in a patient at low risk of fracture, no evidence that this reduces MRONJ risk.
- AR drugs for cancer:
  - Decision to alter AR therapy lies with **specialist managing the cancer**.

Dr Jee-Yun Leung 2025</formatted_text>
  </page>
  <page number="57">
    <text>Alternative Options for Unrestorable Teeth:
RCT and tissue-level restoration

INTERNATIONAL ENDODONTIC JOURNAL
The official journal of the British Endodontic Society and the European Society of Endodontology

Original Article
Root canal treatment of compromised teeth as alternative treatment for patients receiving bisphosphonates: 60-month results of a prospective clinical study

F. Zamparini, G. A. Pelliccioni, A. Spinelli, D. B. Gissi, M. G. Gandolfi, C. Prati
First published: 09 September 2020 | https://doi.org/10.1111/iej.13405 | Citations: 2

Pre-operative
After root canal treatment
After 60 months

Pre-operative
After root canal treatment
After 60 months

Figure 3 Series of periapical radiographs of patients under BPs therapy enrolled in the study and followed for 60 months. (a) 68-year patient with zoledronate-endovenous therapy started for multiple myeloma. Root canal treatment was performed on teeth 4.7, 4.6, 4.5 and 4.4 due to multiple deep caries lesion with no periapical radiolucency (initial PAI was 1 in all cases). (b) roots were shaped with manual step-back instrumentation and filled with carrier-based technique and epoxy resin based sealer. Due to the large coronal destruction of tooth 4.7 and 4.5, these two teeth were restored at tissue level (TL group), the other teeth were rehabilitated with occlusal contact restorations (OC group). (c) At the end-line all teeth demonstrated no peri-apical radiolucency (PAI ≤ 2).

Root canal treatment of compromised teeth as alternative treatment in patients receiving bisphosphonates: 60-month results of a prospective clinical study

F Zamparini, GA Pelliccioni, A Spinelli, DB Gissi, MG Gandolfi, C Prati

Aim
This 60-month prospective study aimed to evaluate tooth survival and healing rates after root canal treatment in patients taking bisphosphonates (BPs). Secondary outcomes were complications and clinical variables observed during and after the treatment.

Methods
Root canal treatment was performed using manual K-file canal instrumentation, a carrier-based filling technique and epoxy resin–based sealer. Teeth without adequate root/crown integrity were restored by trained operators at the tissue level (TL group) to prevent occlusal/mechanical stress and to enable periapical lesion healing without the risk of root fracture. Other teeth were restored with normal occlusal contact (OC group). Healthy patients who had undergone one or more root canal treatments of the same type constituted the control group. The relationships of the following variables to survival and health status were examined (chi-squared test and multivariate analysis, p=0.05): age, gender, smoking habit, tooth location, treatment type, BPs treatment, BPs exposure, initial periapical index (PAI) and occlusal restoration. Survival curves were constructed using Kaplan–Meier analysis, with extraction serving as endpoint.

Results
In total, 65 patients with 109 root canal treated teeth who were taking BPs were included. At 60 months, data from 57 patients (52F, 5M; median-age 65.7±8.6years) who had undergone 96 root canal treatments were analysed (drop-out rate=16.9%). The survival rate was 85% and the success rate was 76%.
The control group consisted of 46 patients (21F, 25M; median-age 60.3±7.2years) who had undergone 102 root canal treatments. The survival rate was 88%, with 12 teeth lost during follow-up. The success rate was 73%. In the BPs group, 55 teeth were restored normally (OC group) and 41 teeth were restored at the tissue level (TL group). No difference in the success or survival rate was observed between the BP and control groups (p&gt;0.05). Univariate Kaplan-Meier analysis revealed that only tooth type significantly affected survival status in the BP group. The analysis revealed the clinical relevance of smoking, tooth location and initial PAI on patients’ health status (p&lt;0.05).

Conclusion
Root canal treatments and post-endodontic restoration with tissue level filling procedures represent a safe approach for severely-damaged teeth in patients receiving bisphosphonates having comparable results to occlusal contact and control group.

Dr Jee-Yun Leung

![(a)](L8 Musculoskeletal Disorders_figures/img_e4e3203e10b6d502.webp)
![(b)](L8 Musculoskeletal Disorders_figures/img_f80830a24c1b7ed9.webp)
![(c)](L8 Musculoskeletal Disorders_figures/img_e3905d89a5816dd4.webp)
![](L8 Musculoskeletal Disorders_figures/img_2a09400d1f170452.webp)
![](L8 Musculoskeletal Disorders_figures/img_a7d9bcda0fbdd01c.webp)
![](L8 Musculoskeletal Disorders_figures/img_fe520caccfb323aa.webp)</text>
    <formatted_text>#### Root Canal Treatment and Tissue-Level Restoration

*Zamparini F, Pelliccioni GA, Spinelli A, Gissi DB, Gandolfi MG, Prati C. Root canal treatment of compromised teeth as alternative treatment for patients receiving bisphosphonates: 60-month results of a prospective clinical study. International Endodontic Journal. First published: 09 September 2020. https://doi.org/10.1111/iej.13405*

**Figure 3.** Series of periapical radiographs of patients under BPs therapy enrolled in the study and followed for 60 months. (a) 68-year patient with zoledronate-endovenous therapy started for multiple myeloma. Root canal treatment was performed on teeth 4.7, 4.6, 4.5 and 4.4 due to multiple deep caries lesion with no periapical radiolucency (initial PAI was 1 in all cases). (b) roots were shaped with manual step-back instrumentation and filled with carrier-based technique and epoxy resin based sealer. Due to the large coronal destruction of tooth 4.7 and 4.5, these two teeth were restored at tissue level (TL group), the other teeth were rehabilitated with occlusal contact restorations (OC group). (c) At the end-line all teeth demonstrated no peri-apical radiolucency (PAI ≤ 2).

**Aim**

This 60-month prospective study aimed to evaluate tooth survival and healing rates after root canal treatment in patients taking bisphosphonates (BPs). Secondary outcomes were complications and clinical variables observed during and after the treatment.

**Methods**

Root canal treatment was performed using manual K-file canal instrumentation, a carrier-based filling technique and epoxy resin–based sealer. Teeth without adequate root/crown integrity were restored by trained operators at the tissue level (TL group) to prevent occlusal/mechanical stress and to enable periapical lesion healing without the risk of root fracture. Other teeth were restored with normal occlusal contact (OC group). Healthy patients who had undergone one or more root canal treatments of the same type constituted the control group. The relationships of the following variables to survival and health status were examined (chi-squared test and multivariate analysis, p=0.05): age, gender, smoking habit, tooth location, treatment type, BPs treatment, BPs exposure, initial periapical index (PAI) and occlusal restoration. Survival curves were constructed using Kaplan–Meier analysis, with extraction serving as endpoint.

**Results**

In total, 65 patients with 109 root canal treated teeth who were taking BPs were included. At 60 months, data from 57 patients (52F, 5M; median-age 65.7±8.6 years) who had undergone 96 root canal treatments were analysed (drop-out rate=16.9%). The survival rate was 85% and the success rate was 76%.

The control group consisted of 46 patients (21F, 25M; median-age 60.3±7.2 years) who had undergone 102 root canal treatments. The survival rate was 88%, with 12 teeth lost during follow-up. The success rate was 73%. In the BPs group, 55 teeth were restored normally (OC group) and 41 teeth were restored at the tissue level (TL group). No difference in the success or survival rate was observed between the BP and control groups (p&gt;0.05). Univariate Kaplan-Meier analysis revealed that only tooth type significantly affected survival status in the BP group. The analysis revealed the clinical relevance of smoking, tooth location and initial PAI on patients' health status (p&lt;0.05).

**Conclusion**

Root canal treatments and post-endodontic restoration with tissue level filling procedures represent a safe approach for severely-damaged teeth in patients receiving bisphosphonates having comparable results to occlusal contact and control group.

Dr Jee-Yun Leung</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="00:49:09" confidence="8" anchor="Root canal treatments and post-endodontic restoration with tissue level filling ">

&gt; [!note] Lecturer — Root Retention
&gt; Root canal treatment may be considered for retained roots or teeth that would otherwise be extracted.
&gt;
&gt; - A small glass ionomer cement cap may be placed when a crown or post is not feasible; this can retain the root while avoiding trauma to the jaw bone, although the restoration may not withstand normal occlusal or masticatory forces.
</insert>
    </audio_inserts>
    <images>
      <img order="0" bbox="110,462,186,550" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="figure" path="L8 Musculoskeletal Disorders_figures/img_e4e3203e10b6d502.webp" caption="(a)">
        <description>A periapical radiograph showing a series of mandibular posterior teeth. The image displays the roots and surrounding bone structure, with visible radiolucent areas at the apices of several teeth.</description>
      </img>
      <img order="1" bbox="196,463,270,551" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="figure" path="L8 Musculoskeletal Disorders_figures/img_f80830a24c1b7ed9.webp" caption="(b)">
        <description>Radiograph: A cropped periapical radiograph showing multiple molars with visible root canal fillings, labeled '(b)'. The image depicts the internal structure of the teeth and roots following endodontic treatment.</description>
      </img>
      <img order="2" bbox="279,463,356,550" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="figure" path="L8 Musculoskeletal Disorders_figures/img_e3905d89a5816dd4.webp" caption="(c)">
        <description>A periapical radiograph showing the roots of posterior teeth (likely premolars and molars) with visible root canal fillings. The image illustrates the condition at the end-line, demonstrating no peri-apical radiolucency.</description>
      </img>
      <img order="3" bbox="109,595,186,687" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="figure" path="L8 Musculoskeletal Disorders_figures/img_2a09400d1f170452.webp">
        <description>Radiograph: A periapical X-ray image of posterior teeth, marked with the label '(d)'. The radiograph shows multiple molars/premolars with significant radiopaque restorations (fillings or crowns) on their occlusal surfaces.</description>
      </img>
      <img order="4" bbox="196,597,271,687" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="figure" path="L8 Musculoskeletal Disorders_figures/img_a7d9bcda0fbdd01c.webp">
        <description>Radiograph: A periapical radiograph labeled (c) showing the 60-month follow-up of root canal treated teeth. The image displays restored molars with no visible peri-apical radiolucency.</description>
      </img>
      <img order="5" bbox="277,597,357,688" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="figure" path="L8 Musculoskeletal Disorders_figures/img_fe520caccfb323aa.webp">
        <description>Periapical radiograph showing a section of the posterior mandible with multiple teeth restored at tissue level (TL group), including root canal fillings and coronal restorations; no periapical radiolucency is visible, consistent with healing after endodontic treatment in bisphosphonate-treated patients.</description>
      </img>
    </images>
  </page>
  <page number="58">
    <text>Alternative Options for Unrestorable Teeth:
Orthodontic Extrusion

FIGURE 3. Teeth after exfoliation of the second molar and extrusion
of the first premolar.

FIGURE 5. Complete healing 2 months after exfoliation.
Regev, Lustmann, and Nashef. Extraction in Bisphosphonate-
Treated Patients. J Oral Maxillofac Surg 2008.

FIGURE 6. Dentin bulge (arrows) preventing elastics from sliding
apically.

o Regev E, Lustmann J, Nashef R. Atraumatic Teeth Extraction in Bisphosphonate-Treated Patients. Journal of oral and maxillofacial surgery. 2008;66(6):1157-61.

Dr Jee-Yun Leung

![A](L8 Musculoskeletal Disorders_figures/img_57100e661b82a715.webp)
![FIGURE 3. Teeth after exfoliation of the second molar and extrusion of the first premolar.](L8 Musculoskeletal Disorders_figures/img_546c0d511a4817b3.webp)
![FIGURE 4. Sockets immediately after exfoliation of both teeth.](L8 Musculoskeletal Disorders_figures/img_807fee16b7cb6a6b.webp)
![FIGURE 5. Complete healing 2 months after exfoliation. Regev, Lustmann, and Nashef. Extraction in Bisphosphonate-Treated Patients. J Oral Maxillofac Surg 2008.](L8 Musculoskeletal Disorders_figures/img_489086738924c263.webp)
![FIGURE 6. Dentin bulge (arrows) preventing elastics from sliding apically.](L8 Musculoskeletal Disorders_figures/img_4341bd68a7c96d24.webp)</text>
    <formatted_text>#### Orthodontic Extrusion

- Figure 3. Teeth after exfoliation of the second molar and extrusion of the first premolar.
- Figure 5. Complete healing 2 months after exfoliation.
- Figure 6. Dentin bulge (arrows) preventing elastics from sliding apically.

*Regev E, Lustmann J, Nashef R. Atraumatic Teeth Extraction in Bisphosphonate-Treated Patients. Journal of Oral and Maxillofac Surgery. 2008;66(6):1157-61.*

Dr Jee-Yun Leung</formatted_text>
    <images>
      <img order="0" bbox="41,282,260,494" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="L8 Musculoskeletal Disorders_figures/img_57100e661b82a715.webp" caption="A">
        <description>Clinical photograph showing the lower left posterior mandible with a retracted cheek using a plastic mouth opener. A premolar tooth is visible in an extruded position, adjacent to a healed edentulous site where a molar was previously removed.</description>
      </img>
      <img order="1" bbox="295,283,482,466" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="L8 Musculoskeletal Disorders_figures/img_546c0d511a4817b3.webp" caption="FIGURE 3. Teeth after exfoliation of the second molar and extrusion of the first premolar.">
        <description>Clinical intraoral photograph showing the mandibular arch with a retracted cheek, revealing an empty tooth socket (alveolus) in the posterior region and adjacent teeth. The image illustrates the state of the dentition following the exfoliation of the second molar and the orthodontic extrusion of the first premolar.</description>
      </img>
      <img order="2" bbox="58,518,255,706" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="L8 Musculoskeletal Disorders_figures/img_807fee16b7cb6a6b.webp" caption="FIGURE 4. Sockets immediately after exfoliation of both teeth.">
        <description>Clinical photo showing the interior of a mouth, specifically the lower arch. The image depicts two empty tooth sockets in the gum tissue, corresponding to the caption 'Sockets immediately after exfoliation of both teeth.' Adjacent teeth are visible on the right side of the crop.</description>
      </img>
      <img order="3" bbox="295,518,475,690" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="L8 Musculoskeletal Disorders_figures/img_489086738924c263.webp" caption="FIGURE 5. Complete healing 2 months after exfoliation. Regev, Lustmann, and Nashef. Extraction in Bisphosphonate-Treated Patients. J Oral Maxillofac Surg 2008.">
        <description>Clinical photo showing an intraoral view of the lower left mandibular arch with a cheek retractor in place. The image illustrates complete soft tissue healing at the site of exfoliated teeth two months post-procedure, displaying healthy pink gingiva and intact mucosa.</description>
      </img>
      <img order="4" bbox="586,307,805,662" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="L8 Musculoskeletal Disorders_figures/img_4341bd68a7c96d24.webp" caption="FIGURE 6. Dentin bulge (arrows) preventing elastics from sliding apically.">
        <description>Clinical photo of an extracted tooth root with a distinct dentin bulge indicated by arrows, showing how the anatomical feature prevents orthodontic elastics from sliding apically.</description>
      </img>
    </images>
  </page>
  <page number="59">
    <text>Alternative Options for Unrestorable Teeth:
Orthodontic Extrusion

Dr Jee-Yun Leung

Smidt A, Lipovetsky-Adler M, Sharon E. Forced eruption as an alternative to tooth extraction in long-term use of oral bisphosphonates Review, risks and technique. JADA. 2012;143(12):1303-12

Dr Jee-Yun Leung

![Figure 3. The roots of the first and second mandibular molars are separated during fabrication of the temporary acrylic bridge.](L8 Musculoskeletal Disorders_figures/img_31b301065f5be431.webp)
![Figure 4. A. The distal root of the mandibular first molar is pulled toward the bridge. B. The erupted root. C. Radiograph before root eruption. D. Radiograph after root eruption.](L8 Musculoskeletal Disorders_figures/img_8338a1a5604ac267.webp)
![Figure 6. A. Occlusal view after placement of the rubber bands. B. Occlusal view of the sockets. Note the appearance of the tissue around the extraction sites. C. The modified acrylic bridge cemented after extraction of the distal roots.](L8 Musculoskeletal Disorders_figures/img_120a272c11eb9019.webp)</text>
    <formatted_text>#### Orthodontic Extrusion

*Smidt A, Lipovetsky-Adler M, Sharon E. Forced eruption as an alternative to tooth extraction in long-term use of oral bisphosphonates: Review, risks and technique. JADA. 2012;143(12):1303-12*

Dr Jee-Yun Leung</formatted_text>
    <images>
      <img order="0" bbox="47,377,303,598" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="L8 Musculoskeletal Disorders_figures/img_31b301065f5be431.webp" caption="Figure 3. The roots of the first and second mandibular molars are separated during fabrication of the temporary acrylic bridge.">
        <description>Clinical photo showing a close-up view of mandibular molars in the mouth, where the roots of the first and second molars appear separated. The image illustrates the preparation phase involving the teeth and surrounding gingival tissue.</description>
      </img>
      <img order="1" bbox="596,282,820,475" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="figure" path="L8 Musculoskeletal Disorders_figures/img_8338a1a5604ac267.webp" caption="Figure 4. A. The distal root of the mandibular first molar is pulled toward the bridge. B. The erupted root. C. Radiograph before root eruption. D. Radiograph after root eruption.">
        <description>Radiograph: Two periapical X-rays of the mandibular posterior region showing a root canal treated distal root being extruded. C = Radiograph before root eruption, D = Radiograph after root eruption.</description>
      </img>
      <img order="2" bbox="403,533,933,682" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="figure" path="L8 Musculoskeletal Disorders_figures/img_120a272c11eb9019.webp" caption="Figure 6. A. Occlusal view after placement of the rubber bands. B. Occlusal view of the sockets. Note the appearance of the tissue around the extraction sites. C. The modified acrylic bridge cemented after extraction of the distal roots.">
        <description>Clinical photo: A triptych of intraoral photographs showing the occlusal view of mandibular molars. Panel A displays rubber bands placed around teeth for orthodontic extrusion; Panel B shows the sockets and tissue appearance after root extraction; Panel C depicts a modified acrylic bridge cemented in place.</description>
      </img>
    </images>
  </page>
  <page number="60">
    <text>&lt;h3&gt;Thinking it through… BMDs&lt;/h3&gt;

&lt;table&gt;
  &lt;thead&gt;
    &lt;tr&gt;
      &lt;th style=&quot;background-color: #F0AD4E; color: white;&quot;&gt;Medical, Dental and Social Considerations&lt;/th&gt;
      &lt;th style=&quot;background-color: #5CB85C; color: white;&quot;&gt;Optimal Timeframes&lt;/th&gt;
      &lt;th style=&quot;background-color: #17A2B8; color: white;&quot;&gt;Treatment Approaches&lt;/th&gt;
    &lt;/tr&gt;
  &lt;/thead&gt;
  &lt;tbody&gt;
    &lt;tr&gt;
      &lt;td style=&quot;background-color: #FDEBD0;&quot;&gt;
        &lt;ul&gt;
          &lt;li&gt;Chemotherapy cycle and blood counts&lt;/li&gt;
          &lt;li&gt;Long-term prognosis of tooth&lt;/li&gt;
          &lt;li&gt;Compliance with ongoing preventive oral care&lt;/li&gt;
          &lt;li&gt;Previous history BMD vs BMD naïve&lt;/li&gt;
          &lt;li&gt;Concomitant oral disease (periodontal disease, periapical pathology) = infection risk factor for MRONJ&lt;/li&gt;
          &lt;li&gt;Tobacco use&lt;/li&gt;
        &lt;/ul&gt;
      &lt;/td&gt;
      &lt;td style=&quot;background-color: #D4EFDF;&quot;&gt;
        &lt;ul&gt;
          &lt;li&gt;Urgency to commence drug&lt;/li&gt;
          &lt;li&gt;Prioritise care that reduces mucosal trauma or need for future oral surgery impacting on bone (e.g. poor prognosis dental extractions, poorly fitting dentures)&lt;/li&gt;
          &lt;li&gt;Future-proof for foreseeable future
            &lt;ul&gt;
              &lt;li&gt;Bisphosphonate osteoporosis tx: 5-10 years treatment period + 10-year terminal half-life&lt;/li&gt;
              &lt;li&gt;Denosumab: long-term, or cessation followed by another BMD (12 months oral bisphosphonate or 1+ zolendronate infusion)&lt;/li&gt;
            &lt;/ul&gt;
          &lt;/li&gt;
          &lt;li&gt;Dental extractions just prior to 6-monthly injection&lt;/li&gt;
          &lt;li&gt;Avoid delaying next dose = risk spontaneous vertebral fractures&lt;/li&gt;
        &lt;/ul&gt;
      &lt;/td&gt;
      &lt;td style=&quot;background-color: #D6EAF8;&quot;&gt;
        &lt;ul&gt;
          &lt;li&gt;Aggressive vs conservative
            &lt;ul&gt;
              &lt;li&gt;Typically aggressive pre-BMD, conservative options if time permits. Typically conservative post-BMD.&lt;/li&gt;
            &lt;/ul&gt;
          &lt;/li&gt;
          &lt;li&gt;Long-term medical prognosis, physiological tolerance&lt;/li&gt;
          &lt;li&gt;Resulting QOL&lt;/li&gt;
        &lt;/ul&gt;
      &lt;/td&gt;
    &lt;/tr&gt;
  &lt;/tbody&gt;
&lt;/table&gt;

&lt;div style=&quot;display: flex; justify-content: space-between; border-top: 1px solid black; padding-top: 5px; margin-top: 10px;&quot;&gt;
  &lt;span&gt;&lt;/span&gt;
  &lt;span&gt;Dr Jee-Yun Leung&lt;/span&gt;
  &lt;span&gt;2025&lt;/span&gt;
&lt;/div&gt;</text>
    <formatted_text>**Thinking it through… BMDs**

| Medical, Dental and Social Considerations | Optimal Timeframes | Treatment Approaches |
| :--- | :--- | :--- |
| • Chemotherapy cycle and blood counts • Long-term prognosis of tooth • Compliance with ongoing preventive oral care • Previous history BMD vs BMD naïve • Concomitant oral disease (periodontal disease, periapical pathology) = infection risk factor for MRONJ • Tobacco use | • Urgency to commence drug • Prioritise care that reduces mucosal trauma or need for future oral surgery impacting on bone (e.g. poor prognosis dental extractions, poorly fitting dentures) • Future-proof for foreseeable future: bisphosphonate osteoporosis tx: 5–10 years treatment period + 10-year terminal half-life; denosumab: long-term, or cessation followed by another BMD (12 months oral bisphosphonate or 1+ zolendronate infusion) • Dental extractions just prior to 6-monthly injection • Avoid delaying next dose = risk spontaneous vertebral fractures | • Aggressive vs conservative: typically aggressive pre-BMD, conservative options if time permits. Typically conservative post-BMD. • Long-term medical prognosis, physiological tolerance • Resulting QOL |

Dr Jee-Yun Leung 2025</formatted_text>
    <audio_inserts count="3">
      <insert timestamp="00:36:48" confidence="5" anchor="Dr Jee-Yun Leung 2025">

&gt; [!note] Lecturer — Dental Clearance
&gt; “Dental clearance” does not necessarily mean removing all teeth, achieving an ideal 28-tooth dentition, replacing or aligning every tooth, or eliminating every carious or periodontal lesion.
&gt;
&gt; - Treatment should instead be prioritised according to mucosal trauma, bone involvement, infection, risk of bacteraemia, and the urgency of medical treatment.
</insert>
      <insert timestamp="00:51:53" confidence="10" anchor="Dr Jee-Yun Leung 2025">

&gt; [!note] Lecturer — Long-Term Planning
&gt; For bisphosphonates, treatment planning may need to anticipate approximately fifteen to twenty years of future dental needs because patients may receive treatment for five to ten years followed by residual drug persistence for a further ten years.
&gt;
&gt; - In patients with a poor long-term medical prognosis, the teeth only need to outlast the patient; extensive extractions may not improve quality of life and may create a prolonged rehabilitation burden.
</insert>
      <insert timestamp="00:53:00" confidence="10" anchor="## **Management of MRONJ**  Goals: improved quality of life, disease control, pr">

&gt; [!note] Lecturer — Management Goals
&gt; Cure is possible in some patients, but treatment choice must balance symptom and infection control against treatment morbidity.
&gt;
&gt; - Surgery may cause substantial morbidity.
&gt; - Non-operative management may sometimes provide better symptom and infection control.
&gt; - Symptoms should be maintained at a tolerable level.
</insert>
    </audio_inserts>
  </page>
  <page number="61">
    <text># Management of MRONJ

Goals: improved quality of life, disease control, prevention of secondary infection

Non-operative

Operative

---

61 | Presentation title | 20XX</text>
    <formatted_text>Goals: improved quality of life, disease control, prevention of secondary infection

- Non-operative
- Operative</formatted_text>
  </page>
  <page number="62">
    <text># Staging

**Stage 0 (non-exposed bone variant)**
*   No clinical evidence of necrotic bone
*   Non-specific symptoms or clinical and radiographic findings
*   Symptoms
    *   Odontalgia unexplained by an odontogenic cause
    *   Dull, aching jaw bone pain, which may radiate to the TMJ region
    *   Sinus pain, inflammation and thickening of the maxillary sinus wall
    *   Altered neurosensory function
*   Clinical Findings
    *   Loosening of teeth unexplained by chronic periodontal disease
    *   Intraoral or extraoral swelling
*   Radiographic Findings
    *   Alveolar bone loss or resorption unattributable to chronic periodontal disease
    *   Changes to trabecular pattern sclerotic bone and no new bone in extraction sockets
    *   Regions of osteosclerosis involving alveolar bone and/or surrounding basilar bone
    *   Thickening/obscuring of PDL

**Stage 1**
Exposed and necrotic bone, or fistula that probes to the bone, in asymptomatic patients without infection/inflammation

**Stage 2**
Exposed and necrotic bone, or fistula that probes to bone, with infection/inflammation. Patients are symptomatic.

**Stage 3**
Exposed and necrotic bone, or fistula that probes to bone, with infection, and one or more of:
- Exposed necrotic bone extending beyond the region of alveolar bone (i.e. mandible = inferior border and ramus; maxilla = maxillary sinus and zygoma)
- Pathologic fracture
- Extraoral fistula
- Oral antral / oral-nasal communication
- Osteolysis extending to the inferior border of the mandible or sinus floor

![](L8 Musculoskeletal Disorders_figures/img_5d3b66f70354db4b.webp)</text>
    <formatted_text>#### Stage 0 (non-exposed bone variant)

- No clinical evidence of necrotic bone
- Non-specific symptoms or clinical and radiographic findings

*Symptoms*

- Odontalgia unexplained by an odontogenic cause
- Dull, aching jaw bone pain, which may radiate to the TMJ region
- Sinus pain, inflammation and thickening of the maxillary sinus wall
- Altered neurosensory function

*Clinical Findings*

- Loosening of teeth unexplained by chronic periodontal disease
- Intraoral or extraoral swelling

*Radiographic Findings*

- Alveolar bone loss or resorption unattributable to chronic periodontal disease
- Changes to trabecular pattern, sclerotic bone and no new bone in extraction sockets
- Regions of osteosclerosis involving alveolar bone and/or surrounding basilar bone
- Thickening/obscuring of PDL

#### Stage 1

Exposed and necrotic bone, or fistula that probes to the bone, in asymptomatic patients without infection/inflammation

#### Stage 2

Exposed and necrotic bone, or fistula that probes to bone, with infection/inflammation. Patients are symptomatic.

#### Stage 3

Exposed and necrotic bone, or fistula that probes to bone, with infection, and one or more of:

- Exposed necrotic bone extending beyond the region of alveolar bone (i.e. mandible = inferior border and ramus; maxilla = maxillary sinus and zygoma)
- Pathologic fracture
- Extraoral fistula
- Oral antral / oral-nasal communication
- Osteolysis extending to the inferior border of the mandible or sinus floor</formatted_text>
    <images>
      <img order="0" bbox="57,262,949,778" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="table" path="L8 Musculoskeletal Disorders_figures/img_5d3b66f70354db4b.webp">
        <description>A staging table comparing clinical criteria across four stages (Stage 0 through Stage 3), with the left column detailing symptoms and findings for non-exposed bone variants and the right column defining progressively severe conditions involving exposed necrotic bone.</description>
      </img>
    </images>
  </page>
  <page number="63">
    <text>Treatment Strategies by Stage of MRONJ

Staging of MRONJ* | Treatment Strategy†
--- | ---
At risk: No apparent necrotic bone in patients who have been treated with oral or intravenous bone-modifying agents | No treatment indicated&lt;br&gt;Patient education and reduction of modifiable risk factors
Increased risk: No clinical evidence of necrotic bone but nonspecific clinical findings, radiographic changes, and symptoms | Symptomatic management, including the use of pain medication and close scrutiny and follow up&lt;br&gt;Refer to dental specialist and follow up every 8 weeks with communication of lesion status to the oncologist&lt;br&gt;Patient education and reduction of modifiable risk factors
Stage 1: Exposed and necrotic bone or fistulas that probe to bone in patients who are asymptomatic and have no evidence of infection | Antibacterial mouth rinse&lt;br&gt;Clinical follow up on an every-8-week basis by dental specialist with communication of lesion status to oncologist&lt;br&gt;Patient education and reduction of modifiable risk factors
Stage 2: Exposed and necrotic bone or fistulas that probe to bone associated with infection as evidenced by pain and erythema in the region of exposed bone with or without purulent drainage | Symptomatic treatment with oral antibiotics and topical antibacterial rinse&lt;br&gt;Pain control&lt;br&gt;Debridement to relieve soft tissue irritation and infection control&lt;br&gt;Clinical follow up on an every-8-week basis by dental specialist with communication of lesion status to oncologist&lt;br&gt;Patient education and reduction of modifiable risk factors
Stage 3: Exposed and necrotic bone or a fistula that probes to bone in patients with pain, infection, and one or more of the following: exposed and necrotic bone extending beyond the region of alveolar bone (ie, inferior border and ramus in mandible maxillary sinus, and zygoma in maxilla) resulting in pathologic fracture, extraoral fistula, oral antral or oral nasal communication, or osteolysis extending to the inferior border of the mandible or sinus floor | Symptomatic treatment with oral antibiotics and topical antibacterial rinse&lt;br&gt;Pain control&lt;br&gt;Surgical debridement or resection for long-term palliation of infection and pain&lt;br&gt;Clinical follow up on an every-8-week basis by dental specialist with communication of lesion status to oncologist&lt;br&gt;Patient education and reduction of modifiable risk factors

NOTE. Adapted from Ruggiero et al.²
Abbreviation: MRONJ, medication-related osteonecrosis of the jaw.
*Exposed or probable bone in the maxillofacial region without resolution for longer than 8 weeks in patients who were treated with an antiresorptive or an angiogenic inhibitor and who have not received radiation therapy to the jaws.
†Regardless of disease stage, mobile segments of bony sequestrum should be removed without exposing uninvolved bone. Extraction of symptomatic teeth within exposed necrotic bone should be considered because it is unlikely that extraction will exacerbate the established necrotic process.

Adapted from AAOMS 2014.
Source: Yarom N, et al. Medication-Related Osteonecrosis of the Jaw: MASCC/ISOO/ASCO Clinical Practice Guideline. 2019;37(25):2270-2290

63 | 20XX

![TABLE 5. Treatment Strategies by Stage of MRONJ](L8 Musculoskeletal Disorders_figures/img_6b09ba0bea231425.webp)</text>
    <formatted_text>| Staging of MRONJ* | Treatment Strategy† |
|---|---|
| At risk: No apparent necrotic bone in patients who have been treated with oral or intravenous bone-modifying agents | No treatment indicated; patient education and reduction of modifiable risk factors |
| Increased risk: No clinical evidence of necrotic bone but nonspecific clinical findings, radiographic changes, and symptoms | Symptomatic management, including the use of pain medication and close scrutiny and follow up; refer to dental specialist and follow up every 8 weeks with communication of lesion status to the oncologist; patient education and reduction of modifiable risk factors |
| Stage 1: Exposed and necrotic bone or fistulas that probe to bone in patients who are asymptomatic and have no evidence of infection | Antibacterial mouth rinse; clinical follow up on an every-8-week basis by dental specialist with communication of lesion status to oncologist; patient education and reduction of modifiable risk factors |
| Stage 2: Exposed and necrotic bone or fistulas that probe to bone associated with infection as evidenced by pain and erythema in the region of exposed bone with or without purulent drainage | Symptomatic treatment with oral antibiotics and topical antibacterial rinse; pain control; debridement to relieve soft tissue irritation and infection control; clinical follow up on an every-8-week basis by dental specialist with communication of lesion status to oncologist; patient education and reduction of modifiable risk factors |
| Stage 3: Exposed and necrotic bone or a fistula that probes to bone in patients with pain, infection, and one or more of the following: exposed and necrotic bone extending beyond the region of alveolar bone (ie, inferior border and ramus in mandible, maxillary sinus, and zygoma in maxilla) resulting in pathologic fracture, extraoral fistula, oral antral or oral nasal communication, or osteolysis extending to the inferior border of the mandible or sinus floor | Symptomatic treatment with oral antibiotics and topical antibacterial rinse; pain control; surgical debridement or resection for long-term palliation of infection and pain; clinical follow up on an every-8-week basis by dental specialist with communication of lesion status to oncologist; patient education and reduction of modifiable risk factors |

NOTE. Adapted from Ruggiero et al.²

Abbreviation: MRONJ, medication-related osteonecrosis of the jaw.

\*Exposed or probable bone in the maxillofacial region without resolution for longer than 8 weeks in patients who were treated with an antiresorptive or an angiogenic inhibitor and who have not received radiation therapy to the jaws.

†Regardless of disease stage, mobile segments of bony sequestrum should be removed without exposing uninvolved bone. Extraction of symptomatic teeth within exposed necrotic bone should be considered because it is unlikely that extraction will exacerbate the established necrotic process.

Adapted from AAOMS 2014.

*Yarom N, et al. Medication-Related Osteonecrosis of the Jaw: MASCC/ISOO/ASCO Clinical Practice Guideline. 2019;37(25):2270-2290*</formatted_text>
    <images>
      <img order="0" bbox="267,259,727,698" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="table" path="L8 Musculoskeletal Disorders_figures/img_6b09ba0bea231425.webp" caption="TABLE 5. Treatment Strategies by Stage of MRONJ">
        <description>This table outlines treatment strategies for medication-related osteonecrosis of the jaw (MRONJ), categorized by staging. The left column defines stages ranging from 'At risk' and 'Increased risk' to 'Stage 1', 'Stage 2', and 'Stage 3' based on clinical presentation, while the right column lists corresponding management steps such as patient education, antibacterial rinses, pain control, debridement, and specialist follow-up.</description>
      </img>
    </images>
  </page>
  <page number="64">
    <text>Management: Non-operative

**General dental practitioner**

Non-operative management:
*   Improve patient’s oral hygiene
    *   Biofilm (tooth brushing)
    *   Chlorhexidine wound care: dip cotton swab or soft small toothbrush in 0.12% CHX solution, gently mechanically scrub exposed bone or fistula.
*   Monitoring wound healing
*   Management of generalised periodontal disease
*   Adjusting dentures to alleviate pressure on non-healing area
*   N/B. Stage 2 patients may struggle with local wound care and require antibiotics for symptom control

**Specialist measures**

*   Removal of loose bone sequestra
*   Adjunctive medications/treatments?
    *   Teriparatide
    *   Vitamin E and pentoxifylline
    *   Hyperbaric oxygen
    *   Ozone therapy

64 Presentation title 20XX</text>
    <formatted_text>#### General Dental Practitioner

Non-operative management:

- Improve patient's oral hygiene
  - Biofilm (tooth brushing)
  - Chlorhexidine wound care: dip cotton swab or soft small toothbrush in 0.12% CHX solution, gently mechanically scrub exposed bone or fistula
- Monitoring wound healing
- Management of generalised periodontal disease
- Adjusting dentures to alleviate pressure on non-healing area
- N/B. Stage 2 patients may struggle with local wound care and require antibiotics for symptom control

#### Specialist Measures

- Removal of loose bone sequestra
- Adjunctive medications/treatments?
  - Teriparatide
  - Vitamin E and pentoxifylline
  - Hyperbaric oxygen
  - Ozone therapy</formatted_text>
    <audio_inserts count="2">
      <insert timestamp="00:54:28" confidence="2" anchor="- N/B. Stage 2 patients may struggle with local wound care and require antibioti">
- ==Temporarily remove dentures if they traumatise the MRONJ site.==</insert>
      <insert timestamp="00:55:06" confidence="2" anchor="- Adjunctive medications/treatments?   - Teriparatide   - Vitamin E and pentoxif">

&gt; [!note] Lecturer — Adjunctive Therapies
&gt; Evidence for some adjunctive approaches is still emerging in MRONJ.
</insert>
    </audio_inserts>
  </page>
  <page number="65">
    <text>Management: Surgical

• Refer all patients with established MRONJ to a surgical dental specialist for assessment

• Surgery: Marginal or segmental resection (including sequestrectomy)

• Progression of MRONJ can be unpredictable

• Decision to proceed is patient-specific
   • Quality of life, symptoms, ability to clean wound to prevent infection and disease spread, morbidity of procedure, oral function, rehabilitation required after procedure

65 Presentation title 20XX</text>
    <formatted_text>- Refer all patients with established MRONJ to a surgical dental specialist for assessment
- Surgery: marginal or segmental resection (including sequestrectomy)
- Progression of MRONJ can be unpredictable
- Decision to proceed is patient-specific
  - Quality of life, symptoms, ability to clean wound to prevent infection and disease spread, morbidity of procedure, oral function, rehabilitation required after procedure</formatted_text>
    <audio_inserts count="2">
      <insert timestamp="00:56:07" confidence="8" anchor="- Decision to proceed is patient-specific   - Quality of life, symptoms, ability">

&gt; [!note] Lecturer — Surgical Decision-Making
&gt; Surgery may not improve quality of life and should therefore be deferred unless the expected benefits outweigh its morbidity.
&gt;
&gt; - It may require prolonged rehabilitation.
&gt; - It may cause sensory loss.
&gt; - It may affect the ability to eat.
&gt; - Surgery may be considered when there is significant loss of jaw function, such as a fracture.
</insert>
      <insert timestamp="00:22:26" confidence="8" anchor="- Decision to proceed is patient-specific   - Quality of life, symptoms, ability">

&gt; [!example] Dental Assessment Before Bone Modifying Therapy
&gt; A 47-year-old man had pulled out a lower incisor and an upper-right molar with his fingers. He had generalised periodontal disease, heavy calculus, substantial bone loss involving teeth 26 and 48, caries, retained roots, and some minor restorable caries.
&gt;
&gt; - For osteoporosis treatment, definite root remnants should be removed; grade 3 mobile teeth and, in some circumstances, grade 2 mobile teeth could be removed, while other teeth could be retained if the patient was motivated to maintain them.
&gt; - A shortened dental arch could be considered, with assessment of whether the patient would attend regular recalls and maintain oral hygiene.
&gt; - For cancer treatment, a more aggressive approach may be appropriate because of the higher MRONJ risk and the urgency of treating possible infection sources. Teeth with deep probing depths, significant periodontal involvement, poor long-term prognosis, or poor expected maintenance might be removed when there is limited time before therapy.
&gt; - Patient motivation and preferences should be discussed frankly and non-judgementally, including willingness to brush regularly, clean interproximally, attend dental reviews, and maintain periodontal treatment.
&gt; - Restorative treatment could generally be completed after starting the bone-modifying drug, whereas invasive procedures affecting bone should be prioritised beforehand.
</insert>
    </audio_inserts>
  </page>
  <page number="66">
    <text># Thank you

Jeeyun.Leung@uwa.edu.au

66Presentation title

20XX</text>
    <formatted_text>Thank you

Jeeyun.Leung@uwa.edu.au</formatted_text>
    <images>
      <img order="0" bbox="527,226,908,745" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="clipart">
        <description>The image is a piece of clipart featuring a magnifying glass held over a stylized bone with a question mark formed by a porous, trabecular-like texture.</description>
      </img>
    </images>
  </page>
  <page number="67" origin="cases">
    <text>## Case: 47-year-old male with multiple myeloma and poor dentition, OPG and clinical findings

### Question

**Scenario:** A 47-year-old male with a history of multiple myeloma is being assessed for dental fitness prior to starting bone-modifying drugs (denosumab/bisphosphonates).

**What's shown:** An OPG and clinical findings of a patient who extracted a lower incisor and an upper right molar with his own fingers.

**Consider:** Identify the dental findings on the OPG and clinical examination, and consider how the dental workup differs based on the specific medical condition the patient is being worked up for.


### Answer

**Observations:**
- Generalized periodontal disease with heavy calculus.
- Substantial bone loss and likely mobility in teeth 2, 6, and 48.
- Presence of caries and retained roots.
- Possible minor restorable caries.

**Reasoning:** The lecturer walks through the patient's OPG and clinical findings to demonstrate a dental workup for a patient needing clearance for bone-modifying drugs. The assessment highlights that the dental workup and subsequent management must be tailored to the specific medical condition (e.g., myeloma, cardiovascular disease, or solid organ transplant) the patient is being worked up for.

**Outcome:** The patient is being worked up for denosumab/bisphosphonates, and the case will be revisited later in the lecture.

**Takeaway:** A dental workup for patients starting bone-modifying drugs must be individualized, as the assessment and management differ depending on the underlying medical condition being treated.

## Case: Patient workup for bone-modifying drugs, extraction planning

### Question

**Scenario:** A patient is being worked up for osteoporosis or cancer and requires bone-modifying drugs. The lecturer reviews the patient's dentition to decide which teeth to extract to future-proof the patient.

**What's shown:** The patient's dentition, showing mobile teeth, increased probing depths, and compromised anterior teeth.

**Consider:** Which teeth should be extracted to minimize the risk of MRONJ and account for the patient's compliance and motivation?

### Answer

**Observations:**
- Grade 3 and grade 2 mobile teeth.
- Teeth with increased probing depths (greater than 8 mm, or &gt;6 mm).
- Compromised (&quot;dodgy&quot;) anterior teeth in the aesthetic zone.
- The patient has poor motivation, is non-compliant, and pulls out his own teeth with his fingers.

**Reasoning:** 
- Grade 3 mobile teeth should definitely be extracted.
- For a cancer workup, a more aggressive approach is taken, extracting teeth with probing depths &gt;8 mm.
- The lower mandible has a higher risk of MRONJ, so preventing it there is prioritized.
- A shortened dental arch approach is considered because the patient is more likely to maintain the remaining teeth.
- A frank discussion is held with the patient about compliance; if they are unlikely to maintain their teeth or attend regular recalls, it is better to extract them now rather than refer for periodontal treatment.
- Compromised anterior teeth may also be extracted if the patient is non-compliant.

**Outcome:** The plan involves extracting the compromised teeth (including grade 3 mobile teeth and those with deep probing depths) and adopting a shortened dental arch approach, with restorations to be completed after the bone-modifying drugs are delivered.

**Takeaway:** When planning extractions prior to starting bone-modifying drugs, clinical findings must be balanced against the patient's motivation and compliance; a more aggressive extraction or shortened dental arch approach may be necessary if the patient is unlikely to maintain their dentition.</text>
    <formatted_text>## Case: 47-year-old male with multiple myeloma and poor dentition, OPG and clinical findings

### Question

**Scenario:** A 47-year-old male with a history of multiple myeloma is being assessed for dental fitness prior to starting bone-modifying drugs (denosumab/bisphosphonates).

**What's shown:** An OPG and clinical findings of a patient who extracted a lower incisor and an upper right molar with his own fingers.

**Consider:** Identify the dental findings on the OPG and clinical examination, and consider how the dental workup differs based on the specific medical condition the patient is being worked up for.


![](L8 Musculoskeletal Disorders_cases_attachments/v1316770_c0_0a6d8eb98f65db22.webp)
![](L8 Musculoskeletal Disorders_cases_attachments/v1316770_c1_8f8d60c58ba47f4a.webp)
![](L8 Musculoskeletal Disorders_cases_attachments/v1316770_c2_34d2dfcc9d5262d2.webp)
### Answer

**Observations:**
- Generalized periodontal disease with heavy calculus.
- Substantial bone loss and likely mobility in teeth 2, 6, and 48.
- Presence of caries and retained roots.
- Possible minor restorable caries.

**Reasoning:** The lecturer walks through the patient's OPG and clinical findings to demonstrate a dental workup for a patient needing clearance for bone-modifying drugs. The assessment highlights that the dental workup and subsequent management must be tailored to the specific medical condition (e.g., myeloma, cardiovascular disease, or solid organ transplant) the patient is being worked up for.

**Outcome:** The patient is being worked up for denosumab/bisphosphonates, and the case will be revisited later in the lecture.

**Takeaway:** A dental workup for patients starting bone-modifying drugs must be individualized, as the assessment and management differ depending on the underlying medical condition being treated.

## Case: Patient workup for bone-modifying drugs, extraction planning

### Question

**Scenario:** A patient is being worked up for osteoporosis or cancer and requires bone-modifying drugs. The lecturer reviews the patient's dentition to decide which teeth to extract to future-proof the patient.

**What's shown:** The patient's dentition, showing mobile teeth, increased probing depths, and compromised anterior teeth.

**Consider:** Which teeth should be extracted to minimize the risk of MRONJ and account for the patient's compliance and motivation?

### Answer

**Observations:**
- Grade 3 and grade 2 mobile teeth.
- Teeth with increased probing depths (greater than 8 mm, or &gt;6 mm).
- Compromised (&quot;dodgy&quot;) anterior teeth in the aesthetic zone.
- The patient has poor motivation, is non-compliant, and pulls out his own teeth with his fingers.

**Reasoning:** 
- Grade 3 mobile teeth should definitely be extracted.
- For a cancer workup, a more aggressive approach is taken, extracting teeth with probing depths &gt;8 mm.
- The lower mandible has a higher risk of MRONJ, so preventing it there is prioritized.
- A shortened dental arch approach is considered because the patient is more likely to maintain the remaining teeth.
- A frank discussion is held with the patient about compliance; if they are unlikely to maintain their teeth or attend regular recalls, it is better to extract them now rather than refer for periodontal treatment.
- Compromised anterior teeth may also be extracted if the patient is non-compliant.

**Outcome:** The plan involves extracting the compromised teeth (including grade 3 mobile teeth and those with deep probing depths) and adopting a shortened dental arch approach, with restorations to be completed after the bone-modifying drugs are delivered.

**Takeaway:** When planning extractions prior to starting bone-modifying drugs, clinical findings must be balanced against the patient's motivation and compliance; a more aggressive extraction or shortened dental arch approach may be necessary if the patient is unlikely to maintain their dentition.</formatted_text>
    <heading_path>Case: 47-year-old male with multiple myeloma and poor dentition, OPG and clinical findings</heading_path>
    <images>
      <img order="0" type="figure" path="L8 Musculoskeletal Disorders_figures/v1316770_c0_0a6d8eb98f65db22.webp" media="frame" source="video" timestamp="00:21:43">
        <description>A composite image featuring a panoramic radiograph and intra-oral photographs of a patient's teeth for Case 1.</description>
      </img>
      <img order="1" type="figure" path="L8 Musculoskeletal Disorders_figures/v1316770_c1_8f8d60c58ba47f4a.webp" media="frame" source="video" timestamp="00:21:43">
        <description>A composite image featuring a panoramic radiograph and intra-oral photographs of a patient's teeth for Case 1.</description>
      </img>
      <img order="2" type="figure" path="L8 Musculoskeletal Disorders_figures/v1316770_c2_34d2dfcc9d5262d2.webp" media="frame" source="video" timestamp="00:21:43">
        <description>A composite image featuring a panoramic radiograph and intra-oral photographs of a patient's teeth for Case 1.</description>
      </img>
    </images>
  </page>
  <footnotes>[^1]: Original PDF page 1: [[L8 Musculoskeletal Disorders.pdf#page=1|L8 Musculoskeletal Disorders, p.1]]
[^2]: Original PDF page 2: [[L8 Musculoskeletal Disorders.pdf#page=2|L8 Musculoskeletal Disorders, p.2]]
[^3]: Original PDF page 3: [[L8 Musculoskeletal Disorders.pdf#page=3|L8 Musculoskeletal Disorders, p.3]]
[^4]: Original PDF page 4: [[L8 Musculoskeletal Disorders.pdf#page=4|L8 Musculoskeletal Disorders, p.4]]
[^5]: Original PDF page 5: [[L8 Musculoskeletal Disorders.pdf#page=5|L8 Musculoskeletal Disorders, p.5]]
[^6]: Original PDF page 6: [[L8 Musculoskeletal Disorders.pdf#page=6|L8 Musculoskeletal Disorders, p.6]]
[^7]: Original PDF page 7: [[L8 Musculoskeletal Disorders.pdf#page=7|L8 Musculoskeletal Disorders, p.7]]
[^8]: Original PDF page 8: [[L8 Musculoskeletal Disorders.pdf#page=8|L8 Musculoskeletal Disorders, p.8]]
[^9]: Original PDF page 9: [[L8 Musculoskeletal Disorders.pdf#page=9|L8 Musculoskeletal Disorders, p.9]]
[^10]: Original PDF page 10: [[L8 Musculoskeletal Disorders.pdf#page=10|L8 Musculoskeletal Disorders, p.10]]
[^11]: Original PDF page 11: [[L8 Musculoskeletal Disorders.pdf#page=11|L8 Musculoskeletal Disorders, p.11]]
[^12]: Original PDF page 12: [[L8 Musculoskeletal Disorders.pdf#page=12|L8 Musculoskeletal Disorders, p.12]]
[^13]: Original PDF page 13: [[L8 Musculoskeletal Disorders.pdf#page=13|L8 Musculoskeletal Disorders, p.13]]
[^14]: Original PDF page 14: [[L8 Musculoskeletal Disorders.pdf#page=14|L8 Musculoskeletal Disorders, p.14]]
[^15]: Original PDF page 15: [[L8 Musculoskeletal Disorders.pdf#page=15|L8 Musculoskeletal Disorders, p.15]]
[^16]: Original PDF page 16: [[L8 Musculoskeletal Disorders.pdf#page=16|L8 Musculoskeletal Disorders, p.16]]
[^17]: Original PDF page 17: [[L8 Musculoskeletal Disorders.pdf#page=17|L8 Musculoskeletal Disorders, p.17]]
[^18]: Original PDF page 18: [[L8 Musculoskeletal Disorders.pdf#page=18|L8 Musculoskeletal Disorders, p.18]]
[^19]: Original PDF page 19: [[L8 Musculoskeletal Disorders.pdf#page=19|L8 Musculoskeletal Disorders, p.19]]
[^20]: Original PDF page 20: [[L8 Musculoskeletal Disorders.pdf#page=20|L8 Musculoskeletal Disorders, p.20]]
[^21]: Original PDF page 21: [[L8 Musculoskeletal Disorders.pdf#page=21|L8 Musculoskeletal Disorders, p.21]]
[^22]: Original PDF page 22: [[L8 Musculoskeletal Disorders.pdf#page=22|L8 Musculoskeletal Disorders, p.22]]
[^23]: Original PDF page 23: [[L8 Musculoskeletal Disorders.pdf#page=23|L8 Musculoskeletal Disorders, p.23]]
[^24]: Original PDF page 24: [[L8 Musculoskeletal Disorders.pdf#page=24|L8 Musculoskeletal Disorders, p.24]]
[^25]: Original PDF page 25: [[L8 Musculoskeletal Disorders.pdf#page=25|L8 Musculoskeletal Disorders, p.25]]
[^26]: Original PDF page 26: [[L8 Musculoskeletal Disorders.pdf#page=26|L8 Musculoskeletal Disorders, p.26]]
[^27]: Original PDF page 27: [[L8 Musculoskeletal Disorders.pdf#page=27|L8 Musculoskeletal Disorders, p.27]]
[^28]: Original PDF page 28: [[L8 Musculoskeletal Disorders.pdf#page=28|L8 Musculoskeletal Disorders, p.28]]
[^29]: Original PDF page 29: [[L8 Musculoskeletal Disorders.pdf#page=29|L8 Musculoskeletal Disorders, p.29]]
[^30]: Original PDF page 30: [[L8 Musculoskeletal Disorders.pdf#page=30|L8 Musculoskeletal Disorders, p.30]]
[^31]: Original PDF page 31: [[L8 Musculoskeletal Disorders.pdf#page=31|L8 Musculoskeletal Disorders, p.31]]
[^32]: Original PDF page 32: [[L8 Musculoskeletal Disorders.pdf#page=32|L8 Musculoskeletal Disorders, p.32]]
[^33]: Original PDF page 33: [[L8 Musculoskeletal Disorders.pdf#page=33|L8 Musculoskeletal Disorders, p.33]]
[^34]: Original PDF page 34: [[L8 Musculoskeletal Disorders.pdf#page=34|L8 Musculoskeletal Disorders, p.34]]
[^35]: Original PDF page 35: [[L8 Musculoskeletal Disorders.pdf#page=35|L8 Musculoskeletal Disorders, p.35]]
[^36]: Original PDF page 36: [[L8 Musculoskeletal Disorders.pdf#page=36|L8 Musculoskeletal Disorders, p.36]]
[^37]: Original PDF page 37: [[L8 Musculoskeletal Disorders.pdf#page=37|L8 Musculoskeletal Disorders, p.37]]
[^38]: Original PDF page 38: [[L8 Musculoskeletal Disorders.pdf#page=38|L8 Musculoskeletal Disorders, p.38]]
[^39]: Original PDF page 39: [[L8 Musculoskeletal Disorders.pdf#page=39|L8 Musculoskeletal Disorders, p.39]]
[^40]: Original PDF page 40: [[L8 Musculoskeletal Disorders.pdf#page=40|L8 Musculoskeletal Disorders, p.40]]
[^41]: Original PDF page 41: [[L8 Musculoskeletal Disorders.pdf#page=41|L8 Musculoskeletal Disorders, p.41]]
[^42]: Original PDF page 42: [[L8 Musculoskeletal Disorders.pdf#page=42|L8 Musculoskeletal Disorders, p.42]]
[^43]: Original PDF page 43: [[L8 Musculoskeletal Disorders.pdf#page=43|L8 Musculoskeletal Disorders, p.43]]
[^44]: Original PDF page 44: [[L8 Musculoskeletal Disorders.pdf#page=44|L8 Musculoskeletal Disorders, p.44]]
[^45]: Original PDF page 45: [[L8 Musculoskeletal Disorders.pdf#page=45|L8 Musculoskeletal Disorders, p.45]]
[^46]: Original PDF page 46: [[L8 Musculoskeletal Disorders.pdf#page=46|L8 Musculoskeletal Disorders, p.46]]
[^47]: Original PDF page 47: [[L8 Musculoskeletal Disorders.pdf#page=47|L8 Musculoskeletal Disorders, p.47]]
[^48]: Original PDF page 48: [[L8 Musculoskeletal Disorders.pdf#page=48|L8 Musculoskeletal Disorders, p.48]]
[^49]: Original PDF page 49: [[L8 Musculoskeletal Disorders.pdf#page=49|L8 Musculoskeletal Disorders, p.49]]
[^50]: Original PDF page 50: [[L8 Musculoskeletal Disorders.pdf#page=50|L8 Musculoskeletal Disorders, p.50]]
[^51]: Original PDF page 51: [[L8 Musculoskeletal Disorders.pdf#page=51|L8 Musculoskeletal Disorders, p.51]]
[^52]: Original PDF page 52: [[L8 Musculoskeletal Disorders.pdf#page=52|L8 Musculoskeletal Disorders, p.52]]
[^53]: Original PDF page 53: [[L8 Musculoskeletal Disorders.pdf#page=53|L8 Musculoskeletal Disorders, p.53]]
[^54]: Original PDF page 54: [[L8 Musculoskeletal Disorders.pdf#page=54|L8 Musculoskeletal Disorders, p.54]]
[^55]: Original PDF page 55: [[L8 Musculoskeletal Disorders.pdf#page=55|L8 Musculoskeletal Disorders, p.55]]
[^56]: Original PDF page 56: [[L8 Musculoskeletal Disorders.pdf#page=56|L8 Musculoskeletal Disorders, p.56]]
[^57]: Original PDF page 57: [[L8 Musculoskeletal Disorders.pdf#page=57|L8 Musculoskeletal Disorders, p.57]]
[^58]: Original PDF page 58: [[L8 Musculoskeletal Disorders.pdf#page=58|L8 Musculoskeletal Disorders, p.58]]
[^59]: Original PDF page 59: [[L8 Musculoskeletal Disorders.pdf#page=59|L8 Musculoskeletal Disorders, p.59]]
[^60]: Original PDF page 60: [[L8 Musculoskeletal Disorders.pdf#page=60|L8 Musculoskeletal Disorders, p.60]]
[^61]: Original PDF page 61: [[L8 Musculoskeletal Disorders.pdf#page=61|L8 Musculoskeletal Disorders, p.61]]
[^62]: Original PDF page 62: [[L8 Musculoskeletal Disorders.pdf#page=62|L8 Musculoskeletal Disorders, p.62]]
[^63]: Original PDF page 63: [[L8 Musculoskeletal Disorders.pdf#page=63|L8 Musculoskeletal Disorders, p.63]]
[^64]: Original PDF page 64: [[L8 Musculoskeletal Disorders.pdf#page=64|L8 Musculoskeletal Disorders, p.64]]
[^65]: Original PDF page 65: [[L8 Musculoskeletal Disorders.pdf#page=65|L8 Musculoskeletal Disorders, p.65]]
[^66]: Original PDF page 66: [[L8 Musculoskeletal Disorders.pdf#page=66|L8 Musculoskeletal Disorders, p.66]]</footnotes>
</document>
